biotop-report 2010 - berlin partner · pdf filejournal of biotechnology in berlin-brandenburg...

J o u r n a l o f B i o t e c h n o l o g y i n B e r l i n - B r a n d e n b u r g

I s s u e 40 · A p r i l 2010

J o u r n a l o f B i o t e c h n o l o g y i n B e r l i n - B r a n d e n b u r g

BioTOP-Report 2010

Here for you. For your health.Medical knowledge is our fascination. Together with our associates in research, science and education we help millions of people all over the world. We are obliged by our medical improvement, because health matters!

www.sanofi -aventis.com

AV

S 90

3 10

022

av219784_1Image_your_health_022.indd 1 17.03.10 09:37

3B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0

Content

Imprint

Publisher: BioTOP Berlin-Brandenburg

Fasanenstraße 85 · D-10623 Berlin

Phone +49 30 318622-0

Fax +49 30 318622-22

[email protected] · www.biotop.de

Editor: Thilo Spahl

Design & Production: supiran.de

Translation: Textbüro Reul GmbH · Frankfurt

Photos: p.8: World Health Summit, ATB

p.9: David Ausserhofer/MDC

p.11: Stephanie Eißrig

p.13: f650biker

p.23: José Giribás, World Health Summit

p.26: Bayer Technology Services

p.34: Stephanie Eißrig

Others: Authors or BioTOP

BioTOP is a joint initiative of the state of Berlin and the state of Brandenburg under the umbrella of the TSB Innovationsagentur Ber-lin GmbH.BioTOP is funded by the federal state of Berlin, the federal state of Brandenburg and the Investitionsbank Berlin, cofunded by the European Union (European Fund for Regional Development). BioTOP coordinates the implementation of the master plan of the health region Berlin-Brandenburg in the field “Biomedicine/Bio-technology”

The BioCapital Region 5

A Reputation for Excellence in Life Sciences 6

New Platform for Diagnostics R&D 10

TOP 50 Supports Technology Transfer 12

Translational Research in Regenerative Medicine 13

Successful Business Development in Biotech 14

Biotech Stands up to the Financial Crisis 18

A Place Where Big Pharma and Biotech Join Forces 22

To a Successful Partnership 24

Factories of the Future 26

Excellent Corporate Locating and Project Development Services 28

The BioCampus Network Berlin-Brandenburg 30

Biotechnology in Schools 34

Profiles 41

Addresses 57


The establishment of new platforms for in-vitro diagnostics was an especially

important achievement in 2009. In may the Center for Molecular Diagnostics and

Bioanalytics (ZMDB) was established as a flagship project of the joint Innovation

Strategy Berlin-Brandenburg. As an independent technology transfer platform that

is open to all players in the field, the ZMDB is a unique institution which connects

basic research, technology development, clinical research and industrial applica-

tion. Alongside the founding of the ZMDB, two big R&D platforms were established

with a total of 16 projects and a volume of 34 million Euros over the next five

years: the technology platform TERA Diagnostics is devoted to the development of

new biosensor systems in conjunction with terahertz technologies for signal trans-

mission. The aim of the Impulse Center for Integrated Bioanalytics is to integrate

all analytical process steps at the molecular level.

2009 was also an important year for a number of companies engaged in drug

development. Several innovative therapies were tested in clinical studies for the

first time: MOLOGEN completed the Phase 1 study of its immune modulator for

cancer therapy with excellent results. Silence Therapeutics started the first study

worldwide, in which siRNA is administered systemically as a cancer therapy.

NOXXON was the first company worldwide to administer a molecule of the Spiegel-

mer class to humans, and Glycotope started clinical development of its glyco-

optimized antibodies. Four very promising developments in Berlin that may well

shape the future of medicine.

BioTOP is proud to support this development as the central network node and your

first contact in the Biocapital region Berlin-Brandenburg. Based on our expertise,

our direct contacts with industry and academia and our extended network we are

continuously servicing the biotech industry in all questions regarding infrastruc-

ture, financing, tech transfer, human resources and business development.

Dr. Kai BindseilDirector BioTOP Berlin-Brandenburg

The BioCapital Region

Berlin-Brandenburg is one of Europe’s leading biotech regions. 25 renowned life science

research institutions, almost 200 biotech companies and more than 20 pharmaceutical

corporations conduct research here and develop new products in close and fruitful coop-

eration. BioTOP has supported the development of the cluster for almost 15 years. In our

annual report, we review important developments during the past year and present an

overview of the industry.

6 B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0

Impulse Center for Integrated Bioanalysis (IZIB)The new Impulse Center for Integrated Bioanalysis (IZIB) is a joint

project implemented under the auspices of the Fraunhofer IBMT

and the University of Potsdam by 14 partners, including com-

panies from the region that form part of the DiagnostikNet-BB.

It was a prize winner in the competition „Spitzenforschung und

Innovation für die Neuen Länder“ organized by the German

Federal Ministry of Education and Research (BMBF) as part of its

regional development initiative „Unternehmen Region“ and is to

receive funds of 14 million euros by autumn 2014. The compa-

nies involved in the project will contribute a total of 1.3 million

euros from their own funds.

The task of the Impulse Center is to analyze molecular identifica-

tion systems and replicate their functions in biohybrid or biomi-

metic form. This can result in substantial analysis simplification

because the measurement itself only requires minimal effort. The

entire measurement intelligence is concentrated in the combi-

nation of the biological identification element, transducer and

electronic measuring equipment. The joint projects at the center

will focus on different diseases. The main indication areas will

be infections and inflammatory as well as nutrition- and age-

related diseases.

The Impulse Center will make insights into molecular identifica-

tion and technologies available for the development of inno-

vative bioanalytical processes and diagnostics and initiate new

developments in the field of bioanalytics. It is to become a lead-

ing international research center in this field and attract the best

scientists in this and adjacent disciplines. As a communication

and translation platform, the center is to provide a focus of inno-

vative impulses for regional industry.

World Health SummitThe first World Health Summit took place from October 14-18,

2009 in Berlin under the heading “The Evolution of Medicine”.

International leaders from politics, industry and the scientif-

ic community met in Berlin to discuss urgent aspects of global

A Reputation for Excellence in Life Sciences

The exceptional research community remains a strong driving force in the development of

the Berlin-Brandenburg region as a biotech location. About half of the approximately 195

biotech companies in the region originated in universities and other academic institutions.

Among other major successes, important new project alliances were established in 2009

in the field of in vitro diagnostics. The first World Health Summit was held in Berlin, and

for the first time a European team received the international award for developing the

“Molecule of the Year”.

Scientific News

January 2009 p The European Strategy Forum on

Research Infrastructures (ESFRI)

includes EU-OPENSCREEN, the

European Infrastructure of Open

Screening Platforms for Chemical

Biology at the Leibniz Institute for

Molecular Pharmacology (FMP), in its

roadmap.

p Chemists at Freie Universität Berlin

identify a new active pharma-

ceutical ingredient class based

on polyglycerol sulfates (dPGS) as

inflammation inhibitors.

p The Max Delbrück Center for Molecu-

lar Medicine (MDC) receives a new

7 Tesla MRT for human diagnostics

and a 9.4 Tesla scanner for small

animals.

p Walter Rosenthal is appointed new

Chairman of the Board of Directors

of the MDC.

March 2009 p The Max Planck Institute of Colloids

and Interfaces presents a new

carbohydrate synthesizer.

April 2009 p Diana Bachran at the Charité wins

the BIONNALE Speed Lecture Award.

May 2009 p The Center for Molecular Diagnostics

and Bioanalytics (ZMDB) launches a

platform for in-vitro diagnostics in

Berlin-Brandenburg.

June 2009 p Jan Mumme at the Leibniz Insti-

tute for Agricultural Technology

Potsdam-Bornim is one of the win-

ners in the competition “Ideenwett-

bewerb Bioenergie” of the German

Federal Ministry of Education and

Research (BMBF).

p The BMBF awards funds of €1.7

million to Charité – Universitäts-

medizin Berlin for the systems

biology network “ColoNET”.

September 2009 p Leif Schröder at the Leibniz Institute

for Molecular Pharmacology (FMP)

receives a €2°million research grant

from the European Research Council.

p Francesca M. Spagnoli at the Max

Delbrück Center for Molecular

Medicine (MDC) receives a €1 million

research grant from the European

Research Council.

p A joint program between Germany

and California in the field of regen-

erative medicine is launched at the

initiative of the Berlin-Brandenburg

Center for Regenerative Therapies

(BCRT).


health. The World Health Summit was also the first event in a year

of celebrations to mark the 300th anniversary of the Charité hos-

pital in 2010. Topics covered at the summit included prevention,

pandemic control, infectious diseases, access to health systems,

personalized medicine, the impact of climate change on health,

health economics and the funding of healthcare systems. Among

the speakers at the Summit were approximately 30 national and

international health and research ministers and secretaries of

state from four continents. Further speakers included represen-

tatives of the World Health Organization and the Global Fund to

Fight AIDS, Tuberculosis and Malaria, CEOs from the pharmaceuti-

cal industry and medical technology sector, several Nobel Prize

Scientific News

p The Fraunhofer Institute for Applied

Polymer Research (IAP) builds a

new application center for polymer

nanotechnologies for € 23 million

October 2009 p The first World Health Summit takes

place in Berlin.

p The bioinformatics expert Tim

Conrad is awarded the Klaus Tschira

Prize.

p The state of Brandenburg supports

the joint research project „Technol-

ogy Platform TERA Diagnostics“ with

€10 million.

p Irene Coin at the Leibniz Institute

for Molecular Pharmacology (FMP)

receives the Junior Researcher Prize

2009 of Forschungsverbund Berlin

(FVB)

November 2009 p Roland Lauster is one of the win-

ners of the Go-Bio competition

sponsored by the German Federal

Ministry of Education and Research

(BMBF). He receives €°3 million for

the development of a multi-organ

bioreactor in chip format.

December 2009 p Peter Fratzl, biomaterials researcher

at the Max Planck Institute of Col-

loids and Interfaces in Potsdam, is

awarded the Leibniz Prize 2010.

p The European Research Council

awards a €2 million Advanced

Investigator Grant to Regine Hengge

at Freie Universität Berlin.

January 2010 p Systems biologist Nikolaus Rajew-

sky of the Max Delbrück Center for

Molecular Medicine (MDC) Berlin-

Buch receives the Science Award of

the Governing Mayor of Berlin

p Christian Rosenmund and Klaus-

Peter Hofmann at the Charité receive

each a €2.5 million research grant

from the European Research Council.

p The jumping gene “Sleeping

Beauty” generated by Dr. Zsuzsanna

Izsvák, Dr. Zoltán Ivics and Dr. Lajos

Mátés of the Max Delbrück Center is

elected “Molecule of the Year 2009”

Prof. Dr. Frank Bier

Director

Fraunhofer Institute for Biomedical

Engineering · Branch Potsdam-Golm

The Lab in a Hanky

» The direct molecular linkage of an identification reaction with signal generation is the ulti-

mate integration in bioanalytics. It means that further transduction steps or devices are no

longer needed. This is the fundamental idea behind the development of sensor-actor molecules

which is the focus of activity at the Impulse Center for Integrated Bioanalytics, an initiative of

14 research facilities and companies, most of which are located at Potsdam-Golm Science Park.

The integration of such sensory modules into everyday appliances can supply important infor-

mation directly.

World Health Summit

» At the Charité, we started to build the global M8 Alliance, which is modeled on the G8, with support from the

German and French governments and in close cooperation with Université Paris Descartes. The M8 Alliance

is a group of 8 leading medical scientific centers in Germany, France, the USA, Britain, Russia, Japan, Australia

and China as well as the Inter Academy Medical Panel (IAMP), which represents 65 national academies, and the

Association of Academic Health Centers (AAHC). Our shared aim is to introduce the theme of health to the global

political agenda. The central activity of the M8 is the annual World Health Summit (WHS), which coincided in

2009 with the opening of a year of events celebrating the 300th anniversary of the Charité. This is wonderful, of

course, because the WHS follows the maxim of Rudolf Virchow: „Medicine is a social science, and, in fact, politics

is simply medicine on a grand scale.“ This comprehensive view of medicine can, in my view, be promoted best

by academic health centers like the Charité, which work in all areas of medicine, are in the vanguard of research

and are at the same time independent of lobby groups. The tremendous response to this concept from leading

scientists confirms that there is a clear need for this global initiative. The 2nd World Health Summit will take

place on October 10th - 13th, 2010, in Berlin.

Prof. Dr. Detlev Ganten

President of the

World Health Summit


Biotechnology Patent Applications Per One Million Residents Per Year (2000-2005)

Berlin 15,8

Hessen 9,9

Bavaria 9,7

Baden-Wuerttemberg 8,4

Hamburg 8,1

Saxony-Anhalt 7,8

North Rhine Westphalia 7,1

Brandenburg 6,6

Rhineland-Palatinate 6,2

Thuringia 5,0

Mecklenburg Vorpommern 4,9

Lower Saxony 4,2

Schleswig Holstein 4,0

Saxony 3,9

Bremen 3,9

Saarland 3,1

winners and presidents of leading national and international sci-

entific bodies. The World Health Summit 2009 under the patron-

age of Federal Chancellor Angela Merkel and the French President

Nicolas Sarkozy was the first in a series of annual Summits.

Molecule of the year 2009The jumping gene or “Sleeping Beauty” transposon is “Molecule

of the Year 2009”. The transposon was generated by Dr. Zsuzsanna

Izsvák, Dr. Zoltán Ivics and Dr. Lajos Mátés of the Max Delbrück

Center (MDC) in Berlin, Germany. It was selected out of 15 mole-

cules nominated in the contest because it holds great promise for

gene therapy. This was the first time that the Molecule of the Year

has been awarded to major recipients outside the USA in Europe.

In its award citation, the jury noted that this hyperactive trans-

poson promises to be a revolutionary technology platform for

genetic engineering. With their new tool, the scientists were able

2002 Nobel Prize Laureate Sir John E. Sulston and German Federal Minister for

Education and Research Prof. Dr. Annette Schavan were among the speakers at

the opening ceremony of the World Health Summit.

Ursula Haufe

Managing Director ipal Gesellschaft für Patentverwertung Berlin mbH

Dr. Jan Mumme

Head of the APECS Junior Research

Group at the Leibniz Institute for

Agricultural Engineering

Potsdam-Bornim

www.atb-potsdam.de/apecs

Turning Agriculture into a Carbon Sink

» Global warming and the intensification of agricultural production have already resulted in a

substantial reduction in soil fertility worldwide. Biochar could be used for land restoration

because it can perform the role of natural humus to increase the sorption capacity of soil for

nutrients and water substantially. Our project APECS - Anaerobic Pathways to renewable Energies

and Carbon Sinks - aims to establish the agricultural sector as a true carbon sink, while protect-

ing regional materials flows.

Life Science Inventions

» Berlin’s high concentration of excellent universities gives

it outstanding competence in research and science. Espe-

cially in the life sciences we have an ever increasing number of

patent applications during the last several years. This fact sug-

gests enormous potential which is not yet fully realized. Most

of these life science inventions are made at the Charité, 64 in

2009. Ipal shares the goal of creating value out of these ideas,

thereby supporting the economic development of Berlin.


to introduce genes into cells of vertebrates which was impos-

sible before, as researchers previously lacked effi cient transpo-

son technologies to do so. However, the effi ciency of the new

transposon remained limited in some cells, such as stem cells.

The scientists solved this problem by slightly changing the genetic

code of Sleeping Beauty, resulting in a hundredfold increase in its

activity. Now, a transferred gene (transgene) fi nds its way into the

cell’s genome more easily.

The MDC researchers hope that their new tool is going to become

the new standard method to introduce genes into cells. Since

2002 the Molecule of the Year has been awarded by the Inter-

national Society for Molecular and Cell Biology and Biotechnol-

ogy Protocols and Researches (ISMCBBPR), which was founded in

2000. Prior to 2002 the award was conferred by the journal Sci-

ence.

Dr. Zsuzsanna Izsvák

Dr. Zoltán Ivics

Dr. Lajos Mátés

Max Delbrück Center (MDC)

A New Tool for Gene Therapy

»Our hyperactive Sleeping Beauty is safer, easier, and cheaper than any oth-

er method before. Currently, scientists use disarmed viruses or a variety of

non-virus based methods to get genes into cells. However, these methods are

either too dangerous or too ineffi cient for broad application in gene therapy.

The new transposon system is able to introduce genes into cells and to stably

insert them into the cell’s genome at an effi ciency comparable to that of viral

strategies. Gene therapy strategies using Sleeping Beauty-based vector systems

could reduce the risk of insertional mutagenesis and immunogeneticity prob-

lems imposed by viral vectors. Even after a year, the genes were still active.

Network of cooperation Berlin-Brandenburg

Number of joint projects (N ≥ 3)

31018

Max-Planck-Institutfür Molekulare Genetik

Deutsches Rheuma-Forschungszentrum

Berlin

Freie UniversitätBerlin

Philipps-UniversitätMarburg

Technische Universität Darmstadt

Friedrich-Schiller-Universität Jena

Leibniz-Institut fürMolekulare Pharmakologie

UniversitätsmedizinBerlin

Max-Delbrück-Centrum für Molekulare Medizin

Max-Planck-Institut für Infektionsbiologie

Max-Planck-Institut für Molekulare Pflanzenphysiologie

Technische Universität Berlin

Humboldt-Universität zu Berlin

Number of projects (N ≥ 3)

16 330

Universities

Helmholtz-Association

Max-Planck-Society

Leibniz-Association

MPI

MPI

MPI

DRFZ

HU

FMPUP

FU

UM

TU

UJ

Ludwig-Maximilians-UniversitätMünchen

LMU

TU

CharitéMDC

UniversitätPotsdam

Nowhere else in Germany is the network of cooperation between research institutions as tight as in Berlin-Brandenburg. The graph shows the participation of

scientifi c establishments in the coordinated programs of the German Research Foundation (DFG) and the relations of cooperation in the life sciences estab-

lished through them.


The year 2009 saw a tremendous increase in regional activities in

the fi eld of diagnostics development. Alongside the founding of

the ZMDB, two big R&D platforms were established with a total of

16 projects and a volume of 34 million Euros over the next fi ve

years: the technology platform TERA Diagnostics is devoted to the

development of new biosensor systems in conjunction with tera-

hertz technologies for signal transmission. The aim of the Impulse

Center for Integrated Bioanalytics is to integrate all analytical pro-

cess steps at the molecular level. In addition, eight other project

alliances were initiated in the following fi elds:

p POCT Emergency Diagnostics

p Infection Diagnostics

p Transplantation Immunology

p Hematology

p Metabolic Diseases

p Stem Cell Research

p Oncology

To enhance communication in the industry, two new conference

series were launched: the Berlin-Brandenburg Technology Forum

for In-Vitro Diagnostics and Bioanalytics, and the Potsdam Bio-

analytics Colloquium.

New Platform for Diagnostics R&D

Berlin-Brandenburg provides exceptionally broad expertise in the fi elds of bioanalytics

and in vitro diagnostics in a large number of high-performing companies and research

facilities. In May 2009 the Center for Molecular Diagnostics and Bioanalytics (ZMDB) was

established as a fl agship project of the joint Innovation Strategy Berlin-Brandenburg. As

an independent technology transfer platform that is open to all players in the fi eld, the

ZMDB is a unique institution which connects basic research, technology development,

clinical research and industrial application. It has a clear focus on the indication areas

cancer, cardiovascular diseases, infections and immunology.

Dr. Tim Bölke

Managing Director metanomics Health GmbH and

Chairman of the ZMDB Advisory Board

Ralf Christoffers

Minister for Economic and European

Affairs of the State of Brandenburg

Download brochure at

www.zmdb.de/materialien/

Biomarkers for Diagnostics and Drug Development

» New technologies and the trend towards personalized

medicine are opening up major growth potentials for

the diagnostics industry. At the same time, pharmaceutical

companies increasingly use innovative analytical methods to

understand the effectiveness and side-effects of develop-

ment compounds better. Metanomics Health uses its metabo-

lite profi ling platform to perform drug development and sub-

stantiate food health claims on behalf of its clients – and for

its own research into biomarkers for early diagnosis. With the

Center for Molecular Diagnostics and Bioanalytics (ZMDB) in

Berlin-Brandenburg, we have established a platform which

combines our capabilities with those of many partners, espe-

cially in science and research.

Important Pillar for Advancing Biotechnology

» Berlin-Brandenburg is already one of Germany’s leading

locations for the rapidly growing molecular biology diag-

nostics sector. The prospects for further consolidation and

extension of this market position are excellent. The Center for

Molecular Diagnostics and Bioanalytics (ZMDB) is one impor-

tant pillar for that endeavor. Its successful establishment has

created the basis for accelerated development of in-vitro

diagnostics in the Berlin-Brandenburg region.


1

6

14

15

7

8 9 12

10

13

17

191816

3

2

4 5

11

BIONNALE speakers 20091 Dr. Klaus Bosslet · 2 · Dr. Dominik Mumberg · 3 · Dr. Matthias Schroff · 4 · Dr. Susanne Danhauser-Riedl · 5 · Dr. Andreas Brüderle · 6 · Andreas Mietzsch · 7 · Senator Harald

Wolf · 8 · Dr. Frank Mathias · 9 · Isabella Guido · 10 · Staatssekretärin Almuth Nehring-Venus · 11 · Dr. Peter Lange · 12 · Staatssekretär Dr. Johann Komusiewicz · 13 · Beatrix

Becker · 14 · Marco Schmidt · 15 · Minister Ulrich Junghanns · 16 · Dr. Christian Wischke · 17 · Marie Weinhart · 18 · Dr. Bernd Wegener · 19 · Jean-Claude Muller · 20 · Michael

Schlenk · 21 · Dr. Kai Bindseil · 22 · Dr. Holger Hiemisch · 23 · Geert Walther Nygaard · 24 · Prof. Dr. Manfred Dietel · 25 · Dr. Sabine Sydow · 26 · Prof. Dr. Andreas Radbruch ·

27 · Dr. Metod Miklus · 28 · PD Dr. Ulrike Stein · 29 · Dr. Bernd Lepenies · 30 · Diana Bachran

20

25 22

3029

21

23

24 26 27 28


The research institutions in Berlin-Brandenburg region possess

a tremendous reservoir of innovative marketable product ideas.

Demand for customized support in the form of evaluation and

consulting by industry experts and the project managers in the

TOP 50 team is correspondingly high. TOP 50 shows how innova-

tive project concepts in academic research can be converted into

real products for the future with relatively limited resources.

Support activities focus on project ideas from regional science

institutions, which display big market potential, abut are still

at such an early stage of development that they do not yet fi nd

interest among entrepreneurial partners for R&D cooperation or

out-licensing projects. The aim of TOP 50 is therefore always to

initiate key projects to close the gap between academic research

and industrial product development.

The record to date has shown that this approach is successful. Of

a total of 64 projects identifi ed and evaluated, 39 are currently

being qualifi ed and supported by the project team. As a result of

the funding granted, ten projects are now at the proof of concept

stage, two are in preparation for company founding, and funding

decisions or the fi ling of funding applications are about to take

place for the majority of the remaining projects. The preferred

instruments for technical development are the ZIM program of the

German Federal Ministry of Economics and Technology (BMWi) and

the Berlin ProFIT program. Building networks between scientists

and regional companies is always the main priority, but this is

successful in only about 25% of cases because the technological

gap to be closed before commercial development can begin is

often too large and must still be closed by critical experiments. As

a side-effect of TOP 50 activities, 10 new inventor registrations

and one application for orphan drug status at the EMEA were fi led

from the projects supported.

A total of 25 projects were terminated prematurely. This was either

because external experts assessed the chances for realization as

too limited due to the lack of market potential, excessive devel-

opment requirements or an uncertain patent situation or because

the TOP 50 team regarded cooperation with individual scientists

as insuffi cient. Technical qualifi cation and the development of

a project plan depend on intensive cooperation and continuous

exchange of information. If scientists are not prepared to engage

in that effort, support by TOP 50 is also inevitably of limited use.

TOP 50 Supports Technology Transfer

The joint technology transfer program of Charité, Freie Universität Berlin, University of

Potsdam and BioTOP was inaugurated in mid-2008 and had a very successful year in 2009.

The aim of TOP 50 is to identify exploitable ideas and support them up the proof of concept

stage, which is when the chances of fi nding external partners or investors are considerably

better.

The Berlin universities occupy a leading position in biotechnology.

Direct R&D grants of the federal government in the fi eld of biotechnology

(2005-2007, percent of total federal biotechnology R&D grants)

Kiel 7,3

Berlin, Freie Universität 5,5

Berlin, Humboldt-Universität 5,5

Heidelberg 5,2

München, LMU 5

Göttingen 4,8

Würzburg 4

Tübingen 3,8

München, TU 3,8

Freiburg 3,6


In recent years the significance of regenerative medicine has

increased rapidly world-wide and it has become a highly compet-

itive field internationally. In Germany six new centres have been

established. One of them is the BCRT, a joint facility of Europe’s

largest university hospital, the Charité, and of Germany’s leading

research organisation, the Helmholtz Association. The aim is to

use findings from basic research and bio-engineering to develop

clinical applications and products. This is possible only by crossing

the boundaries between disciplines and individual research facil-

ities. More than ten first-class research institutions are involved

in this research program. Key areas of research include immu-

nology, the musculoskeletal system and cardio-vascular diseases,

with a special focus on endogenous regeneration through the

application of cells, biological factors and biomaterials.

In 2009 the BCRT initiated a Memorandum of Understanding

agreeing on a joint funding program to expand the research

and development efforts of Germany and California in the field

of regenerative medicine that was signed by State Secretary of

the Ministry for Education and Research (BMBF), Professor Frieder

Meyer-Krahmer, and the President of the California Institute for

Regenerative Medicine (CIRM), Dr. Alan Trounson. The agreement

makes it easier for researchers in California and Germany to obtain

joint funding to broaden the potential pool of expertise that can

be applied toward research in a specific area. Researchers in both

jurisdictions can apply jointly for funding through a process that

builds upon routine CIRM and BMBF procedures. For those that are

approved, CIRM is funding the California researchers and BMBF is

funding the German researchers.

Translational Research in Regenerative Medicine

Regenerative medicine is a focus of development in the Berlin-Brandenburg region. The

nucleus of activities in this field is the Berlin-Brandenburg Center for Regenerative Thera-

pies (BCRT). In the context of the Regenerative Medicine Initiative Berlin-Brandenburg

(RMIB), researchers at the BCRT cooperate closely with about 20 companies that manufac-

ture regenerative medicine products themselves or provide specific services.

There are brilliant minds all over the world

» California was the first state in the nation to support and fund stem cell research, and

now we are expanding our commitment to finding therapies for chronic diseases with yet

another international partnership. There are brilliant minds all over the world, especially here

in California, and with collaborations like this we can help ensure that potentially life-saving

breakthroughs can come more quickly and more often.

Approval of Products for Regenerative Medicine

» It is very important to involve academic and university hospital institu-

tions in the ongoing development of the legal regulations governing the

approval and use of advanced-therapy medicinal products (ATMPs). The Com-

mittee for Advanced Therapies (CAT) was founded in January 2009 and pre-

pares a draft opinion on each ATMP application submitted to the European

Medicines Agency, consults interested parties on request, including associa-

tions and university medical institutions, and involves them in the develop-

ment of new guidelines. University hospitals and start up’s that are developing

ATMPs can present their special concerns to CAT through the services of the

Berlin-Brandenburg Centre for Regenerative Therapies (BCRT).

Arnold Schwarzenegger

Governor of California

Commenting on the Joint

German-Californian RegMed

funding program

Dr. Barbara Pfüller

represents the Berlin-Brandenburg Centre for

Regenerative Therapies (BCRT) as an „interested party“

on the Committee for Advanced Therapies (CAT) of the

European Medicines Agency (EMA)


Corporate Performance in 2009Berlin-Brandenburg has Germany’s largest corporate biotech sec-

tor. Every year, BioTOP conducts a survey of the regional cluster

to analyze current trends and present a comprehensive overview

of the industry in the database at www.biotop.de. The following

developments were determined for 2009.

The number of companies grew by one compared to the prior year

to a total of 195. Twelve companies joined the sector, including

eight newly founded enterprises and four companies that had

previously not been recorded. Eleven companies quit the regional

cluster, for reasons not directly related to the crisis, due mainly to

strategic restructuring and, in some cases, because technological

concepts proved unfeasible. The twelve new companies created

52 jobs in all. Company closures and job losses in the context of

the acquisition at Jerini AG resulted in the loss of 211 jobs. At

the same time, 186 new jobs were created in existing companies

(prior year 144).

After six years of employment growth by 3.5 % annually on aver-

age, the year 2009 ended with positive zero growth. In view of

the difficult economic environment, this is an impressive sign of

stability and confirms that the industry is now firmly established

and more resilient to economic turbulence than the market as a

whole.

With eight new companies, founding activity remained at the

level of the preceding years. Business models, too, followed the

established trend. As before, newly founded companies tend to

be smaller firms with 1-10 employees focused predominantly on

service-oriented business models rather than capital-intensive

product developments. The prime reason is that too little venture

capital is available for the industry as a whole – and especially for

founding new companies.

Successful Business Development in Biotech

The global economic crisis has now entered its second year and still continues. But to date,

the biotech industry in Berlin Brandenburg has fared better than many feared and even

proven very robust. The sector currently comprises 195 companies with a total of 3,727

employees, whereby employment stayed stable last year at a slightly higher level. The crisis

has not caused a downturn in this industry.

Commercial Development

January 2009 p Sysmex and Epigenomics AG

announce strategic R&D collabora-tion in colorectal cancer diagnostics

p Scienion launches Microfluidic sciSWIFTER – joint commercialization with Matrical Bioscience.

p Silence Therapeutics’ partner Quark initiates next stage of clinical trials on DGF prevention drug developed using Silence’s chemistry

p Revotar Biopharmaceuticals AG starts phase II clinical trial in psoriasis with its Bimosiamose 5% cream

February 2009 p Epigenomics AG successfully

places shares at premium in capital increase (5.1 Mio. Euro)

p Caprotec Bioanalytics announces the appointment of Funakoshi as distributor for its products on the japanese market

p Sanofi Pasteur accesses ProBioGen´s AGE1.CR® cell lines for various pox-vectored vaccine products under development

March 2009 p Dr. Kai Bindseil is re-elected as

spokesman of the Council of German Bioregions

p FDA submission of B·R·A·H·M·S MR-proANP Kryptor.

April 2009 p Epigenomics AG licenses biomarker

for development of prostate cancer test to Predictive Biosciences

p Bayer Crop Science closes research facility in Potsdam

p Winthrop Arzneimittel GmbH, a subsidiary of sanofi-aventis, moves from Cologne to Berlin

p Invitek Gesellschaft für Biotechnik & Biodesign mbH, Berlin is acquired by the STRATEC Group, Germany.

May 2009 p TheraCode GmbH acquires JPT Pep-

tide Technologies GmbH

June 2009 p MOLOGEN uplisted to the Prime

Standard of Deutsche Börse p NOXXON announces initiation of

first clinical trial with a Spiegel-mer® (NOX-E36 for the treatment of inflammatory kidney diseases including diabetic nephropathy)

p Silence Therapeutics receives approval to initiate Phase I clini-cal trials on Atu027 for treatment of patients with advanced solid tumours

p DSM acquires the Berlin based biogas specialist Biopract

July 2009 p JPK Instruments opens offices in

Japan p Revotar to initiate phase IIa study of

bimosiamose to support develop-ment in COPD

August 2009 p BIOTECON Diagnostics GmbH and

BIOTEST AG start worldwide sales cooperation

p Silence Therapeutics signs siRNA delivery collaboration with Dainip-pon Sumitomo Pharma

September 2009 p B.R.A.H.M.S launches new blood

test for acute myocardial infarction based on a copeptin assay

p Human BioSciences starts construc-tion of ist new production facility in Luckenwalde


Deals and Product DevelopmentsBiotech companies in Berlin-Brandenburg achieved major mile-

stones in product development and in the establishment of coop-

eration projects in a year that was also shaped by three takeovers.

Below, we present some examples from the broad range of cor-

porate activities in 2009:

B.R.A.H.M.S AG in Hennigsdorf was acquired by Thermo Fisher Sci-

entific for 350 Mio Euro. B·R·A·H·M·S is Germany’s third largest

biotech company and owns several hundred patents with a focus

on innovative biomarkers. Thermo Fisher Scientific announced

that a European Center of Excellence for clinical diagnostics with

a focus on innovative biomarkers is to be established in Hen-

nigsdorf.

Invitek Gesellschaft für Biotechnik & Biodesign mbH, Berlin was

acquired by the STRATEC Group, Germany. In terms of the STRATEC

Group’s corporate structure, Invitek will be incorporated under

the wholly-owned subsidiary Robion AG, Switzerland. STRATEC

expects cooperation with the highly-qualified Invitek Team

in Berlin in the development of molecular biological applica-

tions and a shared strategic focus to generate additional growth

potential in this future market. Berlin based Biopract GmbH was

acquired by Royal DSM N.V., the global Life Sciences and Materials

Sciences company headquartered in the Netherlands. The acqui-

sition serves as an entry point for DSM into the promising biogas

market, which is showing 15-20% growth per year.

Epigenomics AG, a molecular diagnostics company focusing on the

development and commercialization of in vitro diagnostic (IVD)

products for cancer, launched the world’s first in vitro diagnostic

blood test for early detection of colorectal cancer. Epi proColon

is an innovative molecular diagnostic test that can detect tumor

derived methylated DNA of the Septin9 gene (mSEPT9) in blood

plasma as a reliable indicator, or biomarker, for colorectal cancer.

Commercial Development

p Revotar Biopharmaceuticals AG

receives 2.5 Million euro research

grant

p RiNA GmbH and 5 PRIME take over

Roche’s RTS protein expression

portfolio

p PCRFast® Stool Diagnostics of ifp

Institut für Produktqualität will

be marketed and distributed in

Germany by bioMérieux

October 2009 p NOXXON Pharma AG announces

excellent preliminary phase I trial

results for

p Spiegelmer® NOX-E36

p Epigenomics AG launches its Epi

proColon product in Europe - the

first ever in vitro diagnostic blood

test for colorectal cancer early

detection

p Thermo Fisher Scientific acquires

B.R.A.H.M.S Aktiengesellschaft for

EUR 350 Mio.

p InVivo and CEVEC pharmaceuticals

sign license agreement regarding

the use of human CAP-T™ Technol-

ogy for production of recombinant

proteins

November 2009 p Glycotope GmbH has received

regulatory approval by German and

Italian regulatory authorities for a

Phase I study of Glycotope´s lead

antibody GT-MAB 2.5-GEXTM for the

treatment of various solid cancers.

p caprotec bioanalytics opens US sub-

sidiary in Burlington, Massachusetts

p HC Berlin Pharma is starting a

field study for antimalarial drug

ArTiMist™

p MicroDiscovery and Bayer Schering

Pharma renew their successful

cooperation in the field of bioin-

formatics

p MOLOGEN applies for clinical study

with cell-based gene therapy for

renal cancer and reaches primary

end points in MGN1703 study.

p Attomol launches new Real-Time-

PCR-technology

p NOXXON announces initiation of

first-in-human clinical trial with

hematopoietic stem cell mobilizing

Spiegelmer® NOX-A12

p MagForce Nanotechnologies reaches

primary study endpoint in pivotal

glioblastoma study

December 2009 p ProBioGen receives Innovation

Award Berlin-Brandenburg

p MagForce Nanotechnologies AG

appoints Dr. Peter Heinrich as Chief

Executive Officer

p Eckert & Ziegler: capital increase

successfully concluded / clear over-

subscription (21,5 Mio. EUR)

January 2010 p Silence Therapeutics announces

completion of merger with Intra-

digm Corporation and issue of new

shares (17 Mio. EUR)

The view from abroad

» Within the European biotechnology

scene Berlin-Brandenburg is perceived

as a ‘mature cluster’ offering a wide range

of services and instruments to strengthen

the local Life Science sector and possess-

ing a competitive infrastructure for business

and research – an excellent starting point

for joint projects and initiatives with other

regions to benefit from the opportunities

that Europe has to offer.

Montserrat Vendrell

Directora General

Biocat – BioRegió de Catalunya


Scienion AG and Matrical Bioscience, Washington launched the

sciSWIFTER™. It will be jointly commercialized by Scienion AG and

Matrical Bioscience, both leading suppliers in the life science

market. The time and reagent saving drop on demand dispenser,

can dispense up to 16 different substances in parallel into various

multi well plate formats. Dispense range is 100 pl - 100µl with

dead volumes close to zero. Each nozzle has online-drop-control

and optical volume determination.

NOXXON Pharma AG announced successful completion of the first

phase I trial with its anti-inflammatory Spiegelmer® NOX-E36.

This drug candidate will be developed for the treatment of com-

plications of type 2 diabetes, preferentially diabetic nephropathy,

but also others. In November NOXXON started dosing of healthy

volunteers in a first-in-human clinical trial with hematopoietic

stem cell mobilizing Spiegelmer® NOX-A12.

MOLOGEN AG has reached the primary objectives of the phase 1b

clinical study with the cancer drug MGN1703. Toxicity, i.e. seri-

ous intolerability, that would limit the dose has not been found.

MOLOGEN will therefore be able to use the maximum dosage of 60

mg twice a week in the planned phase 2 clinical study, which was

approved early in 2010.

Glycotope GmbH, Berlin, has received regulatory approval by

Germany and Italian regulatory authorities for a Phase I study

of its lead antibody GT-MAB 2.5-GEX™ for the treatment of vari-

ous solid cancers. The approvals further underline the suitabil-

ity of Glycotope´s proprietary GlycoExpress™ technology for the

improvement, glycooptimization and high yield production of

therapeutic proteins for the use in humans.

Silence Therapeutics received approval to initiate phase I clinical

trials on Atu027 and started dosing in June. The trial is being

conducted at the clinical study centre of the Cancer Hospital

SanaFontis in Freiburg, Germany as an open-label, single-cen-

tre, dose-finding Phase I study in patients with advanced solid

(malignant) tumours. In December Silence agreed to buy the US

company Intradigm Corporation in a share-swap deal worth $26

Million.

The biotech company Human BioSciences invested 40 million euros

in a new production plant in Luckenwalde (Teltow-Fläming). The

enterprise will manufacture collagen-based bandages and band-

aids for chronic wounds and will create 100 jobs. The company’s

products are also used in cosmetics and cosmetic medicine.

Second Generation Antibodies

» 2009 has been extremely successful for Glycotope. With the approval of our development platform GlycoEx-

press and the onset of clinical phase I for our proprietary antibody GT-Mab 2.5-GEX, we are highly excited to

see the enormous pre-clinical effects of our core technology for optimizing a protein´s glycosylation now as well

in the clinic. Further, we have completed the development of our first 2nd-generation antibody CetuxiMab-GEX

and are expecting to start trials in Q3/2010. Finally, following our move to new premises within the campus in

Buch and with the support of the BBB, we are happy that we could largely expand our lab- and office-space for

our now more than 70 employees just in Berlin to successfully proceed with our projects.

Dr. Steffen Goletz

CEO/CSO

Glycotope GmbH

Num

ber

of

emplo

yees

4000

3500

3000

2500

2000

1500

1000

500

0

With 3,727 employees employment stayed stable over the year. The num-ber of companies rose to 195, reflecting the arrival of twelve companies (8 of which were newly founded) and eleven departures. (Source: Internal survey, BioTOP database, 195 companies questioned, February 2010)

Employees in Biotech SMEs

96 98 00 01 02 03 04 05 06 07 08 09

1.3

05

1.8

40

2.3

59

3.1

64

2.9

42

3.0

03

3.0

07

3.2

13

3.4

27

3.5

90

3.7

00

3.7

27


180

160

140

120

100

80

60

40

20

0

Most companies focus on biomedicine. A total of 84% of companies, focus primarily on development in the areas of new diagnostics, drug development and associated services or technologies. 15% of the companies are active in the agriculture / food sector, white biotechnology / environmental biotechnology increased to 18% of all entries. (Source: Internal survey, BioTOP database, responses from 195 companies, multiple entries, February 2010)

Market Segments of Companies

Nu

mb

er o

f co

mpan

ies

Agriculture/Food

01 02 03 04 05 06 07 08 09

24 29 33 30 33 35 26 29 30

15%

White Biotechnology / Environmental Biotechnology

01 02 03 04 05 06 07 08 09

25 27 22 26 30 30 28 27 36

18%

Biomedicine

01 02 03 04 05 06 07 08 09

108 113 122 109 134 132 155 165 163

84%

1.700

1.600

1.400

1.200

1.000

800

600

400

200

0

In comparison to the previous year, the average payroll per company got reduced by 15% in the 1-10 category and by 7% in the 11-50 category. The average number of employees in the category > 50 employees increased by 10%. (Source: Own survey, BioTOP database, 195 companies questioned, February 2010)

Number of Employees according to Company Size

Nu

mb

er o

f em

plo

yees

115 companies 1-10 employees

98 99 00 01 02 03 04 05 06 07 08 09

65 companies 11-50 employees

98 99 00 01 02 03 04 05 06 07 08 09

15 companies > 51 employees

98 99 00 01 02 03 04 05 06 07 08 09

61

0

139

4

1723


Despite major cause for concern, the biotech industry has proved

far more resilient to the financial and crisis than other sectors.

Not a single biotech company in Berlin-Brandenburg had to close

down in 2009 as a result of the crisis. That the industry is less

dependent on general economic trends is due to stable demand

on the health and research markets, which needs to be met con-

tinuously. In addition, activities in this strongly research-focused

sector are largely financed by stable budgets which are affected

less directly than the investment goods industries by turbulences

on the private capital markets.

This may be the reason why the majority of regional companies

that participated in a BioTOP survey do not anticipate a decline

in sales and expect the biotech industry to fare better than the

market as a whole. This positive business climate in the region

was also confirmed in another survey conducted by the industry

association BioDeutschland.

This positive impression is nonetheless surprising, considering the

situation on the capital markets. In Germany VC investments have

been in decline for five years in succession. According to a survey

among a panel 38 leading VC investors by Fleischhauer, Hoyer &

Partner, VC investments in Germany dropped from €565 million

in 2008 to €341 million in 2009 (panelists only) – a reduction

by 40%. Most venture capital went to the software industry (€71

million), internet (€47 million) and biotechnology (€46 million).

About one quarter of investments were made in Bavaria, followed

by North-Rhine Westphalia (15%) and Berlin (13%).

The private equity industry finds itself in a very difficult period.

That is also reflected in current figures from the European industry

association EVCA. Total losses rose by the factor 3.5 to €3.2 billion,

while the number of new fund launches fell by 40%. Although

these figures relate to all industries, the downward trend was

naturally also felt in the biotech sector. It is therefore not aston-

ishing that 49% of VC investments covered by the above-men-

tioned panel study were publicly funded. And, much to the ben-

efit of the region, most of these public investments came from IBB

Beteiligungsgesellschaft Berlin.

Biotech Stands up to the Financial Crisis

The overall economic situation could hardly be worse: a global economic downturn, a

continuous decline in VC investments and a very problematic environment for innovative

companies. But the mood in the industry and its economic performance are nonetheless

better than expected.

Focus on the Biogas Market

» DSM New Business Development regards the biogas market segment as especially important

and has therefore set up its DSM Biogas division. It is evident that bioenergy in general has

tremendous growth potential. Although public debate often focuses on biofuels, biogas will play

a key role in the future because it is in energetic terms the most efficient method of biomass-

based energy generation. This sector is currently growing by 15 to 20 percent annually. At DSM

Biopract, we are now developing the second generation additives for this market together with

our enzyme specialists, in particular at DSM Food Specialities. These additives are enzyme com-

plexes that perform many different activities and therefore support effective depletion of plant

biomass with higher yields and depletion speeds.

Dr. Matthias Gerhardt

Managing Director DSM Biopract GmbH

www.dsmbiogas.com


Overall, the analysis shows that, with only few exceptions, access

to venture capital remains closed to biotech companies. Mat-

ters are even worse as regards debt financing from banks. For

the biotech industry, bank funding was always hard to procure.

Now, however, the more stringent lending requirements imposed

in the context of the financial crisis make it unlikely that financ-

ings for biotech companies, which usually entail certain risks, will

be forthcoming even in the longer term. Ambitions to go public,

which was the most promising financing method in the past, are

currently not entertained in the industry.

In terms of equity funding, Berlin-Brandenburg is well positioned

with IBB Beteiligungsgesellschaft and BC Brandenburg Capital.

Together, they stand for a fund volume of €80 million. The will

Products for cell-free biosynthesis

» In September 2009 we signed a contract with Roche Applied Science on

the transfer of the complete RTS Protein Expression portfolio to RiNA GmbH.

The RTS cell-free expression kits ideally complement the already existing RiNA

product portfolio and its dedicated specific customer service for cell-free bio-

synthesis. Together with 5 PRIME (exclusive partner) products for purification

and detection of recombinant proteins the RTS technology will form a strong

basis for joint development of innovative products in this dynamic field.

Leo W. Tristram

Managing Director of RiNA GmbH

and Dr. Manfred Baier (on the left)

Head of Roche Applied Science


Production in Luckenwalde

» We started planning our production plant in Luckenwalde in 2009. In April 2011, we will start manufacturing

collagen-based products for modern wound care and cosmetics with some 100 employees here. Alongside

Maryland, USA, and Taiwan, Luckenwalde is the third production location for products developed by the US com-

pany BioCore Inc. The Biotechnology Park at Luckenwalde provides us with an excellent infrastructure and perfect

conditions – for new product developments in the future too.

Michaël de Mari

CEO · Human BioSciences GmbH

to invest is strong, and there is also no lack of funding requests.

What acts as a brake on investments is that both state funds are

co-financed by the European Regional Development Fund (ERDF),

so that a private lead investor is usually needed. And they are

presently rare.

Many SME who are denied access to the capital market have simply

vacated that terrain and focus their business models on services,

industry contracts and research alliances. No major VC financing

consequently took place in the region in 2009. There was not a

single VC investment in the eight new companies founded during

the year. The situation appears slightly better for exchange listed

companies, which were able to attract €50.1 million through

capital increases and can therefore continue to develop their R&D

pipelines.

Government therefore remains a prime source of funding for the

implementation of new development projects in biotech com-

panies. Together, the two federal states Berlin and Brandenburg

alone have approved more than €67 million in support funding

for R&D and infrastructure projects in the life sciences sector.

The funding program ZIM under the federal government’s Eco-

nomic Stimulus Package II has played a key role as a driver of new

development projects. Since the program was launched in July

2008, €834 million were approved for all technology sectors, of

which more than €118 million went to the region Berlin-Bran-

denburg. Some €95 million were approved for the life sciences.

Especially in the current period, support funding for the develop-

ment of new products is immensely important. Since the financ-

ing situation will not change in the short term, it is all the more

important that government continues to support the industry.

And not only by direct funding is needed, but also improvements

in the conditions for financing and advancing innovation. The

present tax laws place highly innovative companies at a disad-

vantage in international comparison and deter investors. The

industry association BIO Deutschland has identified the key prob-

lems and launched an initiative to improve that situation.

Despite strong support from the public sector, it will be vital for

the growth of the industry in the medium term to attract more

private capital into the biotech industry again.

New Production Plant of Human BioSciences in Luckenwalde


New Biotech Companies

3B Pharmaceuticals GmbH3b-pharma.com

3B Pharmaceuticals GmbH (3BP) is a privately held pharmaceu-tical R&D company based in Berlin, Germany. The company is dedicated to the development of peptide-based pharmaceuti-cal- and diagnostic products. 3BP is pursuing projects in hemo-philia and nuclear medicine.

Astra Biotech GmbHastrabiotech.de

The Company Astra Biotech offers a wide range of high-quality reagents and diagnostic kits. The catalogue provided by our company includes reagents for detecting of human hormones, genetic diseases, tumor markers and allergens. Besides, we develop cutting-edge, technologically perfect solutions in the field of diagnostics and we are ready to offer our experience, skills and knowledge for realization of your projects.

bbi-biotech GmbHbbi-biotech.com

In the focus of the activities of bbi-biotech lie systems for the sterile sampling from bioreactors for all applications in the biotechnology, pharmaceutical, food, cosmetics and chemical industry. In addition, bbi-biotech develops components - in especially disposable ones - for the preparation of a new gen-eration of fermentors and bioreactors and offers consulting and planning services for biotech projects, its implementation and services.

BioRepro GmbHbiorepro.com

BioRepro is the first pharmaceutical company, whose core com-petency is the breeding of leeches under controlled labora-tory conditions for medical therapies. We concentrate on the establishment of GMP breeding procedures and will be able to provide leeches with standardized quality while equally allow-ing scalability to supply medical demand. Additionally, through the re-initiation of fundamental research, we will gain deeper understanding of further potential in medical and cosmetic treatment areas.

breecon GmbHbreecon.com

The breecon GmbH is an innovative service company in life science with focus on green biotechnology. The objectives of the company are consulting, application and mediation of biotechnological-analytical services as well as their develop-ment and marketing. The breecon GmbH offers his services to plant breeders and companies of the industrial biotechnology and supports the utilization of genetic diversity in the context of SMART breeding.

Metabolomic Discoveries UGmetabolomicdiscoveries.com

Metabolomic Discoveries is an analytical service and research company. We provide mass spectrometry based metabolite pro-filing and fingerprinting of biological material, as well as single compound measurements.

mfd Diagnostics GmbHmfd-diagnostics.com

The mfd Diagnostics GmbH (BT Luckenwalde) is a life science research and development company for diagnostic and thera-peutic application of innovative laser technologies. The main advantages of the developed technologies are the non-/minimally-invasive measurement methods, the non-artificial approach and the possibility of real-time measurement. There-fore, those are promising tools for the diagnosis and therapy monitoring in the neurological practice and in the perinatal surveillance.

nanopartica GmbHnanopartica.com

Nanopartica GmbH optimizes existing products of other com-panies, but is also developing new products and materials. In particular, companies in surface-, bio-, and medical-technol-ogy can benefit from nanopartica. By means of functionalized polymers, we can encapsulate guest molecules (drugs, dyes, vitamins), particles (gold, silver, platinum), or ions. This will indirectly change the guests’ properties and expands its scope.

novojointnovojoint.de

R&D of a new therapy approach for the treatment of severe, inflammatory diseases of the joint and for the support of wound healing after injuries of the skin and bones in man as well as animals. The concept is based on the development of smart gene constructs, which allow the inflammation controlled release of suitable therapeutic proteins at the site of damage/repair. We aim to provide our therapy for three target markets: 1. Small Animal Clinics, 2. Equine Clinics, 3. Human Medicine

opTricon Entwicklungs-gesellschaft für optische Technologienoptricon.de

opTricon develops and produces mobile readers for quantitative analyzes of Immunoassays for Point-of-Care-diagnostics, espe-cially Lateral Flow Assays (LFA). Additional business segments are components and Systems for signal transmission and sensors for lbioanalytics. opTricon develops the devices in partnership with the customers and works as OEM-suppliers and is certified by TÜV Rheinland according EN ISO 13485:2003+AC: 2007 and EN ISO 9001:2008.

ProteaImmun GmbHproteaimmun.de

ProteaImmun GmbH offers human proteases, ELISA, enzyme and antibody. ProteaImmun’s expertise in the recombinant protein expression, especially in human proteases and in the devel-opment of antibodies and modern methods of detection and analysis of proteins, enables us to offer customized solutions and support with single components as well as with complete molecular diagnostic systems.

Financing and Added Value

VC Fonds Technologie Berlin was set up as a joint initiative of Investitionsbank Berlin (IBB) and the State of Berlin. It is co-fi nanced by the European Regional De-velopment Fund (ERDF).

VC Fonds Technologie Berlin

Venture Capital for companies in BerlinIBB Beteiligungsgesellschaft mbH offers equity fi nanc-

ing for high tech companies in Berlin. For our fund

VC Fonds Technologie Berlin (€52m) we are looking

for investment opportunities in the biotechnology and

medical technology sector.

Our investment approach is based on hands-on

invol vement and active management support for

each portfolio company, delivered by our highly expe-

rienced investment team. VC Fonds Technologie Berlin

not only provides capital, but also helps execute the

business plan.

Are you interested? Please do not hesitate to contact us.

IBB Beteiligungsgesellschaft mbH

Mrs. Ute Mercker / Mr. Christian Seegers

Bundesallee 171

10715 Berlin / Germany

Phone: +49 (0)30 2125-3201

www.ibb-bet.de

Selected portfolio companies:


Berlin is one of the birthplaces of the modern pharmaceutical

industry. In 1851 Ernst Schering opened a pharmacy he named

Grüne Apotheke (green pharmacy). Twenty years later, the founder

incorporated the business as a stock company, which later became

Schering AG. In 2006 the company was taken over by Bayer. Since

that merger took place, the health sector has become an impor-

tant area of business for Bayer. In 2008, sales by its health divi-

sion grew by 4.1 percent to 15.4 billion euros and accounted for

almost half of total group sales. 10.7 billion euros came from the

pharmaceuticals business, i.e. Bayer Schering Pharma. Today the

company concentrates on four core areas: Oncology, Cardiology,

Women´s Healthcare, and Diagnostic Imaging. The second biggest

pharmaceutical company in Berlin is Berlin-Chemie. The company

was founded in 1890 and is today the German subsidiary of the

Italian MENARINI group.

It employs more than 4,350 people, around 1,920 of them in

Germany and occupies a leading position among pharmaceutical

companies in Central and Eastern Europe. Berlin-Chemie markets

prescription drugs and OTC preparations. The product portfolio

includes a broad spectrum of therapeutic agents for office-based

doctors and for clinics.

Alongside Bayer Schering Pharma, Berlin-Chemie and some 20

mid-sized companies, other international corporations have

extended their presence in Berlin. In 1984 the US Bausch & Lomb

Group bought the Berlin ophthalmics manufacturer Dr. Mann

Pharma. The company now employs more than 700 people in

Berlin and is expanding its operations here. In 1995 Altana built

a new pharmaceuticals factory in the Brandenburg town of Ora-

nienburg, north of Berlin. In 2006 Altana was sold to the Danish

A Place Where Big Pharma and Biotech Join Forces

The development of the biotech industry in Berlin-Brandenburg has benefited from the

geographical proximity of major pharmaceuticals companies. The region has now become

a leading biotech location, which in turn makes it attractive for other pharmaceuticals

companies.

Grants for Targets

In order to further pool expertise and to join forces for mutual

benefit, Bayer Schering Pharma AG is supporting collaborative

research projects on attractive, novel molecular targets in the

fields of

p Oncology

p Cardiology

p Gynecology

p In vivo Imaging

To promote this new approach, Bayer Schering Pharma AG

intends to allocate grants for the further development of

promising targets. The size of the individual grants depends

on the target specifics and the phase of development. Grants

vary accordingly and are limited to a maximum of €250,000.

Researchers from universities, other academic research insti-

tutes and start-up companies from all over the world are eli-

gible to apply.

For more information, see www.grants4targets.com

Pharma R&D is on the Upswing in Germany

R&D expenses and R&D employees in the german pharmaceutical industry (members of the german association of research-based pharmaceutical companies (VFA))

p German R&D Employees (Thousand)p R&D Expenses (Billion Euros)

14,1

1998

2,76

14,3

1999

3,01

14,1

2000

3,08

14,3

2001

3,36

14,5

2002

3,61

14,5

2003

3,90

14,5

2004

3,95

15,7

2005

4,16

16,8

2006

4,37

17

2007

4,53

17,1

2008

4,84


company Nycomed. Today Nycomed Germany operates two state-

of-the-art production units covering 36,000 sqm in Oranienburg.

In early 2000 the French pharmaceuticals corporation Sanofi-

Synthelabo, formed by merger, moved its German headquarters

from Munich to Berlin. After the merger of Sanofi and Aventis in

2004, the company that is now the world’s third largest pharma-

ceuticals group expanded its operations in Berlin to include mar-

keting and sales and now employs around 1,900 people in the

German capital. In 2008 pharmaceutical group Pfizer Inc moved

its German headquarters to Berlin from Karlsruhe to be in the

vicinity of the federal capital’s growing health-related industry.

Shortly afterwards, the company announced that Berlin will also

be the location of Pfizer’s European oncology business unit. Pfizer

is currently conducting 20 clinical studies in cooperation with

Charité and the Helios Clinics.

In 2009, Berlin-Brandenburg was again strengthened consider-

ably as a pharmaceuticals region by the relocation of the German

operations of Shire AG to Berlin and by the takeover of Wyeth by

Pfizer, which was followed by the relocation of the company’s

German branch to Berlin. Sanofi-aventis decided to merge the

generics and OTC business of its subsidiary Winthrop and the for-

mer activities of sanofi-aventis in the field of unpatented prod-

ucts at its Berlin site. The aim of the new „Commercial“ division is

to enhance the position of both companies on the German mar-

ket under preservation of the ’Winthrop’ brand and of Winthrop

Arzneimittel GmbH as a pharmaceutical manufacturer.

Federal Labor and Social Affairs Minister, Ursula von der Leyen, and Dr. Rein-

hard Uppenkamp, CEO of Berlin-Chemie AG – Berlin-Chemie AG participates in

the vocational training initiative „Ausbildung jetzt“ and has received repeated

awards from the Chamber of Industry and Commerce (IHK) as an exemplary

provider of vocational training. The company is committed to improving

professional opportunities for young people. Berlin-Chemie also operates a

protected workshop where 34 people with physical and mental disabilities

receive care and therapy and can engage in meaningful activities.

Industry and academia are closely interconnected. Chris Viehbacher, CEO of

sanofi-aventis, and Prof. Karl Max Einhäupl, Chairman of the Executive Board

of Charité - Universitätsmedizin Berlin, at the opening press conference of the

World Health Summit.

Berlin can become Germany’s Pharmaceuticals Capital

» Berlin has developed very well. The German capital attracts many talented people. Berlin’s

science landscape has evolved rapidly too, making the city one of Europe’s leading sites

for science and research. For Bayer Schering Pharma, networking with partners in science and

research has always been essential. That is why Berlin is such an attractive location for us. The

city is home to many academic institutions. We cooperate closely with researchers both at the

Charité and in biotech companies in Adlershof and Berlin-Buch. We want to support the devel-

opment of small companies in the region so that it acquires the necessary critical mass. Berlin

can become Germany’s pharmaceuticals capital.

Andreas Fibig

Chairman of the Board

of Management of

Bayer Schering Pharma AG


A company like sanofi-aventis – being one of

the world’s largest pharmaceutical companies –

is very interested in creating partnerships worldwide. Especially

in biotechnology, as pharmaceutical business and biotechnology

business simply belong together.

Prosperous traditionEstablishing and maintaining good partnerships is important to

sanofi-aventis, as the company has a long tradition of a success-

ful integrated international network of core partnerships. Large

companies, small biotech companies and academic institutions

are all involved. Each possesses specific strengths and abilities.

And the cooperation between the partners is paying off – espe-

cially or even if they come from two different worlds. Pharma-

ceutical research is a very complex field, where small and flexible

research units in particular can make a large contribution.

Strong togetherNot only, but also, through our partnerships, we are and remain

at the cutting edge of international research and can identify and

use the latest results of modern medicine. We are absolutely con-

vinced, that international cooperation is main pillar of success-

ful research and development. We can contribute significantly to

medical research by connecting various expertises – for the ben-

efit of our patients, our partners and our company.

Trust and respectPartnership means having shared visions. Therefore, important

partnerships are designed long term and are based primarily on

two things: trust and mutual respect. The creative structure of our

cooperation contributes to this - always considering both part-

ners’ goals and demands. A partnership is much more than a

mere signing of a contract. Our goal is a real partnership in which

both sides can develop and be successful. The focus is always on

the project and good cooperation at all levels between research

groups, departments, division management and company man-

agement. Important requirements for each partnership are that it

matches our strategy and our corporate culture.

Triangle – research, technology and marketingSanofi-aventis has a lot to offer to its partners. Not only a wide

spectrum of pharmaceutical research, knowledge of new thera-

peutic approaches and resulting developments are part of our

strengths. But also their technical implementation. Our extensive

experience makes us an attractive partner, when it comes to com-

bine research with technical know-how and convert them into

successful production and products. And last but not least, our

knowledge in marketing plays a decisive role in business part-

nering. This triangle of research, technical implementation and

global marketing and sales units makes us interesting for many

partners. Globally, we work together in all phases of the value

chain - from research to development and production to market-

ing.

Search for new partners – national and globalWe are always looking for new partners with creative ideas. An

example of this successful search is our “Partnering Day” with

biotech companies in Berlin-Brandenburg in April 2009. The

result of this 2-day meeting with many biotech companies was a

series of promising contacts, of which some are currently becom-

ing concrete. Our continuous monitoring of interesting biotech

companies - as we are doing in this region for example – will

most likely lead to further partnerships.

Our motivation Looking at it globally, at least a fourth of our successful drugs have

been developed in partnerships. This demonstrates that we con-

fidently and successfully work with external partners for the ben-

efit of patients. This motivation defines our partnerships – both

now and in the future.

Contact [email protected]

sanofi-aventis.com

To a Successful Partnership or Shared Visions

When two people get together and plan a common future, this should ideally lead to a

partnership both benefit from. Such a win-win situation does not only exist in private life

– it is also one impetus of a successful partnership between companies. The size of a com-

pany is not the decisive factor. In particular, small businesses, universities and research

institutes have a lot to offer and are therefore interesting partners for Big Pharma.

Peter Guenter

General Manager Commercial Operations Germany

Sanofi-aventis

Die Deutsche Bank und die Initiative „Deutschland – Land der Ideen“ präsentieren die Sieger des Wettbewerbs „365 Orte im Land der Ideen“. Ob es um Biotechnologie, Karriereförderung, Innovationsmanagement oder Nachhaltigkeit geht: Alle „Ausgewählten Orte“ zeigen in verschiedenen Kategorien, wie Erfolgsgeschichten made in Germany mit Know-how und Leidenschaft unsere Zukunft gestalten. Entdecken Sie Deutschlands einzigartiges Netzwerk für Mut, Neugier und Innovation!

Zum 20-jährigen Jubiläum der Wiedervereinigung prämieren wir jeden Monat eine Idee, die sich mit Engagement und Kreativität für das vereinte Deutschland einsetzt, zusätzlich mit dem Sonderpreis „Gelebte Einheit“.

Applaus für Deutschlands Zukunftsmacher!

Alle Sieger auf www.deutsche-bank.de/ideen

365 Erfolgsgeschichten, die unser Land begeistern.

Spot an für die besten Ideenaus Deutschland!

Anzeige – Geschäftsbereich Intern – LDI Phase 2, 2010 – 210 x 148,5 mm – 05.03.2010, 10:56 Uhr

210x148_5_LDI_Phase 2_032010_intern.indd 1 05.03.2010 10:56:45 Uhr

Are you a technology-based firm in the bio-tech branch, and are you planning to investin the State of Brandenburg? We can support your project with grants, loans at reducedinterest rates and risk and equity capital. Just contact us!

InvestitionsBank des Landes Brandenburg Phone: +49 331 660-1256 · E-mail: [email protected] · www.ilb.de

Promotion and Financing for Bio-Tech Firms

150-1471_060306_AZ_Biotech 08.03.2006 13:02 Uhr Seite 1


High throughput times in development, planning and the instal-

lation of manufacturing premises are still common in today’s

business. However, they do not stand in accordance with the

necessity to comply with volatile market prognosis or to react on

changing market situations on short notice. It must be consti-

tuted that the time to market and the scalability of production

processes are critical key success factors in the global business.

This is in particular valid for the Biotech industry. Small, modular

units which are easy to install and thus can be quickly brought

into operation, could provide the appropriate solution for these

challenges. But it is not only the development sector which can

benefit from the new approach, making broader use of small unit

based micro reaction technology. In the lifecycle of a product,

this new technology also enables the industry to easier adapt

the ‘product manufacturing’ scale to the next higher level. This is

made possible through the provision of pre-manufactured stan-

dard units which only must be assembled according to customers

need. Finally this can lead to advantages in each of the areas:

planning, purchasing, installation and the start-up of a new pro-

duction facility. Using a highly flexible plant layout also means to

have a low investment risk.

With the foundation of INVITE in North Rhine Westfalia the first

step is made and the environment is given to further explore

the feasibility and practical operation of this new development

and manufacturing approach for chemical products. In this con-

text, the project ‘Fast Flexible Future Factory’ (F3 Factory), which

is granted by the European Union, can be considered as a light-

house project which enables us to successfully manage the step

towards a new decade for highly efficient and highly flexible

(bio-)chemical production technology.

Today the standard of biotechnological production is mainly char-

acterized by ‘large size’ fermentation vessels and non-removable,

fixed installed stainless steel pipings. These plants are oper-

ated only by a few Pharma-/ Biotec companies worldwide, due

to their high investment costs and their requirements for strin-

gent process control systems. However, this current technology

suffers from limited flexibility (mono purpose plants) as well as

from high operational costs, which is rooted in the high effort

for cleaning and operating these plants. A promising solution to

overcome these shortcomings can be seen in the industrial use of

modular and disposable medium-scale units (up to some 1.000

l volume) which then can be combined to a complete up- and

downstream process train and hence to an integral fermentation

process. Using the principles of ‘Closed Processing’ could even

allow the production of biopharmaceuticals in former lab facili-

ties, since the primary product conditions would then be lev-

eraged to a GMP-compliant environment. Bayer Technology Ser-

vices, together with Bayer Schering Pharma is striving to develop

these new manufacturing technologies to make them available

for single unit operations up to complete process chains. The Bay-

shake system which was co-developed by Bayer Technology Ser-

vices and Sartorius Stedim Biotech allows to increase production

flexibility and production capacity while production costs can be

significantly reduced simultaneously.

Factories of the Future

Global competition in the chemical and biochemical industry is continuously increasing.

Subsequently the importance to substantially reduce the effort and investments necessary

for the development of new technologies and (bio-) chemical products as well as phar-

maceutical drugs is growing at the same time. Already today one can dare to say that an

advantage in this area can decide on the success or failure of an innovative product. In

addition, a clear trend can be observed towards highly specialized and highly individual-

ized products, which in the medical arena are also known under the headline ‘personal-

ized medicine’ and which typically are produced only in small amounts and small lots.

Dr. Helmut Mothes

Member of the Executive Committee and

Head of Division Process Technology of

Bayer Technology Services

Bayshake® Demo System with Disposable Bag: The Bayshake system which was co-developed by Bayer Technology

Services and Sartorius Stedim Biotech allows to increase production flexibility and production capacity while production

costs can be significantly reduced simultaneously


The Life Science Screening Package Berlin-Brandenburg is tailored

to the needs of the biotech sector. This program supports compa-

nies looking for cooperation partners, networks, service provid-

ers and research institutions. All segments of the health industry

are present in the region. The high concentration of international

excellence facilitates interdisciplinary exchange and makes new

landmark developments easier to achieve – this is what makes

Berlin-Brandenburg so interesting and attractive for the life sci-

ences. At the same time, however, the sheer number of players

can make it difficult to find the right partner. Our staff and the

colleagues at BioTOP have been in direct contact with virtually all

companies and scientific institutions in the region for many years

and can therefore provide immediate access to the right contacts.

The other services of Berlin Partner include the Business Welcome,

Business Financing, Business Locating and Business Recruiting

Package. They help our clients test Berlin as a location, procure

support and funding and identify suitable commercial real estate

or professional staff. The Business Location Center (BLC) pres-

ents all relevant economic data and a 3D model online and in

its showroom. Its comprehensive information service covers sec-

tor data, regional information, area maps, geographic data, the

available funding programs, a commercial real estate database as

well as labor market and infrastructure data. At the start of this

year, a new service was launched for companies in the region

offering support in all aspects of corporate expansion and strat-

egy in cooperation with the Berlin Senate Administration for Eco-

nomic Development, Technology and Women, the twelve Berlin

precincts and other service partners.

The performance range of the one-stop agency ZAB includes cor-

porate strategy, innovation, technology and foreign trade services,

support for technology transfer and for the establishment of cor-

porate networks. Under its „Big Directive“, the state of Branden-

burg now also sponsors innovative cooperation projects between

research institutes and companies. Here, landmark initiatives

include the Tele-Diagnostics cooperation project (with funding

of app €10 million) and TERA-Sens (€15 million). The partici-

pating partners include the Fraunhofer Institute for Biomedical

Engineering, the University of Potsdam, the Leibniz Institute for

Innovative Microelectronics (IHP) and the companies B.R.A.H.M.S

AG (Thermo Fisher Scientific), MEYTEC GmbH and LIMETEC Biotech-

nologies GmbH. In 2009, the Life Science Team successfully sup-

ported 64 high-end innovation projects with a total funding vol-

ume of €89 million, creating some 300 new jobs.

The Life Science Team supported expansion projects and provid-

ed locating services to 35 companies in 2009, including Pfizer

Deutschland GmbH which is transferring further divisions to Ber-

lin with some 200 new jobs, Deutsche Gesellschaft für Human-

plasma mbH, Japan Stent Technology Europe GmbH and the Ira-

nian biotechnology firm UGA Biopharma GmbH.

Excellent Corporate Locating and Project Development Services

Berlin-Brandenburg is Germany’s leading life science center and one of Europe’s main

health industry locations. Due to its high concentration of science and research establish-

ments, the region offers outstanding potentials for technological development and coop-

eration. The joint Life Science Team of the economic promotion agency Berlin Partner and

the Brandenburg Economic Development Board (ZAB) supports the life science industry

with a full range of services, including marketing activities at national and international

exhibitions.

Carolin Clement

Head of Business Unit Life Sciences

Berlin Partner GmbH

Dr. Ute Hartmann

Head of Business Unit Life Sciences

Brandenburg Economic Development Board

Good News

for your company

www.up-transfer.de

1 We interconnect science and business.

UP Transfer GmbH provides direct access to science and R & D resources of the University of Potsdam for your company. We realize know-how and technology transfer from the university into practice. Take advantage of our contacts and networks and profit from our efficient project management to take your business to the next level. Please contact us for further information: [email protected]


The BioCampus Network Berlin-Brandenburg

Berlin-Brandenburg boasts six biotechnology parks, which offer optimal space for the

specific requirements of every company. This geographic concentration of specific biotech

parks is unique in Germany and probably in all of Europe. The parks differ in their offers

and strategic focus and provide ideal conditions for newcomers. More than half of the 195

companies are currently utilizing the infrastructure of a publicly or privately managed park.

In addition, the young companies benefit from the closeness to science and the perma-

nent contact and exchange.

Campus Berlin-BuchInteraction of Research, Clinics and Companies

Berlin-Buch is the location of one of the largest biotechnology

parks in Germany, with 26.000 square meters of scalable lab and

office space for start-ups and maturing companies. Situated to

the northeast of the city, the Berlin-Buch Campus is currently

home to 49 companies, 35 of which are biotech companies; the

rest provides support services.

Beside the BiotechPark the Max Delbrück Center for Molecular

Medicine, the Leibniz Institute for Molecular Pharmacology as

well as clinical groups from the Charité University Hospital with-

in the Experimental and Clinical Research Center are part of the

Campus community. The Campus gives access to high-end tech-

nology platforms, state of the art infrastructure, interdisciplinary

communication, projects and expertise in a wide range of items,

especially in translational research.

The BiotechPark at the Campus Berlin-Buch offers:

p Immediately available lab and office space

p Excellent research and clinical expertise on-site

p Training programs for personnel on spot

p An international community of like-minded people

p Interdisciplinary networks and platforms

The BiotechPark including the Innovation and Incubation Center

is managed by BBB Management GmbH Campus Berlin-Buch. Act-

ing as s full-service company BBB’s main tasks are the settlement,

accompanying and support of Biotech businesses.

Biotechnology Park LuckenwaldeSpace for Expansion

Located just 25 miles from the new Berlin-Brandenburg Interna-

tional Airport (BBI) in the rural district of Teltow- Flaeming, the

Biotechnology Park Luckenwalde is one of the most modern facili-

ties of its kind in Germany. It is home to 38 companies with 500

employees from Germany, USA, UK, Korea, India, Italy and Russia.

Companies in the park focus on the development and production

of pharmaceuticals, recombinant proteins and diagnostic kits,

biological/chemical substances for biotech and pharmaceutical

applications, as well as fine chemicals. There are also suppliers

of medical technology, analytical services, and a Biotech Edu-

cation Centre. Technical Equipment comprises completely fur-

nished S2 labora tories (safety workbench, autoclave, dishwasher,

deionized water, water purification system, central media supply

(compressed air, N2, Co

2, O

2, H

2), storage and cool rooms, pharma-

ceutical clean rooms category (B/C), 400 MHz NMR spectrometer,

meeting rooms, conference hall (300 seats), library, restaurant

with catering service. The entire central technique meets GMP/ISO

9001 specifications.

The park management offers comprehensive, individual servic-

es and advice during the settlement and development of firms,

including support for the implementation of quality management

systems and GMP certification. Currently the park offers 15.000

sq.m. labs and office space, and additional 100.000 sq.m.

industrial property ready for expansion.


Berlin AdlershofThe “City of Science, Technology and Media”

Berlin Adlershof is one of the most successful high-tech locations

in Germany with focus on photonics and optical technologies,

material and microsystems technology, information and media

technology, as well as biological, environmental and energy tech-

nology.

There are currently 25 biotech companies in Adlershof occupying

18,200 sq.m of lab and office space. The environmental, biologi-

cal and energy technology companies focus on:

p Analysis Tracing substances in foodstuffs and groundwater, cosmetics,

waste; Quality assurance, Identification of pollutants

p Biotechnology Research development and marketing or manu facture of base

materials for biotechnology and chemical processes, of bio-

chips and biochip-based biomedical procedures, of technical

enzyme preparations

p Environmental technology Remediation work based on innovative microbiological pro-

cesses for degradation of pollutants or production of specific

microbial anacultures; Research in the field of supercritical

media and high-pressure technology; High-sensitivity detec-

tion systems for biotechnology and gene tic engineering; Laser

technology

p Pharmacy, Medicine and Medical Technology Equipment engineering and measurement technology;

Research for medical chemistry

Technical Equipment comprises laboratories with a basic equip-

ment: security-lockers, laboratory basins, work benches, vacuum

supply, preliminary setup for supply of pure gases and com-

pressed air, reconfiguration for further media and gases, central

cooling, preliminary setup for cold water supply in rental areas,

refitting of heat exchanger by the tenant possible.

BIOTECh CAMPUS POTSDAMResearch on the Waterfront

Just a few minutes away from Potsdam’s central railway station

in the direction of Caputh, BIOTECH CAMPUS POTSDAM is located

on the Hermannswerder peninsula in the river Havel. It is owned

and operated by BIOTECH CAMPUS POTSDAM GmbH, a fully owned

subsidiary of the Investment Bank of the State of Brandenburg.

The biotechnology centre is housed in four buildings dating

from around 1900 and one modern complex and offers a total

of 11,400 square meters of laboratory, office, greenhouse and

storage space. With such a large facility at its disposal, it offers

biotechnology companies an ideal environment for successful

operations. All labs are approved as S1 laboratories and meet the

building requirements for approval as S2 labs.

The Hermannswerder site also includes an S3 laboratory as a

special resource. The beautiful, park-like setting of the penin-

sula offers an excellent environment for research activities. The

island hotel and a conference centre are located directly next to

the campus. The site also includes a self-service restaurant and

small island shop.

The philosophy of BIOTECH CAMPUS POTSDAM was, and still is, to

create the freedom for research and innovation in the high-tech

sector of biotechnology. Reputable firms from the industry can

indeed be found here. The work carried out by resident com-

panies is multi-faceted, ranging from green biotechnology, the

development of vaccines, the development of pharmacologically

active substances based on plant materials, the development

and production of PCR tests for food testing and preclinical con-

tract research right through to medical technology. A total of 200

employees work on the site.


berlinbiotechparkIn the very heart of Berlin

berlinbiotechpark is located on a 86,000 m² site in the very heart

of Berlin, currently offering a total of approx. 57,000 m² of office,

laboratory and production space, with a building potential for

another 45,000 m² of rental area.

The site, which is home to 32 Biotech/Pharma/Service Companies

is supplied with a complete range of media for laboratory and

production purposes, with production steam with possibility to

upgrade to HP steam, power supply, compressed-air, nitrogen

and other inert gases, cooling water, DI-water, with possibility

to upgrade to aqua purificata and water for injection, all being

provided at favorable rates. The infrastructure includes a canteen

and conference facilities as well as works security and waste dis-

posal services. It is rounded off by production-related services

such as plant engineers and laboratory technicians, industrial

safety engineers, a medical service as well as best-buy services

and communication services.

Offering flexible growth potential, production-orientated media

equipment and comprehensive industrial-specific services and

infrastructure, berlinbiotechpark is particularly attractive for

growing internationally orientated technology companies. Fur-

thermore, it offers a permanent base in Berlin for developing

companies that have outgrown the size allowed by their limited

start-up funding. The inner-city location and the excellent public

transport guarantee short ways to all scientific institutions and

hospitals of the city.

Science Park Potsdam-Golm Connecting Excellence

Science Park Potsdam-Golm combines cutting-edge international

research and the training of young scientists in a high-powered

location in the immediate vicinity of the German capital Berlin.

Alongside the Faculty of Science and the Human Sciences Faculty

of the University of Potsdam, three Institutes of the Max Planck

and two of the Fraunhofer Society as well as an innovation cen-

ter with currently 18 companies operate in Brandenburg’s largest

science park.

More than 2500 people work at Potsdam-Golm and more than

7500 students are pursuing their academic qualifications here.

The pleasant and very family-friendly working environment on

the edge of a nature conservation area, the high quality of life

in and around Potsdam and continuous growth make Potsdam-

Golm a highly attractive location. Professional site management

is extending the park infrastructure and fosters the integration of

the capabilities and interests of all institutions, associations and

companies that operate at Science Park Potsdam-Golm.

The GO:IN Innovation Center offers young technology-based com-

panies and entrepreneurs a range of office and laboratory spaces

along with extensive services and optimal support for a successful

market launch. Close proximity to the other players at Potsdam-

Golm and the intensive networking of the different institutions

and companies here offer perfect conditions for the development

and exploitation of synergies.

BIOTECH CAMPUSPOTSDAM GmbH


The BioTechnology Center Hennigsdorf

On the northern perimeter of Berlin, a number of biotech and

medtech companies have been established at the Biotechno-

logieZentrum Hennigsdorf around the diagnostics company

B.R.A.H.M.S. As a traditional industrial site with very good trans-

port connections, the 27,000-strong town has evolved into an

important Brandenburg location for technology fi rms.

The BiotechnologieZentrum Hennigsdorf was set up in 2001. It

offers full service for small and mid-sized biotech companies.

Infrastructure and services include:

p Laboratories up to security level S2, isotope labs, clean rooms

(small area)

p Production and storage areas

p Advice on start-up, funding and subsidy issues

p Conference and meeting rooms, conference organisation,

event management

p Security guards, alarm

p Technicians, building surveillance

Apart from these locations with strong focus on biotechnology

which form the BioCampus Network there are many other tech-

nology parks that offer a good technical infrastructure for life sci-

ence companies. Among them is the Innovationspark Wuhlheide

which is in close proximity to the Adlershof technology park.

Addresses

Campus Berlin-BuchRobert-Rössle-Straße 10 · 13125 Berlin

Phone +49 30 94892511 · Fax +49 30 94893812

[email protected] · www.bbb-berlin.de

Contact: Dr. Andreas Mätzold · Executive Manager

Dr. Ulrich Scheller · Executive Manager

Biotechnologiepark Luckenwaldec/o SWFG mbH

Im Biotechnologiepark, TGZ I · 14943 Luckenwalde

Phone +49 3371 681100 · Fax +49 3371 681105

[email protected] · www.bio-luck.de

Contact: Dipl.-Ing. Christoph Weber · Director

Adlershof Zentren für Biotechnologie und UmweltWISTA-MANAGEMENT GMBH

Rudower Chaussee 17 · 12489 Berlin

Phone +49 30 63922221 · Fax +49 30 63922212

[email protected] · www.adlershof.de

Contact: Heidrun Terytze · Head of Center for Biotechnology

and Environment

BIOTECh CAMPUS POTSDAMSteinstraße 104-106 · 14480 Potsdam

Phone +49 331 6601169 · Fax +49 331 6601201

[email protected] · www.biotechcampus.de

Contact: Marco Fredersdorf · Executive Manager

berlinbiotechparkTegeler Weg 33 · Max-Dohrn-Straße 8-10 · 10589 Berlin

Phone +49 30 20364205 · Fax +49 30 20364190

[email protected] · www.berlinbiotechpark.de

Contact: Ingo Schneemann

Standortmanagement Golm gGmbhGO:IN Golm Innovationszentrum GmbhAm Mühlenberg 11 · 14476 Potsdam-Golm

Phone +49 331 237351130

www.wissenschaftspark-potsdam.de · www.goin-potsdam.de

Contact: Friedrich W. Winskowski · Managing Director

Biotechnologiezentrum hennigsdorf/B.R.A.h.M.S Biotech GmbhNeuendorfstraße 24b · 16761 Hennigsdorf

Phone +49 3302 883250 · Fax +49 3302 883666

[email protected]

Contact: Steffi Liniert

Innovationspark WuhlheideKöpenickerstraße 325 · 12555 Berlin

Phone +49 30 65762431 · Fax +49 30 65762799

[email protected] · www.ipw-berlin.de

Contact: Henry Koch | Park Management


Biotechnology in Schools

The biotech industry is growing and needs fresh talents. Young people often take the deci-

sion to embark on a career in this field while still at school. This is why special programs

aimed at promoting excitement about biotechnology among school students have been

established in Berlin-Brandenburg.

Everybody involved in biotechnology in Berlin-Brandenburg

knows BIONNALE, the annual reception at which entrepreneurs,

scientists, financers and others in the industry meet to exchange

their experiences. The themes discussed here are scientific prog-

ress, innovations, the economic environment – and often the

recruitment of junior talents too. After all, the industry is growing

and needs well-trained professionals. However, potential young

recruits are not present at BIONNALE. In fact, they are not invited

because that would simply not be suitable at this event.

So, there should really be a separate BIONNALE for school students,

an event that introduces them to the industry and the careers it

offers, thought Beate Mitzlaff last year, who is reponsible both for

education and events at BioTOP. She decided to develop a con-

cept for the SchülerBIONNALE for school students and went on to

implement it too. Under the motto „Experience and Discover the

Life Sciences“, more than 600 secondary and sixth form pupils

from Berlin and Brandenburg came to Langenbeck Virchow House

in Berlin to find out what is happening in the world of biotech-

nology. The program included a short lecture on stem cells, an

introduction to the different careers in the field, a crash course

for successful applications (Barefoot or Patent Leather?) as well as

experiments and discussions with representatives from compa-

nies and educational institutions. Since not everything there is to

know could be communicated and understood in just two hours,

pupils received extensive material on a USB stick, and the teach-

ers, too, were supplied with documents and posters to continue

presenting the subject in class.

Call a ScientistStudents and teachers who developed an interest in biotechnol-

ogy at the SchülerBIONNALE find it easy to build on that experi-

ence. They can request a bioscientist to give a talk at their school

from the initiative „Call a Scientist“ organized by the Berlin-

Dr. Norbert Gerbsch

Honorary Chairman

Biotechnologieverbund Berlin-Brandenburg

Scientists for Schools

» Natural science education in schools and attracting young

people to careers in science and research is vital for the

future of Germany and our region Berlin-Brandenburg as an

internationally competitive science and technology location.

It is impossible to understand the world without science, and

the biosciences are playing an increasingly important role in

many areas of our global economy. For young people, the

biosciences can therefore provide an opportunity to embark

on exciting and promising careers. This is why our initiative

„Call a Scientist“ sends science experts into schools to present

their areas of expertise to pupils.


Brandenburg Biotechnology Association. On its website www.

call-a-scientist.org, this service, which was launched in 2006,

offers users the choice between more than 100 speakers with

different specialties. And demand is growing continuously. The

initiative has already arranged 114 talks to some 4800 students

in the region to date. In addition, school student laboratories

for experiments have also been well established for many years

(www.genau-bb.de).

Berlin-Brandenburg also offers outstanding international postgraduate programs in the life sciences.

Beate Mitzlaff

Event Manager

BioTOP Berlin-Brandenburg

Learning About Careers in the Life Sciences

» At SchülerBIONNALE, school students can experience and explore the life sciences. We pro-

vide them with personal contact to students, technical assistants, scientists and companies

to find out more about careers and working life in this sector. Information about professions in

the life sciences must be improved to give pupils a realistic understanding of what to expect in

the industry. We want to support them in developing their talents and provide them with initial

insight into the role of the biosciences in everyday life.

p Berlin-Brandenburg School for Regenerative Therapies

p Berlin Institute for Medical Systems Biology PhD Program

p Berlin International Graduate Schools of Natural Science and

Engineering

p Berlin School of Mind and Brain

p Bernstein Center for Computational Neuroscience

p Dahlem Research School Biomedical Sciences

p Dahlem Research School Molecular Plant Science

p Dahlem Research School Molecular Science

p DFG Research Training Group Cellular Mechanisms of Learning

and Memory Consolidation in the Hippocampal Formation

p DFG Research Training Group Genetic and Immunologic

Determinants of Pathogen-Host-Interactions

p DFG Research Training Group Hormonal Regulation of Energy

Metabolism, Body Weight and Growth

p DFG Research Training Group Sex- and Gender-Specific

Mechanisms in Myocardial Hypertrophy

p DFG Research Training Group The Impact of Inflammation on

Nervous System Function

p Helmholtz International Research School ‘Molecular

Neurobiology’

p International Max Planck Research School on Biomimetic

Systems

p International Max Planck Research School Primary

Metabolism and Plant Growth

p International Max Planck Research School for Computational

Biology and Scientific Computing

p International Max Planck Research School for Infectious

Diseases and Immunology

p International Research Training Group (IRTG) Genomics and

Systems Biology of Molecular Networks

p International Research Training Group for Myology

p International PhD Programme Molecular Cell Biology

p International Graduate Program Medical Neurosciences

p Leibniz Graduate School of Molecular Biophysics

p Postgraduate International Process Engineering School (PIPES)

p TransCard Research School

Since 1992, ConsulTech GmbH supports companies and research institutions in the acquisition of funding for their R&D projects by public grants (German, EU and US).We have specialized on projects in the area of biotechnology, medical technology, pharmaceutical development and environmental technology.

p We identify grants that facilitate your innovation.

p We conceive, compose and chaperone your R&D projects by planning, writing, filing and implementing proposals.

p We find and assemble partners from industry and science to build research consortia that fit.

You focus on the scientific success - we take care of the administration and project management.

Anhaltinerstraße 22

14163 Berlin

Phone +49 30 801971 11

Fax +49 30 801971 20

[email protected]

www.consultech.de

Grants for R&D Projects in Life Sciences

Dr. Ulla Peters or Reinhold LauerUHY Deutschland AG Wirtschaftsprüfungsgesellschaft / Zimmerstraße 23 / D-10969 BerlinPhone +49 30 226593-0 / Fax +49 30 22679050 / www.uhy-deutschland.de / www.uhy.com

Life sciences companies are in safe hands with UHY.UHY Deutschland AG is a joint venture of long established medium-sized auditing and consulting firms with a total of 150 employees and partners.

As a member of UHY International, a global association of independent accounting and consulting firms with about 7,600 employees we can provide audit, accounting, tax and consulting services in over 200 business centres across the globe.

UHY Deutschland AG has extensive experience in finan-cial and consulting services for life sciences companies for many years. We offer the following services:

p Audits of financial and consolidated statements under the German Commercial Code (HGB) and IFRS p Accounting & Reporting p Due diligence (financial and tax) and business valua-tions p Consulting services on IPOs p Business Advisory p Mergers & Acquisitions (M&A) p German and international taxation

Berlin / Bremen / Cologne / Hamburg / Munich

Contact


Netzwerk Glykobiotechnologie Berlin-Brandenburg

BIOTECH CAMPUSPOTSDAM GmbH

Biotech Networks

BioHyTec Network for Biohybrid Technologies

BioResponse

Center for Molecular Diagnostics and Bioanalytics (ZMDB)

DiagnostikNet-BB

GABI – Genome Analysis in the Plant Biological System

NetDDD Network for Drug Discovery & Development Berlin-Brandenburg

Network Glycobiotechology Berlin-Brandenburg

Nutrigenomics Network Berlin-Brandenburg

Regenerative Medicines Initiative Berlin-Brandenburg

RiNA Network for RNA Technologies

Ultrastructure Network

Scientific Institutions

Berlin-Brandenburg Center for Regenerative Therapies

Berlin Institute of Technology

Brandenburg University of Technology

Charité Universitätsmedizin Berlin

Fraunhofer Institute for Applied Polymer Research

Fraunhofer Institute for Biomedical Engineering (IBMT)

Freie Universität Berlin

German Heart Instiute Berlin

German Institute of Human Nutrition (DIfE)

German Rheumatism Research Center (DRFZ)

Humboldt-Universität zu Berlin

Institute of Polymer Research of the GKSS Research Centre

Lausitz University of Applied Sciences

Leibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB)

Leibniz-Institut für Molekulare Pharmakologie (FMP)

Leibniz-Zentrum für Agrarlandschaftsforschung (ZALF) e. V.

Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch

Max-Planck-Institute for Colloids and Interfaces

Max Planck Institute for Infection Biology

Max Planck Institute for Molecular Genetics

Max Planck Institute of Molecular Plant Physiology

Robert Koch Institute

University of Applied Sciences Berlin

University of Applied Sciences Wildau

University of Potsdam

J Bioparks

J Scientific Institutions

J Companies

J Networks


FHI I

Wir bei BIOCOM sind ständig für Sie auf dem Quivive!

Seit der Besetzung Preußens durch Napoleon gibt es in Deutschland die Redewen-dung „auf dem Quivive sein“, was so viel bedeutet wie auf der Hut sein, aufpassen, aufmerksam oder auch besonders gut informiert sein. Die Mitarbeiter der BIOCOM AG und ihrer Tochtergesellschaften haben Bioökonomie und Life Sciences europaweit für Sie ständig im Blick. Davon profitieren Sie als Leser unserer Zeitschriften und Bücher, als Gäste unserer Tagungen und Kongresse, als Besucher vieler verschiedener Online-plattformen wie etwa biotechnologie.de, als Kunden unserer erfahrenen Beraterteams, als Nutzer unserer Studien und Umfragen, als Zuschauer von Videomagazinen wie biotechnologie.tv, als Auftraggeber vielfältigster Kommunikationsdienstleistungen rund um die Biotechnologie. In den vergangenen 24 Jahren wurden wir so zum führenden Fachinformationsunter- nehmen für Bioökonomie und Life Sciences in Europa. Was können wir für Sie tun?

BIOCOM AG | Stralsunder Str. 58–59 | 13355 Berlin | Germanywww.biocom.de | [email protected]. +49 (0)30/264921-0 | Fax +49 (0)30/264921-11

A4_Eigenanzeige_Erdmann.indd 1 06.04.2010 11:49:02 Uhr

Profiles

Profiles

metanomics GmbH + metanomics Health GmbH 42

Epigenomics AG 43

caprotec bioanalytics GmbH 43

Silence Therapeutics AG 44

ORGANOBALANCE GmbH 45

BST 45

B·R·A·H·M·S AG 46

LGC Genomics 47

PAREXEL International GmbH 47

RiNA GmbH 48

BLS Preclinical Services 49

analyze & realize ag 49

Analytisches Zentrum Biopharm GmbH Berlin (AZB) 50

Biochrom AG 51

ProteaImmun GmbH 51

provitro GmbH 52

NOXXON Pharma AG 53

Glycotope GmbH 53

Evestra GmbH 54

BIOTECON Diagnostics GmbH 54

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 042

metanomics GmbH + metanomics Health GmbH

Metabolite Profiling for plant biotech-nology, drug development and diag-nosticsMetabolite profiling – or metabolo-

mics - is the parallel measurement of

several hundred up to thousands of

known and unknown endogeneous and

xenobiotic metabolites in a given sam-

ple from plants, microbes, animals or

humans. This unbiased approach allows

the observation of whole systems and

is being employed in a wide range of

applications spanning the entire spec-

trum of biology. Whilst being highly

complex and representing a large range

of different chemistries, the metabo-

lome comprises molecules which are

indicative of the genetic or physiological

status of an organism. The metabolome

reflects the entirety of internal or exter-

nal influences on an organism or tissue

– including environment, behaviour,

chemical treatment and disease. Profil-

ing metabolites is not a new concept –

metabolites have been used as valuable

indices of phenotypes for many decades

– but the improved analytical and

informatics technologies exponentially

increased the power of the approach in

the last years.

metanomics Gmbh Founded in 1998 metanomics has

established the worldwide leading

Metabolite Profiling platform based on

mass spectrometry technologies and

informatics. Being part of the interna-

tional BASF Plant Science research plat-

form metanomics has analyzed more

than 2 million metabolite profiles over

the last years looking at more than

55,000 gene functions. This led to the

worldwide largest gene-function data-

base for plant biotechnology. With this

multi-year experience and knowledge

metanomics has advanced metabo-

lite profiling at an unparalleled scale,

metabolite range and quality of results.

metanomics supports highly successfully

a broad range of applications. With >75

mass spectrometry instruments (GC-MS,

LC-MS/MS and more) metanomics has

the worldwide leading metabolite pro-

filing platform.

metanomics health Gmbhmetanomics Health, founded in 2003,

uses the technology platform and exper-

tise of metanomics for the identification

and interpretation of metabolite bio-

markers for drug efficacy, toxicity, dis-

ease or physiological status. The metab-

olites measured by metanomics Health

include a wide range of known sub-

stances like amino acids, organic acids,

fatty acids, lipids, sugars, hormones etc.

and a multitude of known-unknown

metabolites whose structure can be

identified if they appear as important

biomarker candidates. Metabolite Pro-

filing can be applied for a wide range

of sample types like plasma, urine, CSF,

tissues and many more. metanomics

Health applies statistics to identify spe-

cific changes of single or complex com-

binations of metabolites which correlate

with disease, drug treatment or other

influences.

metanomics Health cooperates with

companies from the diagnostics, phar-

ma and life science industry to support

their product development and further

conducts own and collaborative projects

with leading clinics and academic insti-

tutes to discover, develop and validate

disease biomarkers in a range of indica-

tions.

Addressmetanomics GmbH

Tegeler Weg 33

10589 Berlin · Germany

[email protected]

www.metanomics.de

Phone +49 30 34807100

ContactDr. Arno Krotzky

Managing Director

[email protected]

Phone +49 30 34807 101

Fax +49 30 34807 301

Addressmetanomics Health GmbH

Tegeler Weg 33


[email protected]

www.metanomics-health.de

Phone +49 30 34807400

ContactDr. Tim Boelke

Managing Director

[email protected]

Phone +49 30 34807 400

Fax +49 30 34807 401

B i o T O P i c s 4 0 _ B i o T O P R e p o r t 2 0 1 0 43

caprotec bioanalytics GmbH

caprotec bioanalytics GmbH has devel-

oped a ground-breaking, proprietary

tech nology to reduce the complexity of

protein mixtures and samples in a tar-

geted and directed manner.

Founded in 2006 by scientist and entre-

preneur Prof. Dr. Hubert Köster, founder of

Sequenom Inc. and Biosyntec, caprotec

raised approx. 9 million $ in 2007 and

is operational in Berlin Adlershof since

the beginning of 2008 and currently has

24 employees.

caprotec’s Capture Compound Mass Spec -

trometry (CCMS) Technology is based on

multifunctional small molecules that are

used to target, capture, and isolate pro-

teins based on their functionality. The

company is commercializing the CCMS

technology as kits for research applica-

tions and in the form of collaborations

for drug development.

In collaborations for drug development

caprotec is using small molecule drugs

or drug candidates to establish a profile

of proteins that interact with the specific

small molecule. The profile can be used

to elucidate the mode of action of drugs

and drug candidates and also to discover

off-target proteins that are responsible

for unwanted side effects, e.g. liver tox-

icity.

Addresscaprotec bioanalytics GmbH

Volmerstraße 5


ContactDr. Christian Jurinke

Director, Product Management

Phone +49 30 63 92 3992

[email protected]

www.protec.comcaproKit™ for the characterization of staurosporine binding protein kinases

Epigenomics AG

Epigenomics is a molecular diagnostics

company developing products for cancer

based on DNA methylation technology

and biomarkers.

In cooperation with industry partners,

the company develops diagnostic tests

for the early detection, diagnosis, prog-

nosis and diagnostic follow-up of cancer,

products that address an attractive seg-

ment of the molecular diagnostics mar-

ket. Based on easily obtainable patient

samples that do not require invasive pro-

cedures beyond the current clinical rou-

tine, the tests are aimed at finding can-

cer at an early stage before symptoms

occur and at providing additional diag-

nostic information that may help to treat

the cancer with better success. The com-

panys first CE-marked IVD blood test (Epi

proColon) for colorectal cancer early

detection was introduced in late 2009

and is currently being made available in

more and more countries across Europe.

In the pipeline are tests for improved

diagnosis and prognosis assessment in

lung and prostate cancer indications.

Partners in the health care industry and

the biomedical research community can

access Epigenomics’ portfolio of propri-

etary DNA methylation technologies and

biomarkers protected by more than 150

patent families through research products,

biomarker services, IVD development col-

laborations, and licensing. The company

is headquartered in Berlin, Germany, and

has a wholly owned subsidiary in Seattle,

WA, USA. For more information, please

visit Epigenomics’ website.

AddressEpigenomics AG

Kleine Präsidentenstraße 1


Phone +49 30 243450

Fax +49 30 24345555

[email protected]

www.epigenomics.com


Overview of AtuRNAi Programs

Products Indications Partners Research Preclinical Clinical Milestones 2010

RTP801i Macular Edema (AMD/DR) Pfizer/Quark Continue phase II clinical study

AKli-5 Acute Kidney Injury Quark Continue phase I clinical study

QPI-1002 Delayed Graft Function Quark Continue phase I clinical study

Atu027 Solid Tumors Internal Continue phase I clinical study

Atu134 Acute Lung Injury Internal Progress pre-clinical studies

AHLi-11 Acute Hearing Loss Quark Progress pre-clinical studies

Atu111 Solid Tumors Internal Progress pre-clinical studies

Atu150 Solid Tumors Internal Progress pre-clinical studies

5 Programs Mainly Respiratory Astra Zeneca Advance research

SILENCE Therapeutics AG is the leading

RNAi therapeutics company in Europe.

The Company has developed novel, pro-

prietary short interfering RNA (siRNA) molecules called AtuRNAi and a propri-

etary systemic delivery system for siRNA

called AtuPlex. In June 2009 SILENCE

started its first Phase I Clinical Study for

Atu027.

Strong IP PositionSILENCE’s strong IP position is based on

patents issued in the US, Europe and

other territories.

Validating Pharma PartnershipsSILENCE has established validating

partnerships with AstraZeneca ($15m

upfront payment & equity, $400m mile-

stone payments), Pfizer/Quark ($95m

milestone payments) & Dainippon Sum-itomo Pharma (delivery collaboration).

4 Clinical AtuRNAi ProgramsOut of 8 clinical siRNA programs world-

wide as of April 2010 there are 4 clini-cal programs (one in phase II and three

in phase I) with SILENCE’s AtuRNAi mol-

ecules. These are SILENCE’s internal lead

program Atu027 and three clinical study

programs conducted by SILENCE’s part-

ners Pfizer and Quark. This underlines

SILENCE’s leadership in the field of siRNA

therapeutics.

Internal Lead ProgramSILENCE’s internal lead program Atu027

is currently in a Phase I clinical study recruiting patients with advanced gas-

tro-intestinal, lung and other solid

cancer. The Phase I study started in June

2009.

Recent Corporate Highlights p March 30, 2010 Expansion of the siR-

NA Delivery Collaboration with Dai-

nippon Sumitomo Pharma started in

August 2009 in order to examine the

delivery to additional disease targets.

p February 8, 2010 United States Pat-

ent and Trademark Office issues a

Notice of Allowance to SILENCE for

its RNAi patent application covering

PKN-3, a therapeutic oncology target.

PKN-3 is believed to play an impor-

tant role in the growth of cancer cells

and metastasis formation. The claims

cover the siRNA molecule in SILENCE’s

lead chemical compound Atu027,

which targets PKN-3 for the treat-

ment of advanced solid tumors.

p January 5, 2010 Merger with US

based Intradigm Corporation - The

enlarged company now possesses

multiple RNAi discovery, develop-

ment and delivery technologies, an

advancing internal and partnered

product pipeline and a broad portfo-

lio of intellectual property.

p August 27, 2009 SILENCE starts siRNA

delivery collaboration with Japan

based Dainippon Sumitomo Pharma.

The collaboration includes SILENCE’s

AtuPLEX delivery technology.

p June 3, 2009 SILENCE receives approv-

al from German regulatory authority

BfArM to initiate Phase I clinical trials

on Atu027 for treatment of patients

with advanced solid cancer.

p January 8, 2009 Quark Pharmaceu-

ticals announces further Phase I/II

clinical trials for QPI-1002 (preven-

tion of delayed graft function), a

drug based on SILENCE’s proprietary

chemistry AtuRNAi.

p January 7, 2009 European Patent

Office (EPO) grants patent to SILENCE

that covers the company’s lead

product candidate Atu027. The pat-

ent covers the use of protein Kinase

N3 (PKN-3) gene for drug-screening,

diagnostic and therapeutic purposes.

SILENCE Therapeutics AG, Berlin, is listed

through its holding company SILENCE

Therapeutics plc, London, at the Alter-

native Investments Market (AIM) of the

London Stock Exchange.

Silence Therapeutics AG

AddressSilence Therapeutics AG

Robert-Rössle-Straße 10


ContactThomas Christély

Chief Executive Officer

Dr. Klaus Giese

Chief Scientific Officer

Yme Alkema

Director Business Development

Phone +49 30 9489 2800

Fax +49 30 9489 2801

www.silence-therapeutics.de

[email protected]

mailto:[email protected]


ORGANOBALANCE GmbH

In harmony with Nature ORGANOBALANCE GmbH is a company

specializing in microbial strain develop-

ment and microbiological screening.

ORGANOBALANCE taps into the potential

of beneficial microorganisms, known as

specific probiotic cultures, to compen-

sate imbalances in the microflora on a

natural basis and restore the microbial

equilibrium.

In close cooperation with leading indus-

try partners ORGANOBALANCE develops

new biological products in the areas of

nutrition, cosmetics and preventive health

care. In its development activities, the

company draws on its own collection of

microorganism strains suitable for food

applications and its OASSYS® screening

systems.

Using innovative screening technologies

and individually configured test designs,

those strains of microorganisms are fil-

tered that match application-specific

criteria. For suitable strains, fermentation

and downstream processes are devel-

oped in a pilot scale production facility.

In a long-term partnership with leading

international companies ORGANOBALANCE

developed marketable strains of probiotic

cultures that combat tooth decay, body

odour and skin irritation on a natural

basis.

ORGANOBALANCE has a comprehen sive

knowledge and experience in the field

of industrial biotechnology and devel-

ops strains by means of metabolic engi-

neering.

AddressORGANOBALANCE GmbH

Gustav-Meyer-Allee 25


ContactDr. Christine Lang · CEO

Phone +49 30 46307200

Fax +49 30 46307210

[email protected]

www.organobalance.com

BST

The new generation of glucose measure-ment – BST’s contribution for optimal medical diagnostics and therapy!BST’s history dates back to 1975 when a

biosensor research group started at the

Berlin Academy of Sciences. Already in

1982 the first European glucose analyzer

based on a glucose biosensor could be

launched. Today, BST is the market leader

in multi-way biosensors in Europe

and an international operating com-

pany. Our competence is the develop-

ment, production and distribution of

multi-way biosensors, instruments

based on these multi-way biosensors

and all related consumables. Based

on the competence in development

and production of multi-way biosen-

sors BST is working continuously for the

improvement of quality in diagnostics of

metabolism in clinical laboratories and

the POCT area. Our latest products, the

instruments GLUKOMETERPRO and LACPRO,

bring our lab quality from the clini-

cal laboratory into the POCT area caus-

ing measuring results of lab quality at

the bedside. BST’s latest development

for the application in laboratories is the

LABTREND – a flexible and economical

analyzer for the determination of glu-

cose or lactate concentrations. For more

information, please visit our website at

www.bst-biosensor.de.

Address BST Bio Sensor Technology GmbH

Buchholzer Str. 55-61


ContactDr. Dorothea Zahn

Phone +49 30 76767310

Fax +49 30 767673128

[email protected]

www.bst-biosensor.de


B·R·A·H·M·S AG

B·R·A·H·M·S is a global biotechnology

company that develops and markets its

patent-protected diagnostic biomarkers

worldwide to hospitals, laboratories and

licensees. The company is headquar-

tered near Berlin, Germany with wholly

owned subsidiaries in USA, France, Italy,

Austria, UK and Spain as well as distri-

bution networks in over 65 countries.

Since October 2009 B·R·A·H·M·S is part

of Thermo Fisher Scientific Inc., the

world leader in serving science.

B·R·A·H·M·S Diagnostic Biomarkers

deliver essential information to effec-

tively organize diagnostic processes as

well as medical treatment strategies

through simple blood tests. In the fields

of Thyroid Diseases, Infections, Cardio-

vascular Diseases, Tumor Markers, Pre-

natal Screening and several other indi-

cations B·R·A·H·M·S Diagnostic Biomark-

ers offer solutions meeting unmet diag-

nostic needs in Intensive Care Units (ICU)

and Emergency Departments (ED). These

patent protected biomarker test proce-

dures are available as manual assays,

fully automated laboratory test systems

or in a Point of Care format. B·R·A·H·M·S

Diagnostic Biomarkers benefit patients,

doctors and health care economy.

B·R·A·H·M·S’ key product PCT (Procalci-

tonin) is a test for the early detection of

severe bacterial infections like the sep-

sis. It enables ICU physicians to deter-

mine whether an infection is bacterial

or viral in nature and provide action-

able information on the severity of a

patient‘s condition less than an hour

after a blood sample is drawn.

Another product, the novel cardiac

marker Copeptin, allows in combination

with Troponin a rapid and reliable rule

out of Acute Myocardial Infarction (AMI)

right at the initial blood draw when the

patient presents to the ED. By testing for

both markers, along with an Electro-

cardiogram (ECG) and the clinical find-

ings, approximately two-thirds of the

patients would not need to wait up to

six hours in the ED for the second Tropo-

nin test. This may obviate the need for

prolonged monitoring and serial blood

sampling in the majority of patients.

MR-proANP prooved to be a highly use-

ful marker for diagnosing congestive

heart failure in patients presenting to

the ED with shortness of breath. ANP is a

natriuretic peptide predominantly pro-

duced in the atrium of the heart. It is

involved in natriuresis, diuresis, vasodi-

lation and cardiovascular homeostasis.

The midregional portion of the pro-hor-

mone is termed as MR-proANP.

The cardiac marker MR-proADM shows

promise as a powerful predictor for

future cardiac events in patients with

a history of cardiovascular disease. The

predictive value of MR-proADM is addi-

tive to prognostic information obtained

from existing classical risk models that

include traditional biomarkers such as

BNP and NT-proBNP. Adrenomedullin

(ADM) is a multifunctional peptide syn-

thesized by a variety of tissues including

heart and kidney. It regulates cardiopul-

monary function and vascular tone. MR-

proADM, the stable midregion fragment

of ADM, is more readily measurable than

ADM, yet is secreted in equimolar quan-

tities and therefore provides an accurate

portrait of ADM release.

AddressB·R·A·H·M·S Aktiengesellschaft

Neuendorfstrasse 25

16761 Hennigsdorf · Germany

ContactIngo Buchholzer

Phone +49 3302 883 637

Fax +49 3302 883 635

[email protected]

www.brahms.de

http://www.brahms.de


PAREXEL International GmbH

PAREXEL International is a leading global

biopharmaceutical services organization,

providing a broad range of knowledge-

based contract research, medical commu-

nications and consulting services to the

worldwide pharmaceutical, biotechnology

and medical device industries. Committed

to providing solutions that expedite

time-to-market and peak-market pene-

tration, PAREXEL has developed significant

expertise across the development and

commercialization continuum, from drug

development and regulatory consulting to

clinical pharmacology, clinical trials man-

agement, medical education and reim-

bursement. Perceptive Informatics, Inc., a

subsidiary of PAREXEL, provides advanced

technology solutions, incl. medical imag-

ing, to facilitate the clinical development

process. Headquartered near Boston,

Massachusetts, PAREXEL operates in 71

locations throughout 50 countries around

the world, and has approx. 9,200

employees.

In Berlin, approx. 1,500 employees are

located today. Clients can benefit from

state-of-the-art technologies and equip-

ment provided through PAREXEL’s medical

imaging lab and Early Phase Units, which

provide a safe, high-quality environment

for early phase development activities in

a hospital setting. The PAREXEL Academy

qualifies clinical research associates and

clinical data managers, and offers a

course for a Bachelor of Science degree in

Clinical Research, validated by a British

university. PAREXEL also offers a Master’s

studies program in Clinical Trial Manage-

ment in cooperation with the University

of Applied Sciences in Berlin.

Address

PAREXEL International GmbH

Klinikum Westend, Haus 18

Spandauer Damm 130


Contact

Dr. Ulf Schneider

Managing Director

Corporate Senior Vice President and CAO

Phone +49 30 30685 115

Fax +49 30 30685 7115

[email protected]

www.parexel.com

LGC Genomics

1.4.2010 - AGOWA genomics becomes

LGC Genomics (www.lgcgenomics.com)

LGC Genomics is the division of LGC with

specific expertise in high quality, cut-

ting-edge genomic and related services

and products.

LGC is an international science-based

company and market leader in analyti-

cal, forensic and diagnostic services and

reference standards.

The quality management system is certi-

fied by DIN EN ISO 9001:2000.

AddressLGC Genomics GmbH

Ostendstrasse 25 • TGS Haus 8

12459 Berlin • Germany

Phone +49 30 5403 2200

[email protected]

www.lgcgenomics.com

1. Nucleic acid preparation1.1. Nucleic acid extraction service

» DNA, RNA (manual & automated)

1.2. Automated DNA extraction

» sbeadex® kits

» mag kits

» Magnetic particle manipulators

2. DNA sequencing services » Single read sequencing

» Primer walking projects

» MTP sequencing (96/384 well)

3. Genomic services » Next generation sequencing

(Roche/454 and Illumina GA2)

» Re-sequencing of genes

» Library services

» Cloning and sequencing

» Identification of microorganisms

» Genotyping services

» Bioinformatic services

AGOWA genomics becomes

Advancing genomic services and products

Bild BioTopics 2010.indd 1 26.03.2010 09:48:46


RiNA Gmbh was founded 1998 as a

spin-off from the Institute of Biochem-

istry, Free University of Berlin (Profes-

sor Volker A. Erdmann). Together with

an excellent team of scientists, led by

an experienced Senior Executive (Leo

W. Tristram), RiNA successfully provided

major Research & Development in the

fi eld of prokaryotic and eukaryotic pro-

tein expression systems.

Since 2002 RiNA Gmbh is engaged in

the fi eld of biotechnology and has

strengthened its position on the market

in research, product development and

production.

RiNA’s in house activities are focussing

on two major aspects

p Cell-free protein biosynthesisRiNA’s protein biosynthesis group has

reached an internationally competi-

tive standard and RiNA aims to be one

of the world leading companies in the

fi eld of cell-free protein biosynthesis.

The range of kits for cell-free protein

biosynthesis has been broadly expand-

ed. RiNA specifi cally provides

p Highly active cell lysates from bacte-

rial origin suited for the synthesis of

proteins up to milligram range.

p A methodology for the improvement

of protein solubility and functional-

ity.

p Eukaryotic systems with the ability to

glycosylate proteins and to synthe-

size functional membrane proteins.

p Kits for the rapid generation of linear

DNA templates with options to intro-

duce functional elements e.g. affi n-

ity tags, signal petides.

p A system for the site-specifi c labeling

of proteins, e.g. biotin, fl uorescence,

PEG, reactive groups.

p A special format for high throughput

expression in micro titer plates.

p An effi cient system for the in vitro

transcription enabling the synthesis

of milligram amounts of RNA.

In addition (September 2009) the com-

plete RTS Protein Expression portfolio of

Roche Applied Science was transferred

to RiNA GmbH. These RTS products are

now produced at the same quality stan-

dards originally defi ned by ROCHE.

A dedicated specifi c Customer Service for cell-free biosynthesis provides an

additional chance for RiNAs customers

to receive their desired (highly sophis-

ticated) protein utilizing RiNAs total

expertise.

p Functional RNA moleculesIn this fi eld of nucleic acid, RiNA

develops customized nucleic acids

molecules as tools for environmen-

tal analysis as well as for diagnos-

tic and therapeutic approaches. The

functional RNA group is expanding

its expertise in developing aptamers

(RNA/DNA), which have the property

to bind target molecules with high

affi nity and specifi city.

Recently, RiNA has developed a semi-

automated selection procedure for a fast,

reproducible, and parallelized aptamer

generation by using a robotic worksta-

tion. This process will relieve the devel-

opment of aptamers and new aptamer

applications, e.g. aptamer biosensors.

Additionally, RiNA offers a customized

service for generation of aptamers and

is engaged in several research coopera-

tion projects.

RiNA GmbH

AddressRiNA GmbH

Takustrasse 3


ContactLeo W. Tristram

Phone +49 30 8441660

Mobile +49 172 4360436

[email protected]

www.rina-gmbh.de

Target Customer

Characterizationof Aptamers

Productionand Delivery

Aptamer Cloning andSequence Analysis

In vitro selection

Aptamer

Phase 1

Phase 2

Phase 3

Phase 4

The customized aptamer generation service of RiNA con-sists of four phases for a maximum control of the project.

CustomizedSystems

ProteinExpression

Service

Kits ContractResearch

Individual ProteinRequirements

RiNA provides high quality proteins in accordance to the Customers individual requirements.


analyze & realize ag, located in Berlin,

Germany, is a leading contract research

organization serving the biotech, phar-

maceutical and food industries. Over

35 highly skilled and experienced pro-

fessionals in the fields of food science,

nutrition, bio-chemistry, pharmacology,

medicine and marketing will focus on

exceeding your expectations.

analyze & realize ag is your preferred

partner when it comes to demonstrating

the functionality of your product. Being

an audited CRO, and a member of the

German Association for medical CROs,

we have conducted over 190 clinical tri-

als on functional foods, herbal products,

and dietary supplements.

Take advantage of our in-house study

center with 5 physicians, a network of

over 50 experienced, specialized prac-

titioners and benefit from our strategic

alliances with the Charité hospital in

Berlin, Germany. Our expertise in food

regulations will help you to take advan-

tage of the different regulatory aspects

such as the Novel Food and Health Claim

authorization procedures.

We are always on top of the constantly

changing regulatory landscape of the

European market. Our value added ser-

vices include: regulatory consulting, gap

analysis, dossier preparation, dossier

evaluation and dossier submission.

Addressanalyze & realize ag

Waldseeweg 6


ContactMichael Faber

Head of Business Development

Phone +49 4000 8126

[email protected]

www.analyze-realize.com

analyze & realize ag

BLS Preclinical Services

BLS Preclinical Services is a contract

research organization (CRO) located in

Berlin. BLS provides a range of high-

quality and integrated preclinical ser-

vices in animal models. Through our

highly skilled scientific partners we pro-

vide a “one-stop” service and tailored solution. We take the time to under-

stand your business needs and provide

comprehensive tailored solutions either

in-house or in co-operation of our net-

work. We are backed by a highly skilled

scientific team with a wealth of expe-

rience in all disciplines of preclinical

development.

We offer Medical Device Companies fol-

lowing preclinical studies in small and

large animals:

p Proof of concept

p Medical device biocompatibility

testing

p Medical Device acute/chronic testing

p Medical device function testing

p Physicians hands-on training

We provide Pharmaceutical Companies following services in animal models:

p ADME

p Efficacy

p Pharmacokinetic (PK)

p Pharmacodynamic (PD)

p Toxicology (acute and chronic)

p Behavior research

We work closely with our clients to pro-

vide tailored solutions to their preclini-

cal needs.

AddressBLS Preclinical Services

P.O. Box 191913


ContactChristian Lange

Phone: +49 30 3230 4296

[email protected]

www.bls-germany.com


http://www.analyze-realize.com


http://www.bls-germany.com


Analytisches Zentrum Biopharm GmbH Berlin (AZB)

AZB is a German GLP-certified contract

research organization with long experi-

ence in bioanalytical and pharmaceuti-

cal analysis for human and veterinary

medication. As a service-provider, the

company offers solutions for pharma-

ceutical analysis and bioanalysis for

active pharmaceutical ingredients (API)

in the dosage form, analytics for batch

release, quantitative determination of

analytes in biological matrices and the

determination of physicochemical

parameters of intermediates of the

chemical industry in agreement with

the OECD guidelines.

Pharmaceutical stability studies on

medicinal products and APIs are

achieved according to ICH and in com-

pliance with GMP. AZB has expert knowl-

edge in analysing human pharmaceuti-

cals (solid and semisolid oral dosage

forms, liquids, suppositories), veterinary

pharmaceuticals (powders, solid dosage

forms) and API which are subject to the

Addictive Drugs Act. The equipment and

know-how for analysing cytostatika is

available. The company provides e.g.

the development and validation of

methods indicating stability of content

and purity and the deposition of test

samples under ICH conditions as a ser-

vice for their customers. Analysis is car-

ried out according to the clients test

protocols or to the company-owned test

protocols. Deposition, control of storage

conditions and analysis are organized

and documented in compliance with

GMP. All excel sheets used for calculation

are validated in agreement with the SOP

system and GAMP5.

For bioanalytical studies for human and veterinary pharmaceuticals, a large

pool of validated methods is available

for both the determination of APIs in

plasma and urine and in edible tissues

and milk of farm animals. Quantitative

determination of analytes in plasma of

farm animals and also quantitative

determination in medicated feed or

milk replacers, also in the context of

proof of stability, are likewise possible.

All methods are validated according to

relevant guidelines, e.g. the Guidance

for Industry: Bioanalytical method vali-

dation. The procedures are continuously

developed. Thus, AZB has already short-

ened the time of analysis in some

methods by using short HPLC columns

with constant precision and accuracy.

Analytical techniques available for

assays are HLPC with UV, fluorimetric and

electrochemical detection, LC/MS, LC/MS-

MS and GC/MS.

AZB carries out the determination of physicochemical properties under GLP

in accordance with OECD guidelines.

Quality assurance AZB has an independent quality assur-

ance unit under GLP guidelines that

keeps a high quality standard up-to-

date. All equipment used is qualified

and is subject to the lifetime model. The

quality assurance system is officially

certified (test category 1 and 8) and has

been confirmed by numerous audits.

Address Analytisches Zentrum Biopharm GmbH

Bitterfelder Strasse 19


Contact Dr. rer. nat. Ulrich Kunter

Head of the test facility

Phone +49 30 93652140

Fax +49 30 93652220

[email protected]

www.az-biopharm.de


http://www.analytisches-zentrum-biopharm.de


Biochrom AG

Biochrom AG is a company dedicated to be a primary supplier of cell culture media and quality animal sera. The company manufactures and distrib-

utes the full range of products related to

mammalian cell culturing technique:

standard cell culture media, complete

media tailored for particular cell types

and cell lines, custom formulations, and

animal sera, such as Fetal Bovine Serum

(FBS). All sera are prescreened prior to

acceptance; only those lots that meet

strict quality control requirements are

accepted for further processing and sub-

sequent sale to customers. Serum prod-

ucts are tested for sterility, adventi tious

viral agents, physico-chemical parame-

ters, and biological performance. The

manufacturing processes are de signed

for the specific needs of customers

engaged in biotechnological research,

development, and biopharmaceutical

production. Biochrom AG specializes in

meeting customers‘ specifications and

regulatory concerns, to facilitate the

manufacture of custom media consistent

with Good Manufacturing Practice (GMP).

The media are produced in a strictly con-

trolled environment; chemicals used

conform, where applicable, to grade

standards of European Pharmacopoeia

and US Pharma copoeia. Biochrom AG

produces lot sizes of industrial buffers up

to 4,000 litres, powder media up to

20,000 litres and customized sizes in

smallest quantities.

Biochrom AG and TPP Techno Plastic Products AG (Switzerland) are exclusive partners for the sale of TPP products for cell culture and general laboratory equipment in Germany.

AddressBiochrom AG

Leonorenstraße 2-6


Phone +49 30 779 90 60

Fax +49 30 771 00 12

[email protected]

www.biochrom.de

ProteaImmun GmbH

ProteaImmun is a proteomic company

and was founded on September 2009 as

a spin-off of Invitek GmbH and there-

fore has a long expertise in ELISA and

recombinant protein expression, espe-

cially with human proteases, substrates

and analysis of proteins. Our core com-

petence is a broad knowledge in cell

culture, protein purification and devel-

opment of assays. This enables Protea-

Immun to offer customized solutions

and support with single components as

well as with complete molecular diag-

nostic systems. ProteaImmun supports

the integration of new biomarkers for

neurological diseases, bone disorders in

molecular diagnostics and therapy. The

establishment of the interface between

these two areas poses a challenge for

molecular biological research and devel-

opment as well as for the biotechnolog-

ical industry. ProteaImmun emphasizes

on difficult-to-express proteases as

human MMPs (Matrix Metalloprotein-

ases), human ADAMTS (A Disintegrin And

Metalloprotease with Thrombospondin

motifs) and human HtrAs (High temper-

ature requirement factor A), which play

an important role in diseases as cancer,

Alzheimer as well as rheumatic and car-

diovascular diseases.

Address ProteaImmun GmbH

Robert-Roessle Straße 10 / Haus 85


ContactTatiana Teixeira-Schneider

(Sales & Marketing Manager)

Phone +49 30 9489 3170

Fax +49 30 9489 3172

[email protected]

www.proteaimmun.de


Provitro stand for more than a decade of

biotechnological expertise in high-qua-

lity analytical services, tissue microar-

rays, cell cultures, culture media and

cytokines. Based at the Campus Charité

Mitte in Berlin we combine medical

research excellence and profound expe-

rience in biotechnology to create con-

vincing solutions and applications for

life science research and development.

We focus on the interface of R&D provid-

ing our global university and industrial

customers with state-of-the-art prod-

ucts and unique services to match their

individual needs.

Tissue MicroarraysWith more than 200.000 samples provitro

operates a large human tissue bank giv-

ing us the resources to meet nearly every

demand. Our unmatched tissue micro-

arrays with up to 140 individual FFPE

tissue samples on a single slide minimize

variations in staining intensity. Yielding

consistent results they are ideal for mor-

phological evaluation and rapid locali-

zation of DNA or protein molecules in a

variety of human tissue samples.

Analytical ServicesIn addition, provitro has an exceptional

standing in a wide range of flexible ana-

lytical services. Starting with the develop-

ment of protocols for both manual and

automated immunohistochemical stain-

ing and target validation with antibodies

on normal and tumour tissue samples

from our extensive tissue bank right

through to certified in-process quality

control systems (iCon TMA®) to verify the

specificity of antibody reaction.

Primary Cell Cultures and Culture MediaAs a supplier of premium life science

products our strictly controlled primary

cell cultures are isolated from various

tissues of human origin and shipped

with a batch-specific analysis certificate.

The culture media provided as a set of

basal medium and supplements contain

all necessary growth factors specific to

each cell type.

So if you are looking for a reliable part-

ner who is as innovative as your research

project please contact us:

Addressprovitro GmbH

Campus Charité Mitte

Charitéplatz 1

10117 Berlin • Germany

ContactDr. Manrico Paulitschke

Phone +49 30 450578352

Fax +49 30 450578952

[email protected]

provitro GmbH


Glycotope GmbH

Glycotope has developed a unique and

regulatory approved platform technol-

ogy for the development and produc-

tion of NBEs and improved second gen-

eration biopharmaceuticals / BioBetters.

This toolbox of human cell lines allows

the manifold improvement of key clini-

cal properties (such as activity, availabil-

ity, immunogenicity) for both antibodies

and non-Ab proteins via targeted alter-

ation of the glycosylation. With excel-

lent production features, GlycoExpress

is also the base of Glycotope´s pipeline

of currently 4 therapeutic antibodies –

the first of which has entered the clinic

in 2009 with the second to follow in

Q2/2010 – and 1 protein-hormone.

GlycoExpress p Toolbox of glycoengineered human

cell lines

p Fully human & optimized

glycosylation

p Highly improved bioactivity,

bioavailability & immunogenicity

p Screening and high yield production

system

p New patent protection of products

Pipeline of GlycoOptimized Products p Proprietary NBEs & improved second

generation products

p Currently 4 antibodies,

1 protein-hormone

Via Glycotope Biotechnology: p GMP-Production of biologics

p Fill & Finish of API and drug

AddressGlycotope GmbH

Robert-Roessle-Strasse 10


Phone +49 30 94892600

Fax +49 30 94892609

[email protected]

www.glycotope.com

NOXXON Pharma AG

NOXXON Pharma AG is a clinical-stage

private biotechnology company focusing

on the development of its proprietary

substance class Spiegelmers (L-aptamers)

for the treatment of inflammatory dis-

eases and hematological indications.

Spiegelmers are mirror-image oligonu-

cleotides designed to bind and inactivate

proteins that cause disease. The com-

pany currently targets various disease

areas with its proprietary development

programs: diabetes and related compli-

cations with an underlying inflamma-

tory component, such as diabetic

nephropathy; hematopoietic stem cell

mobilization and/or haematological and

solid tumors; and anemia of inflamma-

tion. NOXXON drug candidates NOX-E36

and NOX-A12 were shown to be safe and

well tolerated in phase I clinical trials

and displayed promising pharmacody-

namic effects.

In addition to its in-house programs

NOXXON discovers and develops Spiegel-

mers in collaboration with partners from

the pharmaceutical industry, including

Eli Lilly and Hoffmann La-Roche. The

declared goal of NOXXON is to establish

its oligonucleotide-based drug discov-

ery platform (Spiegelmers®) as the lead-

ing ‘scaffold’ technology to create new

chemical entities with superior properties.

AddressNOXXON Pharma AG

Max-Dohrn-Strasse 8-10


ContactPhone + 49 30 726247100

Fax + 49 30 726247225

[email protected]

www.noxxon.com


BIOTECON Diagnostics GmbH

BIOTECON Diagnostics was founded in

1998 and currently has 45 employees.

The company provides superior experi-

ence in microbiological service testing

of food, pharmaceutical and cosmetics

products.

The company’s focus is the develop-

ment of rapid and innovative detection

systems for pathogenic, spoilage and

genetically modifi ed organisms (GMO)

based on real-time PCR. The foodproof®

product line includes detection kits as

well as sample preparation kits for the

extraction and purifi cation of DNA from

multiple food matrices.

As an international biotechnology com-

pany, BIOTECON Diagnostics has been

developing, producing and marketing

these products through a continually

growing network of local distributors

and worldwide sales channel partners.

Due to close contacts to many compa-

nies in the industry, BIOTECON Diagnos-

tics is well aware of customers’ current

and future challenges. The company

is able to provide fl exible solutions to

production and processing companies

through new and economical approach-

es. Furthermore, BIOTECON Diagnostics

also offers contract development and

production to other biotech companies.

For safer food: BIOTECON Diagnostics – simply builds up trust.

AddressBIOTECON Diagnostics GmbH

Hermannswerder 17

14473 Potsdam · Germany

ContactKornelia Berghof-Jäger, Ph. D.

Chief Executive Offi cer

Alois Schneiderbauer

Chief Business Offi cer

Phone +49 331 2300200

Fax +49 331 2300299

[email protected]

Evestra GmbH

Evestra GmbH, founded in July 2008, is

a fully owned subsidiary of Evestra Inc.,

located in San Antonio Texas. Evestra is

focused on the development of female

healthcare products for gynecologi-

cal indications such as fertility control,

hormone replacement therapy, endo-

metriosis, and breast cancer. Key com-

petency of Evestra is development of

steroid-based products, including sex-

ual hormones. Evestra GmbH serves as

the development and commercialization

center for Europe and ROW.

Near-TermEvestra‘s leading products are generic

and reformulation products based on

leading oral contraception products.

Regulatory submissions for three prod-

ucts are planned between 2011 and

2012.

Longer-TermEstablish proof of concept Phase II data

for NCE’s in fertility control, breast can-

cer and endometriosis. Evestra’s fi rst

innovative product is an oral contra-

ceptive which includes a novel estrogen

with potentially superior pharmacologi-

cal properties.

AddressEvestra GmbH

Grünlingweg 20


EU ContactProf. Klaus Nickisch

Managing Director

Phone +49 30 66509642

[email protected]

www.evestra.com

Caring for Women’s Health®

Phar

maz

ieU

mw

eltt

echn

olog

ie

Career Gateway

Life

Sci

ence

sCh

emie

Bio

tech

nolo

gie

Med

izin

tech

nik

Stuttgart - Düsseldorf - München

Meeting Point

Elektronisches Firmenportal

Stellenmarkt online

www.t5-futures.de

Jahrespublikation mit Branchenberichten

As your integral technology partner we add our global biotechnological/pharmaceutical expertise to your

processes in order to reduce your time to market while assuring the highest quality standard. Our expertise,

the profound knowledge of the needs and particularities in the biotechnological/pharmaceutical industry and

the ambition to provide individually customized solutions, is rooted in our origin as a Bayer company. With this

heritage and our present-day network of multiple locations on all major continents as well as our innovative drive

we are prepared to accompany you on the way to success – Powering Your Performance.

Our most recent technologies for your optimal process include

Bayer Technology Services GmbH51368 Leverkusen, GermanyE-mail: [email protected]

AZ_BTS_ImagePharma_BioTop_UK_A4_030310.indd 1 03.03.2010 18:18:08 Uhr

Addresses

Addresses

Networks 58

Biotech Parks 59

IP Asset Management 59

Universities and Research Centers 59

Banks and VCs 60

Supporting Organisations 60

Pharmaceutical Companies 61

Contract Research Organisations 62

Biotech Companies 63


Networks

BioHyTec – Verein für Bioanalytik und Biohybrid-Technologien e.V.

BioHyTec is the biohybrid technology network in the life sciences cluster of Berlin-Brandenburg. This new field of technology is the interface between biosensor development and microsystems technology. Biohybrid systems open up new applications in pharmaceutical research, clinical diag-nostics, food analysis and genetic engineering.

biohytec.de

BioResponseNetzwerk BioResponse is an interdisciplinary research and development organisation with members from Brandenburg, Berlin and Saxony. It focuses on the development and marketing of multiplex assays for diagnostic antibody identification based on the proprietary BioResponse technology, which is comprised of fully automated image analysis of fluorescence-encoded microparticles and labelled cell structures.

bioresponse.de

DiagnostikNet-BB Netzwerk Diagnostik Berlin-Brandenburg

DiagnostikNet-BB is the Berlin-Brandenburg network for in vitro diagnostics. Members include bio-tech companies as well research institutes and clinics. Main objectives of the network are: Develop-ment of system solutions, optimizing compatibility, close cooperation with leading clinicians and joint marketing.

diagnostiknet-bb.de

GABI – Genomanalyse im Biologischen System Pflanze

GABI stands for Genome Analysis of the Plant Biological System and is an associative project sup-ported by the German Federal Ministry of Education, Research and Technology (BMBF) as well as a number private enterprise companies. These companies are grouped under the Business Platform promoting Plant Genome Research GABI e.V. (WPG). A Patent and Licence Agency associated with GABI (GVS) has the task of commercialising and protecting research results by means of licence rights.

gabi.de

Glykostrukturfabrik The Network Glycobiotechnology Berlin-Brandenburg brings together scientists with many different areas of competence in studying and utilizing complex carbohydrates. The aim is product-oriented development of the region’s wide range of glycobiological technologies, building a complete glyco-biotechnological process chain and to establish the region as a center of competence in the field of glycobiotechnology.

glykostrukturfabrik.de

Health Capital Berlin-Brandenburg In order to develop the scientific and economic position of the region, the governments of the states of Berlin and Brandenburg have put the master plan „Healthregion Berlin Brandenburg“ into effect. Its key to a continued success is a continued close interplay between research, development and education / vocational training with production, application and supply. All of these activities are integrated and coordinated through the Network „Gesundheitswirtschaft Berlin Brandenburg“ under the brand of „HealthCapital“.

healthcapital.de

Net-DDD Network for Drug Discovery & Development Berlin-Brandenburg

The Network for Drug Discovery & Development Berlin-Brandenburg was launched in 2007 as an open interdisciplinary initiative with the aim to accelerate the transfer of clinical relevant find-ings into innovative drugs and therapeutic concepts. The network, which was co-founded by the Leibniz Institut für Molekulare Pharmakologie (FMP) and the competence network biotechnology, BioTOP Berlin-Brandenburg, offers state-of-the-art technology and expertise in the field of drug discovery.

drugdiscoverynet.de

Netzwerk Nutrigenomik Berlin-Brandenburg

Nutrigenomics is a highly innovative and fast-growing interdisciplinary field of research link-ing genome research, plant biotechnology and molecular nutritional research and offering new applications for medicine and nutrition. Nutrigenomics aims at providing an understanding for how nutrition affects the balance between health and disease. Network partners include local universities and research institutes, private enterprises, public-sector organizations and various collaborative project groups.

nutrigenomik.de

Netzwerk Weiße Biotechnologie Berlin-Brandenburg

The White Biotechnology Network serves as an engine for the advancement of the white biotech-nology in the Berlin-Brandenburg region. By combining of a number of competencies, the partners in the network are capable of developing innovative solutions for complex problems in den fields of chemistry, paper, cosmetics, pharmaceuticals and food.

weisse-biotechnologie-bb.de

Regenerative Medicine Initiative Berlin The mission of the RMIB is to promote the Berlin-Brandenburg region as a center of excellence for Regenerative Medicine particularly for cell-based medical biotechnology. The RMIB promotes networking in the field and supports the further development of clinical studies and education programs. The initiative fosters the collaboration between universities, research institutes, compa-nies (including SMEs) and organizations in the field of science and technology.

rmib.de

RiNA -Netzwerk RNA-Technologien The RNA-Network provides ongoing support and funding for the development of RNA technologies with the goal to commercialize the results. One main focus is the improvement and application of the RNA interference technology. Further projects develop RNA aptamers, cell-free protein biosyn-thesis systems and analyse the structure and function of RNA molecules. The RiNA RNA-Network encourages co-operation and information exchange between academy and industry.

rna-network.com

Ultrastrukturnetzwerk The Ultra Structure Network brings together researchers in the field of structural proteomics with the aim of conducting high-throughput analysis of supramolecular structures using mass spectrometry (MS) and cryoelectron microscopy.

ultrastrukturnetzwerk.de

Zentrum für Molekulare Diagnostik und Bioanalytik

The Centre for Molecular Diagnostics and Bioanalytics (ZMDB) is a virtual centre operated under the auspices of the Fraunhofer Institute for Biomedical Technology and the Charité – Universitätsmed-izin Berlin in close cooperation with the region’s company networks. The aim is to bring together regional expertise in basic research, technology development, clinical research and industrial coop-eration initiatives to set up joint projects that will speed up the development of in vitro diagnostics “Made in Berlin-Brandenburg”.

zmdb.de


Biotech Parks

berlinbiotechpark berlinbiotechpark is located on a 86,000 m² site in the very heart of Berlin, currently offering a total of approx. 57,000 m² of office, laboratory and production space, with a building potential for another 45,000 m² of rental area. Offering flexible growth potential, production-orientated media equipment and comprehensive industrial-specific services and infrastructure, berlinbiotechpark is particularly attractive for growing internationally orientated technology companies.

berlinbiotechpark.de

Biotech Campus Potsdam Just a few minutes away from Potsdam’s central railway station in the direction of Caputh, BIOTECH CAMPUS POTSDAM is located on the Hermannswerder peninsula in the river Havel. It is owned and operated by BIOTECH CAMPUS POTSDAM GmbH, a fully owned subsidiary of the Investment Bank of the State of Brandenburg.

biotechcampus.de

BiotechnologieparkLuckenwalde

Located just 30 miles south of Berlin and 25 miles from Berlin-Brandenburg International Airport in the rural district of Teltow-Flaeming, the Biotechnology Park Luckenwalde is one of the most modern facilities of its kind in Germany. It is home to 38 companies with 500 employees from Germany, USA, UK, Korea, India, Italy and Russia.

bio-luck.de

Biotechnologiezentrum Hennigsdorf co:bios Technologiezentrum GmbH

On the northern perimeter of Berlin, a number of biotech and medtech companies have been established at the BiotechnologieZentrum Hennigsdorf around the diagnostics company B.R.A.H.M.S. The BiotechnologieZentrum Hennigsdorf was set up in 2001. It offers full service for small and mid-sized biotech companies.

cobios- technologiezentrum.de

Campus Berlin-Buchbbb Management GmbH

Berlin-Buch is home to one of the largest biotechnology parks in Germany, with 26.000 square meters of scalable lab and office space for start-ups and maturing companies. Situated to the northeast of the city, the campus is currently home to 49 companies, 35 of which are biotech companies; the rest provide support services.

bbb-berlin.de

Adlershof Zentren für Biotechnologie und Umwelt

Berlin Adlershof is one of the most successful high-tech locations in Germany with focus on Photo-nics and optical technologies, material and microsystems technology, information and media tech-nology, biological, environmental and energy technology. There are currently 25 biotech companies in Adlershof occupying 18,200 sq.m of lab and office space.

wista.de

Other Parks

Science Park Potsdam-GolmGO:IN Golm Innovationszentrum GmbH

Science Park Potsdam-Golm is one of the most innovative and promising locations in Branden-burg. In the GO:IN facility, innovative companies will find an excellent working environment where they will benefit from the synergy effects of the location and the specific equipment offered by its laboratories. The location provides a wide range of services and consulting, as well as integration into the existing regional networks.

wissenschaftspark-potsdam.de goin-potsdam.de

Innovationspark WuhlheideManagementgesellschaft mbH

On the 80,000 acre Technology Campus Innovation Park Wuhlheide, small and medium-sized companies will find perfect conditions to pursue their ideas and business goals. The companies working on the Campus come from a variety of disciplines and sectors and are mainly technology-oriented.

ipw-berlin.de

IP Asset Management

Ascenion Ascenion advises public life science research institutions, universities, hospitals, freelance inventors and companies in all aspects of intellectual property asset management.

ascenion.de

ipal GmbH intellectual propertyasset management

ipal assesses and markets the inventions of Berlins university scientists and academics on an exclu-sive basis and is financed by the Berlin universities as well as the Investment Bank Berlin (IBB). Cooperation agreements exist with Charité, RKI, PEI, BAM and other excellent research institutes.

ipal.de

ZukunftsAgentur BrandenburgGmbH Brainshell

Brainshell is an independent consulting agency specializing in intellectual property services for businesses.Brainshell manages and markets the patent portfolios of all colleges, universities, and research institutes in the State of Brandenburg.

brainshell.de

Universities and Research Centers

BAM Federal Institute for Materials Research and Testing bam.de

Berlin-Brandenburg Center for Regenerative Therapies b-crt.de

Berlin Institute of Technology tu-berlin.de

BfR Federale Institute for Risk Assessment bfr.bund.de

Brandenburg University of Technology tu-cottbus.de

Charité - Universitätsmedizin Berlin charite.de

Deutsches Rheuma-Forschungszentrum Berlin drfz.de

Fraunhofer Institute for Applied Polymer Research (IAP) iap.fhg.de


Universities and Research Centers

Fraunhofer Institute for Biomedical Engineering (IBMT) ibmt.fraunhofer.de

Freie Universität Berlin fu-berlin.de

German Heart Instiute Berlin dhzb.de

German Institute of Human Nutrition (DIfE) dife.de

Humboldt-Universität zu Berlin hu-berlin.de

Institute of Polymer Research of the GKSS Research Centre gkss.de

Institute for the Reproduction of Farm Animals Schönow Inc. ifn-schoenow.de

Lausitz University of Applied Sciences fh-lausitz.de

Leibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB) atb-potsdam.de

Leibniz-Institut für Molekulare Pharmakologie (FMP) fmp-berlin.de

Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch mdc-berlin.de

Max Planck Institute for Infection Biology mpiib-berlin.mpg.de

Max Planck Institute for Colloids and Interfaces mpikg-golm.mpg.de

Max Planck Institute for Molecular Genetics molgen.mpg.de

Max Planck Institute of Molecular Plant Physiology mpimp-golm.mpg.de

Robert Koch Institute (RKI) rki.de

University of Applied Sciences Berlin beuthhochschule.de

University of Applied Sciences Wildau th-wildau.de

University of Potsdam uni-potsdam.de

Banks and VCs

BC Brandenburg Capital GmbH bc-capital.de

Berliner Sparkasse-Kompetenzzentrum Gründungen und Unternehmensnachfolge lbb.de

Berliner Volksbank eG berliner-volksbank.de

bmp Life Science AG bmp.com

Business Angels Club Berlin e.V. business-angels-berlin.de

CCM Columbus Capital Management columbusco.com

Commerzbank AG commerzbank.com

Creathor Venture creathor.de

Deutsche Bank AG db.com

High-Tech Gründerfonds Management GmbH high-tech-gruenderfonds.de

IBB Beteiligungsgesellschaft mbH ibb-bet.de

Investitionsbank Berlin ibb.de

Investitionsbank des Landes Brandenburg ilb.de

KfW-Mittelstandsbank kfw-mittelstandsbank.de

Peppermint Financial Partners GmbH PEPPERMINT-vc.de

Triginta Capital triginta-capital.com/life-science.htm

Supporting Organisations

Berlin Partner GmbH Support of international and domestic companies in all issues regarding locating to Berlin berlin-partner.de


Supporting Organisations

BioTOP Berlin-Brandenburg BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning biotechnology in the German capital region.

biotop.de

Investitionsbank Berlin (IBB) Company financing and consultation on subsidies and processing grant applications in Berlin. ibb.de

Investitionsbank des Landes Brandenburg

Company financing and consultation on subsidies and processing grant applications in Branden-burg.

ilb.de

Landesamt für Gesundheit und Soziales Berlin (LAGeSo)

One Stop Agency for all licensing and approvals, for questions concerning biomedicine, biotechnol-ogy and pharmaceuticals and for more general issues connected with health, disease control and public health in Berlin

berlin.lageso.de

TCC Technologie Coaching Center Specific Coaching offers for innovative high tech companies tcc-berlin.de

Technologie Stiftung Brandenburg The technology Foundation Brandenburg is dedicated to the advancement of science and research, especially in the field of innovative technologies.

ts-bb.de

TSB Technologiestiftung Berlin Gruppe The TSB Technology Foundation Berlin Group is a public private partnership in the German capital region to develop science and industry networks for technology transfer, joint projects, and regional innovation strategies.

tsb-berlin.de

TSB Innovationsagentur Berlin GmbH The TSB Innovation agency supports small and medium-sized companies in the management of innovation processes.

tsb-berlin.de

ZAB Zukunftsagentur Brandenburg The Brandenburg Economic Development Board functions as a one-stop agency for all kinds of business support services.

zab-brandenburg.de

ZAK Zentrale Anlauf- und Koordinie-rungsstelle Senatsverwaltung für Wirtschaft, Arbeit und Frauen

Helps you find your way through the Berlin administration. Supports complex urban development policy and investment projects.

berlin.de/sen/wirtschaft/zak/wir

Pharmaceutical Companies

Bausch & Lomb Dr Mann Pharma Bausch & Lomb is the eye health company dedicated to perfecting vision and enhancing life for consumers around the world. Core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products.

bausch-lomb.de

Bayer Schering Pharma Aktiengesellschaft

Bayer Schering Pharma is one of the ten largest specialty pharmaceutical companies in the world and the company‘s goal is a leading market position in each of its specialist fields. With its distinc-tive expertise in research, the company develops new medicines and therapies which make an essential contribution toward improving patient‘s quality of life

bayerscheringpharma.de

BERLIN-CHEMIE Aktiengesellschaft BERLIN-CHEMIE is a German subsidiary of the MENARINI Group. The company, which was formed in 1886 and is headquartered in Florence, was developed over the generations to become a global, owner-managed pharmaceutical company. Research is centred on the development of innovative drugs for the following areas: inflammatory diseases and pain, cardiovascular diseases, oncology, viral disease.

berlin-chemie.de

CT Arzneimittel GmbH CT Arzneimittel is a pharmaceuticals company that focuses on generics production. Prescription medicines form the bulk of the product portfolio, which includes some 1,200 drugs with more than 200 different active agents that are used to treat the most common clinical syndromes.

ct-arzneimittel.de

Dr. Kade Pharmazeutische Fabrik GmbH The company’s activities concentrate on the production and marketing of drugs in the fields of gynecology, proctology, pain relief/ rheumatism and urology. The potential of proven drugs is expanded systematically by galenic developments to produce innovative products.

kade.de

Heyl chemisch pharmazeutische Fabrik GmbH & Co. KG

HEYL is an independent, entrepreneurial family business that has its headquarters in Berlin, since its establishment in 1926. In cooperation with its international subsidiaries, the main focuses of the work are the Regulatory Affairs and marketing of medicines as well as the sale of active phar-maceutical ingredients (API‘s) and special chemicals.

heyl-berlin.de

Intendis GmbH Intendis is a specialized pharmaceutical company focused on the Dermatologicals category. Headquartered in Berlin, Germany the company was founded in 2005 as a subsidiary of Schering AG. Intendis has a successful track record of providing prescription drug products for the treatment of severe skin diseases and was a pioneer in the development of locally applicable corticosteroid treatments.

intendis.com

Klosterfrau Berlin GmbH For more than 175 years Klosterfrau has been developing, manufacturing and marketing pharma-ceutical products. The profile of traditional yet modern natural medicines has grown significantly in recent times. Based on the latest scientific discoveries combined with the development of new markets, the range is constantly being expanded with innovative products.

klosterfrau.de

medphano Arzneimittel GmbH medphano Arzneimittel in Rüdersdorf stands for proven and cost-effective pharmaceutical prepa-rations. The main products are analgesics/anti-rheumatics, antibiotics, dermatics, diuretics, drugs to stimulate blood circulation, drugs for treatment of gastro-intestinal disorders, vitamins, expec-torants, lipid-lowering agents, ophthalmics, cosmetics, food supplements, diet foods and foods.

medphano.de

MUCOS Pharma GmbH & Co.KG As a specialist in enzyme preparations Mucos supplies a steadily growing market with specific and variably dosed enzyme combinations. The company leads the world market in oral enzymes for therapeutic purposes.

mucos.de


Pharmaceutical Companies

Nycomed Oranienburg GmbH As the competence centre for the development, production and packaging of solid dosage formula-tions Nycomed Oranienburg plays an important part in the global Nycomed operations network. It supplies the global pharmaceutical markets in more than 100 countries, from Europe to the US and Japan. The products include corporate Nycomed products and contract manufacturing for third parties.

nycomed.de

Pfizer GmbH Pfizer is the world‘s largest research-based biomedical and pharmaceutical company. pfizer.de

Sanofi-Aventis Deutschland GmbH Sanofi-aventis is a leading global pharmaceutical company based in Paris and operating in over 100 countries. R&D teams work on a global approach to patients, offering innovative therapeutic strategies in thrombosis, cardiovascular diseases, diabetes, vaccines, oncology, the central nervous system disorders and internal medicine.

sanofi-aventis.de

Shire Deutschland GmbH Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder, human genetic therapies and gastrointestinal diseases.

shire.com

Steiner & Co. Deutsche Arzneimittelge-sellschaft mbH & Co. KG

Production and marketing of pharmacy and prescription drugs, particularly plant-based drugs (tranquillizers, rheumatism drugs, bile duct and gastro-intestinal as well as gynecological and urological drugs), analgesics and mineral preparations.

steinerarznei-berlin.de

Steripharm Pharmazeutische Produkte GmbH & Co. KG

Production and marketing of folic acid products steripharm.de

Contract Manufacturers

Advance Pharma GmbH Contract manufacturer of solid drugs.Galenic development and admissions, analytics and microbi-ology, coating and granulation (organic and aqueous), compacting, packaging.

advance-pharma.eu

ALPHAMADE GmbH Customized formulations as medications: parenteral feeding, intradialytic parenteral feeding, omega-3 fatty acids, cytostatics

alphamade.de

Chemisch-pharmazeutisches Labor, Rolf Sachse GmbH

CPL SACHSE offers: Custom synthesis development of active pharmaceutical ingredients (API’s); Con-tract manufacture of active pharmaceutical ingredients from laboratory to kiloscale; Pharmaceutical analysis

cpl-sachse.de

Gelkaps GmbH Contract manufacturer focussing on the development and production of soft gelatine capsules under GMP conditions. The product portfolio ranges from food supplements to dietary products and pharmaceuticals.

gelkaps.de

Haupt Pharma AG With nine production sites Haupt Pharma is one of the leading contract manufacturers for pharma-ceutical products in the world today. About 2.000 employees produce for an established clientele of more than 200 important international pharmaceutical companies, amongst which 15 of the international TOP 25.

haupt-pharma.de

Pharma Action Pharma Action has extensive expertise in global pharmaceutical marketing and manufacturing since 1988 and offers cutting edge API solutions to the pharmaceutical industry in Europe and abroad.

Pharma-action.com

Spreewälder Arzneimittel GmbH Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food supplements, diet foods and cosmetics in liquid, semi-solid and solid administration forms.

spreewaelder- arzneimittel.de

Contract Research Organisations

Assign International GmbH Assign International in Berlin is part of the Assign Group, a mid-sized full-service CRO with six offices in five countries.Our expertise meets development requirements of pharmaceutical and biotechnological industries. We manage clinical trials from study set-up to final clinical report.Our services, among others, comprise Data Management and Biostatistics, integrated EDC-Systems, Pharmacovigilance, Protocol Writing, Laboratory Services and Quality Management.

assigngroup.com

BLS Preclinical Services BLS Preclinical Services is a contract research organization (CRO) located in Berlin. BLS provides a range of highquality and integrated preclinical services in animal models. Through our highly skilled scientific partners we provide a “one-stop” service and tailored solution. We take the time to understand your business needs and provide comprehensive tailored solutions either in-house or in co-operation of our network. We are backed by a highly skilled scientific team with a wealth of experience in all disciplines of preclinical development.

bls-germany.com

Charité Research Organisation GmbH Based in Berlin, the Charité Research Organisation (CRO) was founded in collaboration with Berlin‘s famous Charité University Hospital. This relationship fosters a level of cooperation with centers of clinical excellence that we think is unique in the industry. The CRO offers a whole new approach to the concept of partnering with centers of clinical excellence to facilitate access to patients, clinical expertise and specialist methodologies in support of early clinical development programs.

charite-research.org

Cooperative Clinical Drug Research and Development (CCDRD) AG

CCDRD is an independent contract research organization (CRO). CCRDR is dedicated to offer creative and innoative full service from planning to market authorization to its customers in the pharma-ceutical, biotechnological and medical device industry.

ccdrdag.com


Contract Research Organisations

CSG Clinische Studien Gesellschaft mbH Since its foundation in 1998, the CSG Clinische Studien Gesellschaft mbH has focussed on aligning clinical research with public health demands, with special attention to facilitating access by physi-cians and patients to clinical studies.CSG cooperates closely with the largest research institute for public health in Germany, the IGES Institut.

csg-germany.com

Dr. Notghi Contract Research Dr. Notghi Contract Research GmbH is a service provider for large, medium and small-sized compa-nies in the pharmaceutical, generics and biotechnology industries. We support and advise you in the conduct and management of national and international projects.

notghi.com

Klinische Forschung Berlin GbR Klinische Forschung Berlin is a study centre that implements clinical studies from phases IIA to IV for the pharmaceuticals industry.

klinische-forschung- berlin.de

Klinische Forschung Gruppe Nord GmbH

The Klinische Forschung Gruppe Nord (Clinical Research Group North) is a network of independent investigator institutes with five centres in Northern Germany, two of them in Berlin.The Klinische Forschung Gruppe Nord has carried out trials with up to 250 patients. Phase II and III studies are the core competence. The test centres have altogether 30 overnight accommodation places for phase I and IIa studies.

kfgn.de

PAREXEL International GmbH The German subsidiary of the US clinical research organization PAREXEL employs more than 1,400 people in Berlin. In two units with a 160-bed capacity (incl. 8 sleep lab beds) and an annual enrollment of approximately 2,500 volunteers in Berlin, more than 75 clinical studies are per-formed each year.

parexel.com

Biotech Companies

3B Pharmaceuticals GmbH 3B Pharmaceuticals GmbH (3BP) is a privately held pharmaceutical R&D company based in Berlin, Germany. The company is dedicated to the development of peptide-based pharmaceutical- and diagnostic products. 3BP is pursuing projects in hemophilia and nuclear medicine.

3b-pharma.com

8sens.biognostic GmbH 8sens.biognostic develops, produces and sells rapid tests (lateral-flow) and ELISAs for different markets (human and veterinary diagnostics, food control). Our products are the QuickSens®-tests for h-FABP, TropI, CRP and hs-CRP and the Reader for quantification QuickSens®OMEGA. Develop-ment-on-demand, feasibility studies and production-on-demand are also offered.

biognostic.de

ABiTEP GmbH The ABiTEP GmbH is working in development and production of biotechnological products for sustainable agriculture. The team of ABiTEP works for development of non GMO customer specific technologies in laboratory scale and scale up with modern equipment and Know how. Capacities for fermentation up to 5.000 L, down stream equipment as well as freeze drier with capacity of 90 L are available for services.

abitep.de

AFOSA GmbH Development, production and marketing of diagnostics (ELISA kits), primarily for use in veterinary medicine

afosa.com

Aglycon Mycoton GmbH Aglycon Mycoton GmbH is active in the research, development and application of biopolymers as well and their manufacture and the sales and marketing of products based on these.

aglycon-mycoton.net

AJ Innuscreen GmbH AJ Innuscreen GmbH, a young life science company, boosts the bio solutions business unit as part of the Analytik Jena Group. Innovative technologies and products are developed and produced for the isolation and purification of nucleic acids. Reagent systems for molecular biology, as well as technologies and products for molecular diagnostics, are also included in the product portfolio.

innuscreen.com

Alcat Europe GmbH Alcat Europe GmbH is the daughter of the US company Cell Science Systems, the original developer of the Alcat test technology. The company is specialized to identify intolerant reactions of the leucocytes to foreign substances like foods, drugs or chemicals.

alcat-europe.com

Alrise Biosystems GmbH ALRISE is a drug delivery company that specializes in the nano- and micro-encapsulation of active ingredients. Using its globally patented ImSus® technology, ALRISE are developing parenteral deposit pharmaceutical forms for proteins, peptides or small molecules. Customers are mainly large pharmaceutical companies who are developing improved administration forms for active ingredients whose patents are expiring together with ALRISE as part of their "Product Lifecycle Management".

alrise.de

Amocol Bioprocedures Ltd. Amocol Bioprocedures Ltd is a Life Science Research & Development and Manufacturing Company headquartered in Germany. Our mission is to supply innovative affinity chromatography media products and protein purification tools for research scientists and clinical customers in public sector institutes and industry.

amocol.com

Anagnostec GmbH AnagnosTec GmbH develops and sells products and services based on MALDI-TOF mass spectrometry. p SARAMIS Software and Database for Identification of Microorganisms p Development of mass spectrometry analyses of complex biological materials p Natural product screening, polymer analy-sis and peptide analysis p Mass-spectrometric quality control of single and multi-step organic p Development of intelligent software solutions to handle and interpret mass spectrometric data

anagnostec.de

AnaKat Institut für Biotechnologie GmbH

AnaKat Institut für Biotechnologie GmbH has specialized on analytical determination of pharma-ceutical ingredients.

anakat.de


Biotech Companies

Analyticon Discovery GmbH AnalytiCon is a biotechnology company focusing on the development of compound libraries consisting of natural product (NP) and synthetic small molecules. As the global market leader in NP small molecule screening compounds, AnalytiCon is the only company which is able to provide vast collections with completely disclosed structural information. As a pure compound provider the company is offering its products and services to the pharmaceutical, chemical, biotech, cosmetical and nutraceutical industry.

ac-discovery.com

Analytisches Zentrum Biopharm Berlin GmbH

Analytisches Zentrum Biopharm GmbH Berlin is a contract research organization providing services on pharmaceutical analysis and bioanalysis for active compounds in the dosage form, for the quantitative determination of analytes in a biological matrix and also the determination of physi-cochemical parameters of chemicals according to OECD guidelines. AZB carries out these services in compliance with GLP and GMP and has the GLP certificate.

analytisches-zentrum-biopharm.de

AnaTox GmbH & Co. KG The AnaTox GmbH & Co. KG deals with the development and optimization of analytical methods and devices for HPLC and dissolution.

anatox.de

ANiMOX GmbH Development of applications for the use of natural peptide / amino acid mixtures in chemistry and biotechnology, f.i. as a scavenger material in formaldehyde bounded formulations, foaming or hydrophobic Tensid compounds or as a N-source in biotechnological fermentation processes, distri-bution of a technology for the production of such basic materials from raw and residual materials.

animox.de

aokin AG aokin AG is a Berlin biotechnology company that is specialized in the development and commer-cialization of innovative analytical systems on the base of the rapid kinetic assay technology. The aokin systems are unique in their precision and operating speed. Areas of application are food and antibody analytics as well as clinical diagnostics. We also offer laboratory services in the area of food analytics, Pharmacoanalytics and chemical synthesis.

aokin.com

AptaRes AG AptaRes is a developer and manufacturer of aptamers as an alternative to antibodies. The aptamers are isolated in vitro by using a proprietary technology. AptaRes is also developing aptamer-sup-ported processes and analytical methods. It provides also consumables required for the aptamer applications. In collaboration with financial partners AptaRes supports with its enabeling technol-ogy entrepreneurs and the expansion of biotechnology companies.

aptares.de

ARGUS Umweltbiotechnologie GmbH ARGUS is a medium-sized company. Since 1987 ARGUS works on the field of remediation of contaminated groundwater, soil, waste water and waste air. ARGUS is able to elaborate a specific remediation program in each different pollution case considering economic aspects beside ecological aspects. All necessary treatment steps can be planned and carried out. The combina-tion of microbiological steps with classic processes leads to a successful remediation of complex contamination.

argus-umwelt.de

ASCA GmbH Angewandte Synthesechemie Adlershof GmbH

ASCA is a partner for contract research in the field of medicinal chemistry. The synthesis and optimization of lead structures, the development of new active structures and their check on a laboratory scale are offered. We take a lot of care on working out the synthetic schemes, rapid preparations and exact analysis of the samples. All our results are carefully documented for our customers. Access to literature databases and in-house analytical facilities are available.

asca-berlin.de

Astra Biotech GmbH The Company Astra Biotech offers a wide range of high-quality reagents and diagnostic kits. The catalogue provided by our company includes reagents for detecting of human hormones, genetic diseases, tumor markers and allergens.Besides, we develop cutting-edge, technologically perfect solutions in the field of diagnostics and we are ready to offer our experience, skills and knowledge for realization of your projects.

astrabiotech.de

ATLAS Biolabs GmbH ATLAS Biolabs GmbH is a leading provider of microarray based genomic services such as genome wide gene expression and SNP analysis, CGH analysis and diagnostic services for registered doctors and hospitals, as well as for pharmaceutical, biotechnological and diagnostic enterprises.

atlas-biolabs.de

Attomol GmbH Molekulare Diagnostika The company's aim is to develop, produce and distribute medical diagnostics for human medicine in the field of molecular genetics, infectious and autoimmune diseases.

attomol.de

AutoTissue GmbH The company is engaged in the development, production and marketing of medical devices for car-diovascular surgeons. The products are specially made for the patients and have less side effects. The first certified product was a pulmonary heart valve (Matrix P) for the right ventricular outflow tract reconstruction (RVOT). The second product is also a heart valve which considerably shortens the operation time (Matrix P plus).

autotissue.de

B·R·A·H·M·S Aktiengesellschaft B·R·A·H·M·S explores, develops and produces new diagnostic test procedures to improve the diagnosis, and thereby the treatment, of life-threatening illnesses. This takes place with over 400 employees, in the disease areas infectiology, thyroid, autoimmunity and cardiology on the basis of our own patented biomarkers. Since October 2009 B·R·A·H·M·S is part of Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science.

brahms.de

Bavarian Nordic GmbH Bavarian Nordic A/S is a leading international biopharmaceutical company developing, producing and marketing innovative vaccines to prevent and treat infectious diseases and cancer.

bavarian-nordic.com

bbi-biotech GmbH In the focus of the activities of bbi-biotech lie systems for the sterile sampling from bioreactors for all applications in the biotechnology, pharmaceutical, food, cosmetics and chemical industry. In addition, bbi-biotech develops components - in especially disposable ones - for the preparation of a new generation of fermentors and bioreactors and offers consulting and planning services for biotech projects, its implementation and services.

bbi-biotech.com

BEB BioEnergy Berlin GmbH Planning, Design, Construction, Supervision and Implementation of Biogas/Hydropower plants, Pre-planning, Feasibility Studies and Research activities in the field of renewable energies, Optimiza-tion of the process in existing biogas plants

bebgmbh.de


Biotech Companies

Bioanalyt GmbH BioAnalyt GmbH brings easy-to-use diagnostic tools to the front lines of food production and processing as well as of global health programmes. BioAnalyt is developing, manufacturing, and marketing on-demand diagnostic tests for a variety of analytic focuses. Our innovative work and products have been awarded with several prizes. BioAnalyt GmbH is a spin-out of a university, which is focusses on the investigation of nutrients in food and biological fluids.

bioanalyt.com

Bioassays GmbH Service related to the development of medical in vitro diagnostic products. Basic science to clinical development. Profiling of biomarkers in clinical trials.

Biochrom AG Biochrom is Germany’s largest manufacturer of cell culture products (media, sera, and others). They are distributed to universities, industrial cell culture laboratories and industrial manufacturers. Service is of special significance for users of cell cultures. Special media developments and produc-tion optimizations are offered.

Biochrom.de

BIOCYC Gesellschaft für Biotechnologie und Recycling mbH & Co.KG

Production of bio-chemicals, peptides, in-vitro-diagnostics, test-kits. Development of consumer service for peptides and biochemicals.

quartett.com

BioGenes GmbH BioGenes is a full service immunoassay and antibody (monoclonal and polyclonal) development company with outstanding problem solving capabilities specializing in challenging projects that are carried out by an exceptionally experienced and interdisciplinary team.

biogenes.de

Bioline GmbH Bioline GmbH develops, produces and markets innovative reaction agents which are essential for scientists in all sectors of molecular biology. The product range also includes high quality nucleo-tides, enzymes, DNA ladders and puffers. In addition to production, Bioline GmbH also conducts research to develop innovative products to ensure that the company is always a development leader and can satisfy customers' ever increasing needs.

bioline.com

BioMedion GmbH IT-Service for all GxP-Regulatory Tasks Data- and Document Management, Long-Term-Archiving and Digital Signature, SOP-Management, CAPA, Raw Data Management, Consulting for Validation of Computerized Systems according to GAMP4/5

biomedion.com

biorefinery.de GmbH Based on main precursors of plants, carbohydrates in kind of sugar, starch and cellulose, and pro-teins, the biorefinery.de company has developed four complex product lines (Biorefinery systems) which leads to a great number of valuable products with the help of chemistry and biotechnology.

biorefinery.de

BioRepro GmbH BioRepro is the first pharmaceutical company, whose core competency is the breeding of leeches under controlled laboratory conditions for medical therapies. We concentrate on the establishment of GMP breeding procedures and will be able to provide leeches with standardized quality while equally allowing scalability to supply medical demand. Additionally, through the re-initiation of fundamental research, we will gain deeper understanding of further potential in medical and cosmetic treatment areas.

biorepro.de

BioS Biotechnologie Schönow GmbH Embryo transfer and associated biotechnologies in animals. Service, training and research in this field.

bios-schoenow.de

BIOSYNTAN Gesellschaft für bioorganische Synthese mbH

BIOSYNTAN offers the custom synthesis of standard peptides, the synthesis of modified peptides (e.g. glyco- and phosphopeptides, dye labeled peptides) and hapten modifications for the conjugate synthesis. In cooperation with BIOGENES GmbH Berlin we offer poly- and monoclonal antibodies.

biosyntan.de

Biotech-Laboratorium für Environment BLE GmbH

Development of detection systems which are able, economically and rapidly, to detect oil contami-nations and industrial oil waste, in soil and in water and their biological depletion. The BLE GmbH is concerned with the biological degradation of oil contaminations and the development of a set of bio-preparations consisting of different bacterial strains which break down oil.

BIOTECON Diagnostics GmbH BIOTECON Diagnostics has been well known as a qualified partner in the field of molecular and microbiology for the last 11 years. We focus on development, production and marketing of PCR-based rapid detection systems. BIOTECON Diagnostics offers solutions for the food and beverage industry as well as for producers of pharmaceuticals and cosmetics.

bc-diagnostics.com

BioTeZ Berlin-Buch GmbH p Services (Custom Oligonucleotide synthesis, Immuno affinity columns) p Development of Enzyme Immunoassays, e.g. for Therapeutic Antibodies p R&D (Low Density Biochip)

biotez.de

BIOWORX-BiotechnologielaborThomas Grimm

BIOWORX offers services in the fields of contract research for customer-specific Biotransforma-tions, the screening, isolation and production of Biocatalysts from microorganisms and plants and the bioanalytic syntheses. Further organic compounds and metabolites will be synthesized with enzymes for customer in kg scale.

bioworx.de

BiRDS Pharma GmbH BiRDS Pharma GmbH, integrated into the BDD/CCDRD group, provides services in the field of drug development to pharmaceutical and biotech companies, including management of drug develop-ment projects as well as consulting services. The company also pursues own drug development projects based on intellectual property generated within BDD/CCDRD group, with a focus on drug candidates derived from Atomic Substitution Technology (AST).

birdspharma.com

breecon GmbH The breecon GmbH is an innovative service company in life science with focus on green biotechnol-ogy. The objectives of the company are consulting, application and mediation of biotechnological-analytical services as well as their development and marketing. The breecon GmbH offers his ser-vices to plant breeders and companies of the industrial biotechnology and supports the utilization of genetic diversity in the context of SMART breeding.

breecon.com


Biotech Companies

BST Bio Sensor Technology GmbH BST develops and produces biosensors to provide high quality analysis at moderate prices. In 1982 BST brought on the market the first multi-way biosensor based blood glucose analyzer in Europe and is since then market leader in Europe. Today BST sells more than 60.000 sensors a year. Since 2008 BST is besides biosensors also manufacturer of POCT and laboratory instruments.

bst-biosensor.de

caprotec bioanalytics GmbH caprotecs Capture Compound Mass Spectrometry (CCMS) Technology allows to separate and identify proteins based on functionality. For many applications, CCMS is clearly superior to conventional methods - thus addressing an unmet need in the proteomics research community. The company develops caproKits for proteomics research and plans to enter into collaborations with the pharma-ceutical industry for small molecule / drug optimization and development.

caprotec.com

Capsulution Pharma AG Capsulution Pharma AG develops innovative nano- and micron-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the capsules can be used for a mul-titude of different applications. Accordingly, the precisely sized capsules (500 nm to 50 µm) can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer.

capsulution.com

Cavira GmbH Cavira is active in the field of infectious diseases and oncology. For the time being two products are in preclinical stage with encouraging in vitro and in vivo data. One product is a derivate of a well known chemotherapeutic. The other one is combination therapy based on the amino acid deplet-ing enzyme Histidinase with broad potential in both, oncology and infectious diseases. Research and development are conducted in cooperation with very well known universities or contract research organizations.

cavira.de

celares GmbH Specialist for Drug Delivery of peptides/proteins by using PEGylation. Modification of Biopharma-ceuticals with polyethylene glycol in order to substantially improve pharmacological properties. Offers the unique CelaSYS-PEGylation technology, which is patented by celares. CelaSYS: non-dis-persed, highly branched polyethylene glycol based reagents. Additionally celares offers customized PEGylation solutions as well as synthesis of customized PEG-reagents.

celares.com

CellServe GmbH CellServe is a service provider for research groups in regenerative medicine, especially in the production, functional characterization and monitoring of cells as therapeutic agents and research tools, each in accordance with the most recent regulatory guidelines and cGMP standards. With its services and products, the company fills an important gap in the conversion of applied treatment concepts from research into marketable products.

cellserve.de

CellTrend GmbH Celltrend is certified according to ISO 9001, ISO 13485 and GMP - Cell culture systems for research on active substances (bioassays, preclinical research, for quality control) - Development and production of antibody-based detection systems (ELISA) - Chemosensitivityassay for optimisation of chemotherapy (tumor patients)

celltrend.de

chemicell GmbH chemicell develops and produces magnetic, fluorescent and coloured nano- and microparticles, reactive fluorescent dyes and special chromatography-materials for the separation or detection of cells, bacteria, viruses, proteins or DNA/RNA and new gene transfer systems.

chemicell.com

Chipron GmbH Chipron GmbH specializes in production and distribution of array based detection systems for DNA / pathogens

chipron.com

CHIRACON GmbH chiracon is a qualified partner to develop chiral intermediates at a constant high quality for innovative drugs regarding economic, environmentally acceptable and scaleable aspects. We offer support through expert knowledge and key technology to meet your increasing needs. Our core competence is chirality. In addition we have a broad variety of chiral building blocks as an inhouse raw material source for high-level API production and development.

chiracon.de

CMZ-Assay GmbH Marketing of diagnostic reagents for measuring concentrations of proteins, hormones and their isoforms, exclusively for research purposes.

cmz-assay.com

co.don AG co.don® AG is one of the leading biopharmaceutical companies in the area of Regenerative Medi-cine/Tissue Engineering. Since 1997, co.don® AG has developed, manufactured and distributed human Tissue engineering therapeutics for the regeneration of articular cartilage, bone and intervertebral discs.

codon.de

CompoundSelect CompoundSelect offers customized compound databases, consisting of e.g. medicines, natural compounds or scents.The databases are provided with a variety of screening options, a comfortable usability, physico-chemical properties and additional information such as availability, supplier and functional features for each compound.

bioinformatics.charite.de/compoundselect

CONGEN Biotechnologie GmbH CONGEN is specialized in food testing by molecular analytics based on DNA and RNA detection. CONGEN has been a pioneer for over a decade in the development and application of food and feed analytics by real-time PCR. The methods are available as complete analytic kit as well as a Service.Our mission is to serve the food industry with an excellent service and with standardized and reli-able test kits in order to realize highest possible food safety and food quality.

congen.de

CREATOGEN Laboratories GmbH Development of vaccines for application in veterinary and human applications.

Cyano Biofuels GmbH The company focuses on the biotechnological use of cyanobacteria, especially the development and optimization of cyanobacteria for the production of environmentally friendly biofuels and chemical feedstocks.

cyano-biofuels.com

Cyano Biotech GmbH Cyano Biotech identifies and characterizes natural products from cyanobacteria and optimizes their pharmacological activities employing a biocombinatorial approach. The company conduct further development of identified lead structures till the preclinical phase.

cyano-biotech.com


Biotech Companies

Diaglobal GmbH Development, production and distribution of in-vitro-diagnostics for analytical purpose and the distribution of medical products.

diaglobal.de

DIZG Deutsches Institut für Zell- und Gewebeersatz gemeinnützige GmbH

DIZG German Institute for Cell and Tissue Replacement engages in cell and tissue preservation as well as in cell and tissue replacement, and provides tissue preparations of human origin to clinics, teaching and research organisations. Further service is culturing of skin cells (keratinozytes) for serious burns and other skin defects not healing well or affecting large areas. DIZG supplies cell cultures to help avoid experimentation with animals e.g. in the cosmetics industry.

dizg.de

Dr. Götz Verfahrenstechnik Biotechnik Umwelttechnik

Contract research and contract manufacturing using bacteria, yeasts and fungi. drgoetz.de

Dr. Lerche KG Innovative company engaged in development, production and marketing of specialized microcap-sules for bio- and medical technology p Development and production of novel DNA-Purification-Kits with proprietary technology p Production and marketing of microcapsules (LUMiTainer), microbeads and cell based sedimentation standards for blood analysis (Sedi-Val ESR standards) p Encapsulation of cells - Contract analysis for characterization of microcapsules, porous mem-branes and hollow fibres

lerche-biotec.com

Dr. Otto GmbH p Research and development of ecological products, process development, production and mar-keting p Production and refinement of plant ingredients p Operation of an analytical laboratory for renewable resources and chemical analysis

dr-otto-gmbh.de

Dr. Rölleke Labor für Genetische Analytik GmbH

Dr. Roelleke is specialized on the identification of microorganisms, particularly in the area of food safety. Furthermore, Dr. Roelleke is authorized expert on paternity tests for courts and the private sector.

dr-roelleke.de

DSM Biopract GmbH Service and Additives (enzymes, trace elements, microbes) for biogas and waste water sludge treat-ment. Enzyme analysis in Food and agriculture industry.

dsmbiogas.com

durakult durakult GmbH discovers and optimizes starter cultures and novel whole-cell catalysts for custom-ers in the food, chemical and renewable energy industries. durakult provides a new technology to explore microorganisms from natural untapped biodiversity for industrial applications. durakult stabilizes genetically manipulated cells which show weak growth or unstable metabolic properties and fits them to industrial purposes.

durakult.com

E.R.D.E.-AAK-Diagnostik GmbH E.R.D.E.-AAK-Diagnostik GmbH is a laboratory that offers antibody testing for commercial purposes. aak-diagnostik.de

Eckert & Ziegler AG Eckert & Ziegler Strahlen- und Medizintechnik AG, headquartered in Berlin, is a globally active isotope technology company and holding company for a number of specialised subsidiaries that process radioisotopes as well as develop, manufacture and sell isotope technology components, medical technology equipment and related products.

ezag.de

EMP Biotech GmbH Production of fluorescent dyes and chemiluminescent reagents. Contract chemical synthesis of small molecules. Contract labeling and purification of proteins, antibodies and oligonucleotides. Production of size-exclusion gels, columns and filter plates. Production of high quality reagents for DNA synthesis.

empbiotech.com

Epigenomics AG Development and commercialization of innovative molecular diagnostic test products based on DNA methylation for cancer screening and for cancer specialty applications.

epigenomics.com

Epiontis GmbH Establishing methylation fingerprinting as Gold Standard for quality control in Regenerative Medi-cine and Immunomonitoring.

epiontis.com

Epo Experimentelle Pharmakologie & Onkologie GmbH

The pharmaceutical and oncological testing of new drugs or treatment concepts for cancer is a spe-cialized market segment. Using the equipment available, all experimental and animal experiment techniques can be carried out in first-rate quality. That means that EPO is an attractive partner for the drug development section of large pharmaceutical companies, for partners from the Biotech industry and for research institutions.

epo-berlin.com

Eurovir Hygiene-Institut/Dr. Thraenhart

Laboratory service for testing the efficiency of products against viruses (virucides) and of processes for inactivating or eliminating viruses (virus safety)

eurovir.de

EVESTRA GmbH EVESTRA is a newly founded biotech company focusing on developing female health products. The company's expertise resides with steroid chemistry and biology. EVESTRA's product pipeline includes products for contraception, hormone replacement therapy, gynecological disorders and hormon dependent cancers.

evestra.com

Evotec AG Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programs and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.

evotec.com

F.A.T. Forschungsinstitut für Antioxidative Therapie GmbH

Measuring instruments and kits for evaluating the antioxidant properties and the degree of oxida-tive damage in biological substrates

antioxidant-research.eu

fermtec GmbH Development of non-alcoholic beverages, beers and beer mix beverages, lactic acid fermentation, innovative foods and beverages and auxiliary substances for the food industry

fermtecgmbh.de

Ferropharm GmbH Development of very small super para-magnetic nano particles as contrast agent for MRI ferropharm.de

FILT Lungen- und Thoraydiagnostik GmbH

Development of innovative, non-invasive diagnostic methods in the area of respiratory diseases and allergies

filt.de


Biotech Companies

Formula Pharma GmbH p Galenic and chemical development-Import, manufacturing, quality control (re-test) and release of clinical supplies and market products p GMP-certificat / Manufacturing license in accordance with §13 AMG

formula-pharma.de

GA Generic Assays GmbH Development, manufacturing and distributing of in-vitro-tests, focussing on autoimmune diseases, hereditary and infections diseases.

genericassays.com

Gene Analysis Service GmbH We offer quick and complete molecular biological diagnostic and analysis service for hospital, research and industry. Our service includes nucleic acid isolation, PCR-amplification and DNA-sequencing. We design custom protocols and are specialized in the analysis of rare genetic diseases that require complete exon sequencing.

gene-analysis-service.de

GenExpress Gesellschaft für Proteindesign GmbH

GenExpress is a flexible company providing services in molecular biology. For over a decade we have successfully worked for customers in clinical laboratories, research institutions and the industry. We offer cloning of PCR targets, preparation of synthetic genes, expression of proteins, evaluation of LightCycler® assays, furthermore production of internal controls and standards for Real Time PCR systems, also cloning, expression and purification of proteins.

genexpress.de

GILUPI GmbH GILUPI is a medical diagnostics company with an initial focus on the prenatal and cancer market. The company is developing an innovative new diagnostic product based on nanotechnology. Our goal is to catch specific cells, which can be found only in very low concentration in the blood. The first application for our new nanosensor device will be prenatal diagnoses of chromosomal aberra-tion out of maternal blood. The second application will focus on the early diagnosis of cancer.

gilupi.com

GlucoMetrix PVS GmbH The GlucoMetrix AG focuses on the early detection and management of diabetes mellitus-after-math. At the foreground of research and development is enhancing the quality of life of diabetics. In addition, the life science company develops some IT-based diagnostic procedures and medical devices as well as biopharmaceuticals and other highly effective products in order to raise the quality of life of diabetics sustainably.

glucometrix.de

Glycon Biochemicals GmbH Production of carbohydrate components used for the synthesis of new pharmaceutical compounds or diagnostics

glycon.de

Glycotope GmbH Glycotope is a leading company in glycomics and immunotherapeutics. It has developed novel therapeutic antibodies and unique platform technologies to optimize the glycosylation of new bio-logical entities. Glycotope Biotechnology, with 25 years of experience in GMP-production, enables us to offer the entire process of biopharmaceutical development with a dedicated focus on our unrivalled expertise in protein glycosylation from the gene to production and fill & finish of clinical grade material.

glycotope.com

Götz Protein Engineering Offering a wide range of protein technology up to the final purified protein goetz-protein-engineering.de

HC Berlin Pharma AG Pharmaceutical products, intellectual property, patents, know how and expertise have been com-piled in the new HC Berlin Pharma AG. The uniqueness of the various products especially the new malaria treatment will generate immense revenues based on the high market demand.

hcberlinpharma.ag

HealthTwiSt GmbH HealthTwiSt is a service provider for "Genetic Contract Research" in the fields of Functional Genom-ics, Pharmacogenomics, Proteomics or Functional Food / Nutriceuticals. In particular, HealthTwiSt is offering access to extensively characterized human subjects and samples as well as prospective studies in twins, together with know-how in the analysis of complex genetic traits. Furthermore, database development, data management and statistical analyses for clinical projects are provided.

healthtwist.de

HF Biotec Berlin GmbH Development, selling and operating of digestion plants using liquid substrates of industrial and agricultural provenience, Development and operating of combined plants to upgrade biogas into bio methane useable in public gas grids with parallel production and selling of high quality PCC, Development of innovative biotechnological processes and plants.

hf-biotec.com

Human BioSciences GmbH The biotech-company Human BioSciences Inc. is specialized in manufacturing and distribution of modern collagen based wound and skin care products.

HumanBioSciences.de

HUMAN GmbH For over 35 years HUMAN has been serving the healthcare sector. HUMAN develops and manufac-tures in Germany laboratory diagnostic products for the world market. HUMAN stands for quality and service in over 160 countries. In our new competence centre for autoimmune diagnostics, an expert team of highly specialized scientists and technicians develop and produce the IMTEC product line, a range of high-quality autoimmune diagnostic products. Further innovative products are to be launched soon!

human.de

icon biotech Icon biotech is an innovative biotechnology company, which uses the extraordinary characteristics of Ciliates for the development of bio-analytical and toxicological model systems.

icon-biotech.com

ifp Institut für Produktqualität GmbH Laboratory and competence centre for state-of-the-art food and feed analysis produktqualitaet.com

IGV Institut für Getreideverarbeitung GmbH

The range of services offered by the Biotechnology Division of the private research IGV GmbH insti-tute is based on 25 years of experience in R&D for the cultivation of phototropic micro-organisms. Excellent, world-wide contacts to biomass producers, food producers, to the pharmaceutical and cosmetics and energy industry provide the fundament for innovative, market-oriented develop-ments. In focus are development of photo bioreactor technology and active substances from algae.

igv-gmbh.de


Biotech Companies

IKDT Institut Kardiale Diagnostik und Therapie GmbH

IKDT was founded in August 2002 in Berlin-Steglitz and is one of the leading laboratories on Viral Infections of Heart Muscle Tissue and Dilatated Cardiomyopathy (DCM) in Germany. IKDT lab is per-forming a comprehensive molecular diagnostic examination of endomyocardial biopsies as one of a limited number of specialized cardiological labs worldwide. Its service enables physicians firstly to start an efficient, pathophysiologically based causal therapy.

ikdt.de

ILBC GmbH Research, consulting, production, trade & services in the areas biology, molecular biology and protein chemistry - Expression and production of antimicrobial peptides

imaGenes GmbH RZPD spin-off, premier service center for genome research in Europe, provides one of the largest clone collections in the world via its clone search engine GenomeCube®. Certified Service Provider for comprehensive microarray application on Affymetrix, Agilent, and NimbleGen platforms, high throughput RT qPCR, complete portfolio of Next Generation Sequencing services. ISO 9001:2008 certified.

imagenes-bio.de

In.vent DIAGNOSTICA GmbH in.vent DIAGNOSTICA GMBH is a biomedical company. We are focused on the project-oriented provi-sion, processing and distribution of biological raw material for development and production of diagnostics and control material. We are your reliable partner for the customised development of assays for medical in vitro diagnostics.

inventdiagnostica.de

inbion GmbH inbion GmbH provides services to support research in the interface between university, students and industry. For companies, we provide the benefit of outsourcing projects quickly and cost-effi-ciently to competent teams. Cooperation with research groups in the university is also facilitated, so that targeted knowledge transfer can take place here.

inbion.de

Innovative Optische Meßtechnik Fluorescence Assay Solutions and Instrumentation (Microplate Readers) iom-berlin.de

Institut für Medizinische Molekulardiagnostik (IMMD)

Gene tests for prenatal, predictive and tumor -diagnostics immd.de

Institut für Molekular- und Systemmedizin I.M.S.M. GmbH

Scientific-practical works in the area of System medicine with the purpose of the patenting of new treatment methods, e.g. to the treatment of diabetes. International cooperation in this area.

Invitek GmbH Invitek, a member of the STRATEC group, is a globally active provider of innovative system solutions for nucleic acid sample collection, stabilization, and both manual and automated purification from any sample type. Since 1992 the company is internationally respected for its outstanding and high performance technology platforms and offers a broad spectrum of superior products for molecular diagnostics, drug discovery and Life Science research.

invitek.eu

InVivo Biotech Services GmbH As a contract manufacturing company (CMO) Invivo offers a wide range of services: the development and production of monoclonal antibodies and recombinant proteins for diagnostic and pre-clinical use (endotoxin-free antibodies and compliant documentation), cell line development and tran-sient transfection. We are an ISO9001:2000 certified company.

invivo.de

Jerini AG Jerini is a pharmaceutical company based in Berlin, Germany. Shire Limited's German wholly-owned indirect subsidiary Shire Deutschland Investments GmbH currently holds 100 percent of Jerini's shares. Jerini is a subsidiary of Shire plc and a member of the Shire group of companies.

jerini.com

JPK Instruments AG JPK Instruments AG is a leading manufacturer of nanoanalytic instruments for the life sciences and soft matter sectors. The company was the first to recognize the innovative opportunities of nano-technology for the biological, medical and pharmaceutical sciences and tailored its instruments platform to the requirements of this area of application. JPK implements comprehensive solutions for high-resolution imaging, power measurements, nanomanipulation and lithography.

jpk.com

JPT Peptide Technologies GmbH JPT Peptide Technologies GmbH, a wholly owned subsidiary of Jerini AG, is a DIN EN ISO 9001:2000 certified biotechnology company based in Berlin and a leading supplier of innovative peptide-based services and products. JPT provides peptide arrays, peptide libraries and specialty peptides.

jpt.com

Klinomed GmbH Development of new technologies for manufacturing bio-active nano particles / development of therapeutic formulations based on nano particles

klinomed.de

KNAUER - Wissenschaftliche Gerätebau Dr. Ing. Herbert Knauer GmbH

KNAUER UHPLC and HPLC systems as well as columns are used in research and development, quality control and production plant laboratories around the world. Customers are typically governmental and industrial organizations as well as universities. Fields of application are wide-ranging and include pharmaceutical and medical research, analysis of foodstuffs and cosmetics, as well as environmental analysis. With our biochromatography solutions we focus on high resolution separa-tions.

knauer.net

L.U.M. Gesellschaft für Labor-, Umweltdiagnostik & Medizintechnik mbH

Analysis, diagnosis and sensor technology as well as stability, rheology and segregation behavior of dispersions

lum-gmbh.de

Lab4you GmbH Development and distribution of lab devices for biochemistry, biotechnology and medical analytic lab-4-you.com

LAROVA Biochemie GmbH Research, development and production of nucleotides, nucleosides, oligonucleotides in natural and modified forms

larova.com

LGC Production of calibration substances for purity testing of drugs mikromol.de


Biotech Companies

LGC Genomics LGC Genomics (formerly AGOWA genomics) is the division of LGC with specific expertise in high qual-ity, cutting-edge genomic and related services and products.LGC Genomics delivers:p Next genera-tion sequencing services p DNA sequencing- Genomics services p Nucleic acid extraction services p DNA extraction products. LGC is an international science-based company and market leader in analytical, forensic and diagnostic services and reference standards (www.lgc.co.uk).

agowa.de || lgc.co.uk

Limetec Biotechnologies GmbH The core competence lies in the development of high-speed and high-quality proof systems for the detection of pathogens, as well as in the allelic discrimination of hereditary diseases. All products are marked with the CE-Certificate. The second area of expertise is the creation of communication networks which connect out-patient and hospital patient treatments, intensify data exchange and provide information to all health institutions, thus establishing partner relationships between them.

limetec-biotechnologies.de/

MagForce Nanotechnologies AG MagForce has developed a new process for local treatment of tumors – the Nano-Krebs® therapy. Temperatures between 41°C and 70°C can be generated within the tumor. The method is based on the principle of direct, minimally invasive addition of magnetic nano-particles into the tumor and their subsequent heating in a magnetic alternating field. Treatment has been tested in clinical studies since 2003.

magforce.com

Marinpharm GmbH Development and marketing of genetically altered cell lines on the basis of new fluorescence mark-ers.

marinpharm.com

MedInnovation GmbH MedInnovation GmbH has developed a new method and a special ESR-analyser, which for the first time allows a simple routine laboratory test for evaluation of functional characteristics of plasma proteins and further opens a reliable possibility for cancer diagnostic, named MMS-technology (mobility of molecular structure).

medinnovation.de

Medipan GmbH Development, manufacturing and international distribution of radioactive (125J-IRMA) and non-radioactive (Elisa) in-vitro diagnostic tests, covering the field of Autoimmunity, mainly in Thyroid and Diabetes Typ 1, automated interpretation of cell-based immunofluorescence tests by the AKLIDES system.

medipan.de

MerLion Pharmaceuticals GmbH The business purpose of the Company is the research, production, optimization and the develop-ment by way of pre-clinical as well as clinical trials of new molecules for the treatment of infec-tious diseases

merlionpharma.com

Merz Pharmaceuticals GmbHStandort Potsdam

Merz is one of the leading research-based health care companies. Merz Pharmaceuticals has achieved a leading position in Alzheimer’s research with the world’s first drug for the treatment of moderate to severe Alzheimer’s disease. With high quality products from tetesept® and Merz Spezial®, Merz is making a key contribution to health and wellbeing.

merz.de

Metabolomic Discoveries UG Metabolomic Discoveries is an analytical service and research company. We provide mass spec-trometry based metabolite profiling and fingerprinting of biological material, as well as single compound measurements.

metabolomicdiscoveries.com

metanomics GmbH Metabolite Profiling for identification of gene function relationship in plants, metabolite biomark-ers and metabolic networks

metanomics.de

metanomics Health Identification of metabolic biomarkers for pharmacology, toxicology, diagnostic and nutrition metanomics-health.de

MetrioPharm AG MetrioPharm AG develops innovative therapies for infectious diseases on the basis of new and innovative medicines.

metriopharm.com

mfd Diagnostics GmbH The mfd Diagnostics GmbH (BT Luckenwalde) is a life science research and development company for diagnostic and therapeutic application of innovative laser technologies. The main advantages of the developed technologies are the non-/minimally-invasive measurement methods, the non-artificial approach and the possibility of real-time measurement. Therefore, those are promising tools for the diagnosis and therapy monitoring in the neurological practice and in the perinatal surveillance.

mfd-diagnostics.com

MicroDiscovery GmbH MicroDiscovery GmbH is a leading provider of high quality software for biomolecular research, innovative diagnostics and personalised medicine. The company is ISO 9001 certified and has a strong track record in creating software systems in accordance with relevant regulatory directives for the life science and IVD industry. Customised services ranging from biostatistical data analysis to bioinformatical design and support of complex research projects complete the product line of MicroDiscovery.

microdiscovery.de

microparticles GmbH Development, manufacture, surface modification and characterization of mono-disperse polymer particles in the nano- and micrometer range. In addition to classic polystyrol and polyacrylate-based polymer particles, microparticles GmbH has launched new melamine resin particles on the market with exceptional chemical and physical qualities. The main areas of application are in particle measurement technology, medicine, biochemistry and microelectronics etc.

microparticles.de

Mikrobiologisches Labor Dr. Th. Bernhard GmbH

Accredited test laboratory for drinking water, clean rooms, sterility, bioburdens, DAC-PL-0302-04-00, EN 17025. Accreditation according to VDI 6022

mikroberlin.de

Minerva Biolabs GmbH Minerva Biolabs develops and produces IVD kits for diagnosing pathogens and for contamination control, especially mycoplasma in cell cultures and biopharmaceutical products. Minerva Biolabs is also active in ensuring water quality with sensitive processes for detecting legionella. Our distribu-tors ensure that our products are available worldwide, quickly and at a good price.

minerva-biolabs.com


Biotech Companies

mivenion GmbH mivenion is a life-science company founded in Berlin aiming on the development and com-mercialization of diagnostic and therapeutic products. The company is built on two innovative technologies: the fluorescence camera system Xiralite for diagnostic imaging of early rheumatoid arthritis and a proprietary bioactive polymer drug development platform. Xiralite is mivenion´s first product on the market.

mivenion.com

molConcept GmbH We offer computational drug design, rational drug design, and efficient simulation algorithms for molecular systems

molconcept.com

Molnar-Institut für angewandte Chromatographie

Molnar-Institute, established in 1981, offers you a complete scientific and technical service for all problems concerning HPLC-analytics. We develop for you the HPLC-solution and we offer detailed HPLC-courses and show you, how to develop robust methods and how to save time. We supply and implement the DryLab-software and train your coworkers. We assist you in the selection of the proper instruments, its installation and use.

molnar-institut.com

MOLOGEN AG MOLOGEN AG is a biopharmaceutical company based in Berlin and specializes in the development of novel DNA-based medicines against cancer and vaccines against infectious diseases. The propri-etary platform technologies MIDGE® and dSLIM® build the foundation for all business activities. The company was founded 1998 and was one of the first biotechnology companies to go public.

mologen.com

MolTech Molekular Technology GmbH Custom research and process development in the area of bioluminescence, production of restrictase and photo proteins

mt-berlin.com

Nano Access Technologies Limited The company addresses the combined access to key technologies such as life science and nano-technology. As a first product, a low cost AFM for operation with so-called active cantilevers has been developed. Besides this, functionalized cantilevers for future biosensors are another focus of the company.

nano-access.com

Nanolytics Gesellschaft für Kolloidanalytik mbH

we are a contract laboratory specializing in the physico-chemical characterization of pharma-ceutical proteins, biopolymers, nanoparticles and colloidal systems. Our core-competences are Analytical Ultracentrifugation, in combination with Static and Dynamic Light Scattering as well as spectroscopic (CD, fluorescence) and thermodynamic techniques (ITC, DSC).

nanolytics.de

nanopartica GmbH Nanopartica GmbH optimizes existing products of other companies, but are also developing new products and materials. In particular, companies in surface-, bio-, and medical-technology can benefit from nanopartica. By means of functionalized polymers, we can encapsulate guest mol-ecules (drugs, dyes, vitamins), particles (gold, silver, platinum), or ions. This will indirectly change the guests' properties and expands its scope.

nanopartica.com

nanoPET Pharma GmbH As a technology and service provider to the biopharmaceutical industry nanoPET focuses on the R&D, production as well as marketing of innovative drug substances for diagnostic imaging based on novel nanoparticular materials. nanoPET offers consulting and contract research services, pre-clinical contrast agents (MRT, CT, US, NIR, PET) as catalog items and pursues the preclinical develop-ment of its patented core technology of inorganic nanoparticle PET tracers.

nanopet-pharma.com

NovaBiotec® Dr. Fechter GmbH Microbiological and chemical investigations, in particular of soil, water and air samples, planning / inspection of sanitation, in particular analytics and sanitation support for mould and dry rot, incl. education in this field. Delivery of production auxilliaries and support for biogas plants with biological treatment processes incl. application, insulation and preservation of enzymes. Research, development and marketing of test kits for breweries and malthouses.

novabiotec.de

New Medical Enzymes AG Medical Enzymes AG is a privately held innovative biopharmaceutical company with a focus on therapeutically useful enzymes. The company has developed a new product family based on amino acid depleting enzymes. This unique approach is highly effective against cancer - the major target market of Medical Enzymes AG.

medical-enzymes.com

Novamol Development and manufacture of human and veterinary food supplements and health-enhancing products

novamol.com

novojoint R&D of a new therapy approach for the treatment of severe, inflammatory diseases of the joint and for the support of wound healing after injuries of the skin and bones in man as well as animals. The concept is based on the development of smart gene constructs, which allow the inflammation controlled release of suitable therapeutic proteins at the site of damage/repair. We aim to provide our therapy for three target markets: 1, Small Animal Clinics, 2. Equine Clinics, 3. Human Medicine

novojoint.de

NOXXON Pharma AG NOXXON Pharma is a private clinical-stage biotechnology company focusing on the development of its proprietary Spiegelmers® for treatment of inflammatory diseases and hematological indications. The company targets various disease areas: diabetes-related complications with an inflammatory component, autologous stem cell mobilization as blood cancer support therapy, and anemia of inflammation. In addition NOXXON has partnered with the pharmaceutical industry, including Eli Lilly and Roche.

noxxon.com

NutriNeu GmbH NutriNeu GmbH develops a new generation of pre and probiotics. First products are based on microorganisms that were isolated with our proprietary GlycoScreen technology (antibody directed isolation of microorganisms expressing specific carbohydrate structures). Besides developing own products, NutriNeu GmbH offers services in the fields of microbiology, process development and Glycoanalytic. NutriNeu GmbH also helps customers to investigate the probiotic properties of their microorganisms.

ocCure GmbH ocCure´s goal is to improve the diagnostics and therapy of ovarian cancer. The young biotechnol-ogy company focuses on the discovery, validation, and marketing of novel genetic features using established analytical technologies.

oc-cure.com


Biotech Companies

opTricon Entwicklungsgesellschaft f. optische Technologien

opTricon develops and produces mobile readers for quantitative analyzes of Immunoassays for Point-of-Care-diagnostics, especially Lateral Flow Assays (LFA). Additional business segments are components and Systems for signal transmission and sensors for lbioanalytics. opTricon develops the devices in partnership with the customers and works as OEM-suppliers and is certified by TÜV Rheinland according EN ISO 13485:2003+AC: 2007 and EN ISO 9001:2008.

optricon.de

ORGANOBALANCE GmbH ORGANOBALANCE GmbH is specializing in microbial strain development and microbiological screening. Tapping into the natural potential of beneficial microorganisms and probiotic cultures, ORGANOBALANCE develops new biological products in the areas of nutrition, cosmetics, preventive health care and industrial biotechnology. In its development activities, the company draws on its own collection of microorganism strains suitable for food applications and its own OASSYS® screen-ing systems.

organobalance.de

OSSOGEN Biopharm GmbH OSSOGEN Biopharm GmbH is dedicated to the development of recombinant Parathyroid Hormone-based medicines for various indications. The company is a Joint Venture between German BDD/CCDRD Group and Korean Green Cross Corporation.

ossogen.com

ovalehn GmbH Production and application of specific recipes -containing IgY for diagnostics and oral, passive immune therapy

ovalehn.de

peptides&elephants GmbH Custom synthesis of peptides and peptide libraries - Development parallel Synthesis technologies - Distributor of Peptide Synthesis Automation

peptides.de

PharmaSol GmbH Modification of ingredients or introduction of new metabolic pathways in plants with gene-tech-nology methods

pharmasol-berlin.de

Pharmicell Europe GmbH p Manufacturing of stem cells from bone marrow and adipose tissue for therapeutic and plastic-aesthetical application p Manufacturing of adult stem cells for research (mesenchymal stem cells, endothelial precursor cells) p Banking of stem cells

pharmicell.eu

PlasmaChem GmbH PlasmaChem GmbH is an innovative R&D and manufacturing company specializing in nanomateri-als, plasma- and ultra-thin film technologies. The company manufactures nano-coated medical implants (stents), nanomaterials, additives for metal plating (applied e.g. by Siemens AG), new additives to engine oils on the base of nanodiamonds and other industrial nanoproducts.

plasmachem.com

PolyAn, Gesellschaft zur Herstellung von Polymeren für spezielle Anwendungen und Analytik mbH

PolyAn is specialised in Molecular Surface Engineering (MSE) and Surface Molecular Imprinting (SMI). PolyAn's proprietary MSE-technology platform is used for the production of biochips (microarray slides), microparticles and nanoparticles (fluorescence encoded polymer microspheres) and highly selective membranes, e.g. for Pervaporation, organophilic Nanofiltration. For oligo-, peptide and protein microarrays we offer functionalised glass and polymer slides.

poly-an.de

preclinics Gesellschaft für präklinische Forschung mbH

preclinics is a commercial cooperation partner for preclinical research and development. As a competent, creative and experienced partner preclinics investigates pharmaceutical substances, therapeutic methods and proceedings as well as medical products during the preclinical phase. Additional we provide custom antibody production in llama, goat, sheep, rabbit and other species.

preclinics.com

ProBioGen AG ProBioGen is a specialist in mammalian cell development, process engineering and GMP manu-facturing of biopharmaceutical drug substances. Offering state-of-the-art contract development and manufacturing services as well as access to proprietary cell lines (AGE1.cell lines(R)) for the manufacturing of biopharmaceuticals and vaccines.

probiogen.de

ProteaImmun GmbH ProteaImmun GmbH offers human proteases, ELISA, enzyme and antibody. ProteaImmun's expertise in the recombinant protein expression, especially in human proteases and in the development of antibodies and modern methods of detection and analysis of proteins, enables us to offer custom-ized solutions and support with single components as well as with complete molecular diagnostic systems.

proteaimmun.de

PROTEKUM - Umweltinstitut GmbH Oranienburg

We plan to eliminate fluid und solid waste products in a manner which is compatible with envi-ronment protection. Our methodology is largely based on painstaking analysis. We use modern equipment and scientific methods. Protekum offers high-quality products and services in environ-mental analysis redevelopment.

protekum.de

Proteome Factory AG Biomarker & target discovery, validation, analysis of food and ingredients, absolute quantification of proteins and peptides, sequencing and characterization of proteins and antibodies (CDR), 2DE and LC-MS based proteomics studies, pharmacokinetics, pharmaco, immuno and membrane pro-teomics, protein identification, characterization of proteins and peptides (PTMs, e.g. phosphoryla-tion, glycosilation), quality control, mass determination, N-terminal amino acid sequencing, silver staining kit etc.

proteomefactory.com

provitro GmbH Provitro combines more than ten years of experiences in commercialisation of cell culture technolo-gies, Tissue Microarrays and immunohistochemical analyses with the scientific expertise of the Pathological Institute of the Charité, Berlin. Based on a quality management system according to ISO 9001:2008, we provide our customers not only with high-quality products, CE marked in-vitro diagnostics and state-of-the-art services but also with individual solutions for their specific requests.

provitro.de

Rapidozym Gesellschaft für Laborhan-del und DNA Diagnostika mbH

Expertise of cell biologists cell manufacturing and clean room technology specialists. Focuses on clinical stem cell product development portfolio are stroke, myocardial infarction and plastic surgery.

rennesens GmbH Research and development of myocardial infarction diagnosis, production and worldwide distribu-tion of the fastest and earliest AMI Test with the heart attack marker h-FABP.

rennesens.de


Biotech Companies

Revotar Biopharmaceuticals AG Revotar develops innovative small molecule drugs (SMD) for the treatment of chronic inflamma-tory disorders such as, chronic obstructive pulmonary disease (COPD), Acute Lung Injury (ALI/ARDS) and ischemia / reperfusion. With its drug candidate bimosiamose, Revotar has the worldwide most advanced pan-selectin-antagonist in clinical development in its product pipeline.

revotar.de

RiNA GmbH RiNA has developed systems for cell-free protein biosynthesis based on pro- and eukaryotic cell lysates. A synthesis service is realised in RiNA's own laboratories and complements the EasyXpress Kits (Qiagen). The purchase of Roche´s RTS-products enables RiNA now to be a key player in the field of cellfree biosynthesis with a large variety of products. Another research focus is the develop-ment of aptamers (DNA and RNA) for biosensors.

rina-gmbh.eu

RIPAC-LABOR GmbH RIPAC-LABOR offers high-quality diagnoses of bacterial infections, particularly in poultry, pigs and cattle, but also in other farm and domestic animals. The company uses pathogen differentiation to provide quick and effective methods for fighting pathogens. It performs resistance tests and epidemiological analyses and also focuses on producing herd-specific vaccines.

ripac-labor.de

RNAx GmbH RNAx specializes in RNA-Interference services. It offers functional validations of si- and shRNAs, target validation studies using automated high throughput approaches, as well as whole genome screens with automated assays.

RNAx.de

Roboklon GmbH Distribution, Marketing and Development of Products for Molecular Biological Research and Genetic Engineering.

roboklon.de

ROVALAB GmbH Our Master Mixes for QPCR, Standard-, Hot Start- and High Fidelity PCR as well as our high quality critical raw materials and reagents such as DNA Polymerases and dNTPs are designed to help you successfully and rapidly solve your scientific and manufacturing tasks.

rovalab.com

Royal Biotech GmbH Royal focuses on developing, manufacturing and marketing innovative kits, portable or micro-structured systems, and the next generation of diagnostic chips for near real-time environmental, food safety, disease and laboratory diagnostics

royalbiotech.de

Scienion AG Scienion is a life science company in the markets of dispensing systems and microarray technolo-gies. The product portfolio comprises hardware, consumables and services. Scienion's leading product is the sciFLEXARRAYER dispensing system, available in a product line of six size versions. The dispenser allows the aspiration of ultra low liquid volumes from different reservoirs and non-contact micro drop delivery in the picoliter to microliter range onto a variety of carriers.

scienion.de

Sepiatec GmbH Production, development and sales of automated HPLC machines for high-throughput purification and fractioning of complex substance compounds

sepiatec.com

Seramun Diagnostica GmbH Seramun offers peptide synthesis, purification and conjugation of proteins, production of antibod-ies, customer research, In-vitro Diagnostics. We focus on the development and production of enzyme immunoassays for diagnosis of viral and bacterial infections and autoimmune disease of the gastrointestinal tract, the development of multi-parameter assays as microtitre plate assays and as membrane immunoassays, as well as development of ready-to-use substrate solutions and for protein stabilizers.

seramun.com

SGS INSTITUT FRESENIUS Berlin GmbH & Co. KG

Analytical laboratory services and consulting for development, production and quality control of drugs

institut-fresenius.de

SIFIN Institut für Immunpräparateund Nährmedien GmbH Berlin

Development, production and purification of monoclonal antibodies for use in diagnostics. Devel-opment and production of blood grouping reagents, Serafol® bedside cards and test reagents for serotyping of Salmonellae, Shigellae, E. coli and Yersiniae. Development and production of culture media for microbiological diagnosis.

sifin.de

Signature Diagnostics AG Signature Diagnostics is dedicated to the discovery, validation and commercial development of novel diagnostic products that predict outcome and drug response in patients with colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and ovarian cancer. Signature believes that patient selection and stratification based on molecular gene signatures will soon become an important component of routine cancer treatment.

signature-diagnostics.de

Silence Therapeutics AG Silence Therapeutics has developed novel, proprietary short interfering RNA ("siRNA") molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules as they show increased stability against nuclease degradation. In addition, the Company has developed a pro-prietary systemic delivery system, AtuPLEX. This enables the delivery of siRNA molecules to targeted diseased tissues and cells, whilst increasing their bioavailability and intracellular uptake.

silence-therapeutics.com

SONEX GmbH Biotechnology processes for product synthesis. Byproduct processing and reduction of contaminants sonexgmbh.de

Speziallabor für angewandte Mikrobiologie

Microbiological quality control for medical devices, pharmaceuticals, cosmetics, drinking water, foodstuff, monitoring in clean rooms.

slm-fiedler.de

Strix Diagnostics GmbH Strix Diagnostics is a medical diagnostics company specializing in customized development of certi-fied analytical systems for multiparameter in-vitro diagnostics.

strix-diagnostics.de

Surflay Nanotec GmbH Surflay Nanotec GmbH, a spin-off company from Capsulution NanoScience AG, is specialized on coating colloidal and planar materials with functional films. Key technology is the patented LbL-Technology® with polymers. Applications are in the fields of separation materials, pigment encapsulation, bio-sensing and diagnostic particles. In addition to customer tailored projects Surflay offers an unique range of products of tunable multifunctional nano-or microparticles and dye-labeled polymers.

surflay.com


Biotech Companies

Thanares Thiede Analytik und Research GmbH

Development, use and marketing of analytical process for diagnostic and therapeutic purposes. Future business activities: detection process for bioactive substances in bodily fluids, isolation, characterization and investigation of bioactive compounds from plants, in particular insoluble proteins or low concentrations of proteins, development of low cost genetic systems for over-expression and/or production of such proteins.

TIB Molbiol Syntheselabor GmbH In 1990, TIB MOLBIOL became the first German manufacturer of oligonucleotides. In addition to designing and synthesizing primers and probes for Real-Time-PCR assays, we develop and produce LightMix® kits for Roche Diagnostics LightCycler® instruments, covering applications in Clinical Chemistry, Pharmacogenetics, Pathogen Detection, as well as Cancer Research. TIB MOLBIOL is ISO 13485 certified.

tib-molbiol.com

TransTissue Technologies GmbH TransTissue has been a subsidiary of BioTissue Technologies, Freiburg since September 2001. With more than 15 years of experience in regenerative medicine, the scientists of TransTissue Technolo-gies have developed second-generation autologous tissue replacements, e.g. cartilage and bone grafts. We are mainly concerned with inventions and the development of tissue engineering products for regenerative medicine. We offer a broad panel of services in the field of regenerative medicine.

transtissue.com

Umwelttechnik Dr. Bartetzko GmbH Feasibility studies, development, planning, construction and operation of biotechnological plants for groundwater, process water and waste water purification. Accredited microbiological laboratory for the investigation of drinking water, groundwater, bath water, soils, anti-microbial active ingre-dients and sterility according to Ph.Eur, approved in accordance with BiostoffV and the German infection protection act (Infektionsschutzgesetz).

bartetzko.com

VasoTissue Technologies GmbH The company is active in the field of product development for advanced medical therapies. For its first product - the endothelialised vascular graft ("VasoGraft")- VasoTissue obtained a manufactur-ing license in 2008. Currently, VasoTissue´s focus is on conducting its first clinical trial.

vasotissue.de

WITA GmbH WITA is a high technology service and product company specialized for protein and proteome analysis using high resolution NEPHGE 2-DE (up to 410 mm x 300 mm gel size, up to 10.000 individual protein spots) and mass spectrometry. HPLC, Edman N-terminal sequencing, synthesis of "tricky" unusual peptides

wita.de

Zellwerk GmbH Zellwerk has developed and produces the Z® RP platform comprising rotating bed bioreactor, GMP Breeder, Control Unit and Sponceram® cell carrier. In this culturing system cells grow tissue-like, being embedded in their extra-cellular matrix. The technology opens new horizons for: - unique 3D cultivation of cells and stem cells - regenerative medicine and tissue engineering - gaining cells or stem cells for therapeutic purposes - manufacturing implants - production of bio-pharmaceu-ticals

zellwerk.biz

Zentrum für molekulare Onkologie GmbH

Innovative methods for diagnostic and therapy of tumor diseases - Molecular genetics (K-RAS, PCA3, Septin9, ...) - Chemoresistance assay for prediction of chemotherapy - Pathology Develop-ment of new biomarkers and analytical services for studies

molekulare-onkologie.eu

Zytomed Systems GmbH Zytomed Systems´ focus is the development, production and distribution of antibodies and detec-tion systems for immunohistochemical cancer diagnostics as well as reagents and kits for in-situ hybridisation.

zytomed-systems.de


New drugs mean medical advances and better health. For over 150 years, the people at Pfi zer have developed drugs to cure diseases and improve the quality of life. And our research teams will continue putting forth every effort to improve existing therapies and provide to doctors and patients new preparations to treat to date incurablea diseases – for example, cancer, Parkinson’s, and Aids. For better health.

Research. For better health.

Photo: © www.scienion.com

Small particles,big ideas.

Inventive, leading, improving.With more than 190 biotech companies employ-ing 3,700 specialists, the Berlin-Brandenburg capital region ranks among Europe’s leading locations for biotech. You’ll find the entire spectrum of the value chain, from substance and process development to clinical research, production and services. Companies can also tap into the 3,000 highly qualified students graduating each year from local life science programs. Take advantage of Germany’s exper-tise in the biotech and pharmaceutical fields.

www.biotop.de/business

BPa_AZ_BioTech_210x297_BioTOP.indd 1 30.03.2010 13:34:46 Uhr

biotop-report 2010 - berlin partner · pdf filejournal of biotechnology in berlin-brandenburg...

Documents